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ABSTRACT 
 
In Saskatchewan, stroke is the third leading cause of death as well was the major cause of 
adult disability.  Once a person suffers a stroke or transient ischemic attack (TIA), they are at 
high risk for having a secondary (or recurrent) stroke.  Despite this knowledge, secondary stroke 
prevention is often overlooked in the care of stroke/TIA patients.  With the vision of decreasing 
the incidence and impact of stroke in Saskatchewan, the Saskatchewan Integrated Stroke 
Strategy (SISS) was recently implemented.  The purpose of this study is to begin the 
development of an evaluation measurement system for the SISS based on the guidelines and 
measures from the Canadian Stroke Strategy (CSS) specifically pertaining to secondary stroke 
prevention.   
This multi-year cross-sectional study is an analysis of de-identified health data derived 
from linkage of administrative and laboratory data.  Select indicators from the CSS Performance 
Measurement Manual involving medications use for secondary stroke prevention 
(antihypertensives, antilipidemics, anticoagulants) and intermediate health outcomes (serum 
LDL cholesterol, INR) are calculated.  Regression is used to quantify the association of patient 
demographic and socioeconomic characteristics and geographic location of care with receipt of 
guideline-recommended secondary stroke prevention.  The target population is Saskatchewan 
residents who have been hospitalized for a stroke or TIA between April 1, 2001 and March 31, 
2008.   
The results of this study indicated that secondary stroke prevention in Saskatchewan is 
sub-optimal in the management of hypertension, dyslipidemia, and atrial fibrillation.  Although 
there has been some improvement over the time period, a significant number of patients are not 
taking the recommended medications at discharge from acute care.  Similarly, a considerable 
number of patients are not receiving the appropriate laboratory tests within the year following 
their stroke event.  Through regression analysis it was revealed that a number of correlates (ie. 
age, income, on medication before the stroke event) were significantly associated with receiving 
these specific elements of secondary stroke prevention, suggesting potential differences in 
provision of care.  Finally, regional differences in secondary stroke prevention were found for a 
number of the outcomes, which may indicate differences in care throughout the province. 
 
 ii
The findings of this study serve as a baseline for evaluation of the impact of the 
Saskatchewan Integrated Stroke Strategy in the area of secondary stroke prevention.  The results 
make apparent the fact that secondary stroke prevention in Saskatchewan can be improved, and 
that there is much opportunity for future research in this area.   
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 CHAPTER 1: INTRODUCTION 
 
Stroke is the sudden loss of brain function caused by the interruption of blood supply to 
the brain (1, 2).  In Canada, more than 50,000 people suffer from a stroke each year and over 
300,000 are currently living with the long-term effects (1).  In response to the growing public 
health and economic issue of stroke in Canada, the Canadian Stroke Strategy was implemented 
through the joint cooperation of the Canadian Stroke Network and the Heart and Stroke 
Foundation of Canada (3, 4, 5).  The goal of this program is to support an integrated approach to 
stroke prevention, treatment, and rehabilitation in every province and territory by 2010 (3).  In 
accordance with the goal of the Canadian Stroke Strategy, the Saskatchewan Integrated Stroke 
Strategy was developed with the vision of decreasing the incidence and impact of stroke in 
Saskatchewan (6).   
 
1.1 Study Rationale 
In Saskatchewan, stroke is the third leading cause of death, as well as the major cause of 
adult disability (7).  Approximately 2,000 people are affected each year in the province (6, 7) 
leaving many people disabled, impaired, and in the worst case, deceased.  The risk of stroke 
doubles every ten years after age 55, and as the population continues to age, the number of 
people who suffer a stroke in the province is likely to increase (8).   
To this point, stroke care in Saskatchewan has been suboptimal.  There are a number of 
challenges and barriers to the delivery of quality stroke care in the province, including 
geography, make up of population, distribution of specialized health services, and public and 
professional awareness of stroke risk factors and symptoms (8).  These factors have contributed 
to the stroke care in Saskatchewan being substandard, leaving a number of stroke patients 
without optimal care.   
To address the deficiencies of stroke care in the province, and to be consistent with the 
goals of the Canadian Stroke Strategy, the Saskatchewan Integrated Stroke Strategy was recently 
developed (2003).  The main goal of the program is to improve the provincial health care system 
in the way it deals with stroke across the continuum of care (6).  The “continuum of stroke care” 
is defined by a number of components including primary prevention, hyperacute stroke 
management, acute stroke management, stroke rehabilitation, secondary prevention, and long-
term recovery (5).  This program, however, is still in the early stages, and only recently has a 
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 pilot project commenced in the Sunrise Health Region (Yorkton, Saskatchewan).  In order to 
monitor and evaluate the progress of this initiative, appropriate methods of evaluation are 
necessary.   
Assessing the quality of stroke care across the continuum is a large undertaking.  The 
focus was therefore narrowed down to one area, secondary stroke prevention, since it has 
important implications for future stroke events (1, 6, 9) and previously has not received 
appropriate attention within the province.  Since it is known that secondary (or recurrent) stroke 
prevention in Saskatchewan is below ideal, it follows that a measurement system for quality of 
recurrent stroke prevention has yet to be developed.  Saskatchewan needs a program of 
continuous measurement and reporting for secondary stroke to understand the current state of 
care, assess the impact of improvement efforts, and determine whether gains are being made 
(10).  This program will allow for the assessment of the Saskatchewan Integrated Stroke 
Strategy, determining whether or not the efforts are improving the quality of secondary stroke 
prevention in Saskatchewan. 
 In secondary stroke prevention, prescription drugs are often important for the 
management of conditions, such as hypertension, dyslipidemia, and atrial fibrillation, which 
increase a person’s risk of stroke (4).  Access to data for filled prescriptions for patients in 
Saskatchewan is possible due to the existing provincial drug databases (see Appendix A) 
available at the Health Quality Council.  By calculating the prescription drug indicators for 
hypertension, dyslipidemia, and atrial fibrillation, an understanding will be gained regarding 
management of these conditions with medications related to secondary stroke prevention.  There 
is also a current lack of research regarding covariates for receiving secondary stroke care.  The 
Health Quality Council has completed similar calculations for predictors in post heart-attack and 
diabetes care (11).  By determining the factors and relationships that predict receiving evidence-
based secondary stroke prevention, a better understanding will be gained regarding stroke 
prevention.  Finally, the examination of the prescription drug indicators in each of the regional 
health authorities in Saskatchewan will determine the geographical differences in secondary 
stroke care in the province.    Table 1.1 provides an introduction to relevant terms, acronyms, and 
information for the study.   
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 Table 1.1: Introduction to Terms and Acronyms 
 
Term Acronym Information/Definition 
Angiotensin-Converting 
Enzyme Inhibitor 
ACEI A category of antihypertensive medication. 
Canadian Best Practice 
Recommendations for 
Stroke Care 
 A document from the CSS that provides a 
synthesis of best practices in stroke care (4). 
Canadian Stroke Strategy CSS  
Denominator  The bottom portion of the indicator (fraction) 
which represents the whole; the number of 
parts into which the unit is divided. 
Health Quality Council HQC An independent agency that measures and 
reports on quality of care in Saskatchewan, 
promotes improvement, and engages partners 
in building a better health system (12). 
International Normalized 
Ratio 
INR A blood clotting test for the monitoring of 
people taking warfarin.  The target for patients 
on the drug should be 2.5, range 2.0 to 3.0 (4).  
Low Density Lipoprotein 
Cholesterol 
LDL-C A blood test that evaluates the LDL cholesterol 
level.  The treatment target for stroke patients 
should be lower than 2.0 mmol/L (15).   
Numerator  The top portion of the indicator (fraction) 
which represents the number of parts of the 
whole (denominator). 
“On” Medication  If the time from the last dispensing date to the, 
for example, 90th day post-discharge was fewer 
than the number of days of available drug, then 
the patient was said to be “on” the particular 
medication at the 90th day post-discharge 
Performance 
Measurement Manual 
 A document from the CSS that provides the 
framework for monitoring and evaluation of 
stroke services in Canada (5).  
Quality Indicator/ 
Indicator 
 Measure how well a system may be 
performing, and in terms of healthcare allow 
for the quality of care and services to be 
evaluated (32, 33).     
Researcher 
Documentation 
 The first part of the analysis plan used at the 
HQC that details how the numerators and 
denominators for indicators are to be 
developed.  The document includes inclusion 
and exclusion criteria for indicators, as well as 
the rationale for the decisions made regarding 
the inclusion and exclusion criteria.   
Saskatchewan Integrated 
Stroke Strategy 
SISS  
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 Transient Ischemic Attack TIA Also known as a “mini-stroke”, is a major 
warning sign of increased stroke risk (1, 13). 
Caused by a clot that induces short-term lack 
of blood supply to the brain (1, 14, 13) 
Warfarin  A common blood thinning drug (anticoagulent) 
prescribed to prevent the formation of blood 
clots (16). 
 
 
1.2 Objectives and Research Questions 
The purpose of this study is to begin the development of an evaluation measurement 
system for the SISS, specifically in the area of secondary stroke prevention.  The aim is first to 
describe stroke and TIA patients in Saskatchewan in terms of medication-related secondary 
stroke indicators.  Second is to identify correlates of patients’ receipt of specific elements of 
evidence-based secondary prevention in the population.  Third is to determine if there is 
variation in secondary stroke care between the different regional health authorities in 
Saskatchewan. 
This thesis addresses three major questions, and hypotheses are posited for each:    
Question One: What is the quality of medically-driven secondary stroke prevention care in 
Saskatchewan, as indicated by process of care measures and intermediate patient outcomes in the 
areas of control of hypertension, lipidemia, and blood clotting among those at elevated risk of 
cerebral embolism? The quality of care in these areas will be measured based on indicators 
recommended in the CSS Performance Measurement Manual (5).   
Based on evidence on the quality of secondary stroke care in previous research studies (1, 
6, 9, 12) and evidence pertaining to secondary prevention of other vascular disease in 
Saskatchewan (11), it is hypothesized that half or fewer patients discharged from Saskatchewan 
hospitals following stroke will receive the recommended elements of secondary prevention 
studied here. 
Question Two: What factors are associated with whether or not stroke and TIA patients receive 
evidence-based secondary stroke prevention in Saskatchewan?  What is the strength of the 
relationship between those factors and the drug-related processes of care and intermediate 
outcomes (LDL-C and INR tests) reflected in the indicators?   
Considering the results from the HQC Quality Insight report on post heart-attack and 
diabetes care (11), it is thought that there will be variations in quality of secondary stroke 
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 prevention care related to such factors as age, gender, income, and urban/non-urban place of 
residence.  
Question Three: Is there variation in quality of secondary stroke prevention among patients who 
reside in different Regional Health Authority areas in Saskatchewan? 
Again, based on previous research (11) it is believed that there will be variation in 
secondary prevention between the different Saskatchewan Regional Health Authority Areas. 
This type of research is important for various reasons.  First, the SISS will need to assess 
whether or not their efforts in improving stroke care in the province are successful.  This 
research will provide a baseline measurement concerning secondary stroke care in the province.  
Second, evidence of variations of evidence-based secondary stroke care in Saskatchewan will 
provide important information to focus efforts to improve and make equitable the secondary 
stroke prevention across the province.  Overall, the results will be used to identify opportunities 
for, and monitor over time, quality improvement in the prevention of secondary strokes in 
Saskatchewan. 
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 CHAPTER 2: LITERATURE REVIEW 
 
2.1 Stroke  
 
2.1.1 What is a Stroke? 
A stroke is a sudden loss of brain function caused by the interruption of blood supply to 
the brain, usually by a blood clot or a blood vessel burst (1, 2).  In the affected area, this 
disruption of blood flow cuts off the supply of oxygen and nutrients to the brain cells, causing 
cell death and damage to the brain tissue (1, 2).  The amount of damage the brain incurs depends 
on the length of time the blood supply is interrupted, with the risk of permanent brain damage 
increasing over longer spans of hypoxia (1).  The severity of the effects of a stroke depends on 
which part of the brain is affected and how much damage occurred (1,2).  In the worst case, a 
very severe stroke can cause sudden death (2).   
In Canada and Saskatchewan, stroke is a major health and economic concern.  More than 
50,000 people suffer from a stroke each year in Canada, and over 300,000 are currently living 
with the long-term effects (1).  Stroke is also the third leading cause of death in the country with 
14,000 people dying each year from the condition (1).  Annually, stroke costs the Canadian 
economy at least $3 billion in physical services, hospital costs, lost wages, and decreased 
productivity (1, 17).  Put in an individual context, the average acute cost of each stroke is an 
estimated $27,500 (1).  In the province of Saskatchewan, the statistics are comparable.  Stroke is 
the third leading cause of death, as well as the major cause of adult disability (7).  Approximately 
2,000 people are affected each year (7).  Of these people, 300 die, 200 are so severely disabled 
they require long-term care, 800 are left with a moderate to severe impairment, 500 recover with 
a minor impairment or disability, and 200 fully recover (8). 
 
2.1.2 Types of Stroke 
According to a number of sources, there are two major types of stroke: ischemic stroke 
and hemorrhagic stroke (9, 14, 18, 19, 20).  Transient ischemic attack (TIA) is also an important 
issue in stroke.   
 Ischemic stroke accounts for about 80% of strokes (1, 14).  It is caused by an acute 
interruption of blood supply to the brain by a blood clot (1, 9, 14, 18, 19).  This clot deprives 
downstream tissue of oxygen and nutrients (20), damaging that part of the brain.  Ischemic 
strokes can be either “thrombotic” or “embolic” (1, 14) depending on the type of clot disrupting 
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 the blood flow.  Thrombotic strokes are caused by blood clots that formed in a brain artery; 
thrombi (1, 14, 18).  Embolic strokes, on the other hand, are caused by blood clots that formed 
elsewhere in the body, called emboli, travelled via the bloodstream, and lodged in the brain (1, 
14, 18).  Both types of ischemic stroke are generally a result of atherosclerosis, the buildup of 
plaque in the arteries (1, 9). 
Hemorrhagic stroke accounts for about 20% of strokes (1).  It is caused by uncontrolled 
bleeding in or around the brain from broken blood vessels (1, 9, 14, 18).  This flooding puts 
pressure on the brain, killing brain cells and causing damage (1, 18).  Hemorrhagic strokes are 
classified according to the area of the brain the bleeding (hemorrhage) occurs.  There are two 
main types, subarachnoid and intracerebral (1, 18, 12).  Subarachnoid hemorrhage is when 
bleeding occurs on the surface of the brain underneath the thin outer membrane (1, 9, 18).  
Intracerebral hemorrhage, on the other hand, occurs when an artery ruptures deep within the 
brain (1, 9, 18).  Both types of hemorrhagic stroke can be caused by structural problems that 
affect the blood vessels in the brain (1, 18).  A couple of these problems include an aneurysm, a 
weakened area in the blood vessel wall that bulges and bursts, or arteriovenous malformations 
(AVM), which is the abnormality of tiny blood vessels causing the artery walls to be weak and 
break (1, 9, 18).    
 Transient ischemic attack (TIA), also known as a “mini-stroke”, is a major warning sign 
of increased risk for stroke (1, 13).  It is caused by a clot that induces short-term lack of blood 
supply to the brain (1, 13, 14).  The major difference between stroke and TIA is that the 
symptoms generally subside after a short period of time, often just minutes, and there is little or 
no damage done to the brain (1, 13).  In Canada, approximately 15,000 people experience a TIA 
each year with many more going unreported (1).  Since people who have had a TIA are five 
times more likely to have a stroke in the next two years (1), TIA is an important indicator for 
stroke prevention. 
  
2.1.3 Effects of Stroke 
 Since a stroke occurs in the brain, it follows that the effects of stroke involve brain 
functions.  Considering the brain controls every part of a person’s being, the effects of a stroke 
can manifest themselves in a large number of ways, meaning that no two strokes are ever the 
same (1, 9).  A stroke can have devastating effects on many different aspects of a person’s life, 
including, but not limited to, ability to move, see, speak, reason, read and write (1).  Besides 
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 everyday tasks, a stroke can also have an affect on a person’s emotions, memory, and personality 
(9, 18, 21).  What factors affect a stroke patient’s experiences, and their ability to rehabilitate, 
depends on where in the brain the stroke occurred, as well as the severity of the hypoxia and 
ensuing brain damage (1, 9).   
No matter the effects, stroke is devastating for both the patients and the people who care 
about them; it is a major illness that changes people’s lives (1, 9).  Stroke leads to family stress, 
depression, lost income, decreased productivity, and increased care-giving responsibilities (3).  
First dealing with, and then recovering from stroke, is a difficult physical and emotional journey 
for both the survivors and their families. Rehabilitating from stroke takes a long time and is a 
very difficult process (21) requiring ongoing support from both healthcare systems and family 
members.  Unfortunately, and despite best efforts, most stroke survivors only have the ability to 
recover to some extent (9); most will continue to live with lasting effects even after 
rehabilitation.   
The struggles of stroke survivors is outlined in the project by the Heart and Stroke 
Foundation called “Never Giving Up: Stroke Survivor and Caregiver Perspectives on the Road to 
Recovery from Stroke” (8).  Each person who has a stroke suffers different effects, and therefore 
has their own distinct struggles.  For instance, one stroke survivor stated that “the hardest part of 
having a stroke is to accept my shortcomings, what I cannot do anymore, how things have 
changed, what I have lost” (8).  Another stated that “what frustrated me the most was not being 
able to communicate” (8).  Regardless, these people lost their way of being in the world (8) after 
stroke, and these profiles demonstrate the importance of stroke prevention, care, and treatment to 
decrease both the incidence of stroke, and its devastating effects. 
 
2.1.4 Risk Factors for Stroke  
 It has been identified and well-documented that a large number of factors, both non-
modifiable and modifiable, contribute to an individual’s risk of having a stroke (19, 22).  Non-
modifiable risk factors are those that are out of a person’s control, while modifiable risk factors 
can be influenced and changed by the individual (1, 14).  
 Even though non-modifiable risk factors are not subject to intervention or modification 
(19), they are important for identifying those who are at high risk of stroke (23).  These 
individuals may benefit from preventative measures and/or more aggressive control of the 
modifiable risk factors (14, 23).  The non-modifiable risk factors for stroke include: age, gender, 
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 ethnicity/race, family history, and previous TIA or stroke event (1, 14, 19, 23).  As with many 
other diseases, the risk for stroke increases with age (1, 14, 23); the risk of stroke doubles each 
decade after 55 years (14, 23).  In terms of gender, stroke is more prevalent among men than 
women (23).  Until they reach menopause, women are generally at lower risk for stroke (1).  
African Americans, self-described Hispanics, and Asians of Chinese and Japanese descent have 
been shown to have higher rates of stroke (14, 23).  First Nations people are also at higher risk 
compared to the general population (1).  There is an increased risk of stroke for people with close 
family members – parents, siblings, or children – who have a history of stroke (1, 23).  Finally, if 
a person has previously experienced a stroke or TIA, they are at higher risk for having another 
stroke event in the future (1).   
 Modifiable risk factors are a critical aspect of stroke prevention as they are under the 
control of the individual.  Management of these risk factors can reduce the incidence of stroke as 
well as the rate of death and dependence (14).  There are a large number of modifiable risk 
factors, some well-documented, others with less evidence.  Some of the well-documented 
modifiable risk factors for stroke include: high blood pressure, high blood cholesterol, 
dyslipidemia, atrial fibrillation, diabetes, diet, obesity, physical inactivity, smoking, and stress (1, 
14, 23).  
 
2.1.5 Prevention of Stroke 
  
2.1.5.1 Canadian Stroke Strategy (CSS) 
 In recognition of and in response to the growing public health and economic impact of 
stroke in Canada, the Canadian Stroke Strategy was implemented through the joint cooperation 
of the Canadian Stroke Network and the Heart and Stroke Foundation of Canada (3, 4, 5).  “The 
goal of the Canadian Stroke Strategy is to help support an integrated approach to stroke 
prevention, treatment, and rehabilitation in every province and territory by 2010” (3).  Figure 2.1 
illustrates the model of the Canadian Stroke Strategy.   
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 Figure 2.1: Model of the Canadian Stroke Strategy (3) 
 
 
 
It has been frequently reported that new research in stroke does not always reach health 
care providers, administrators, and most importantly, patients with stroke (3, 4).  This lack of 
communication has left a significant gap in the quality of stroke care between what should be 
done and what is being done, meaning that best practices for stroke care are not always applied 
(3, 4).  The Canadian Stroke Strategy responds to this problem, and supports the development of 
provincial stroke strategies across Canada to close the gap between evidence and practice along 
the full continuum of stroke care (3, 4).  The “continuum of stroke care” is defined by a number 
of components including primary prevention, hyperacute stroke management, acute stroke 
management, stroke rehabilitation, secondary prevention, and long-term recovery (5).  Figure 2.2 
illustrates the core elements of an integrated stroke strategy that spans the continuum.   
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 The Canadian Stroke Strategy has five national priority platforms, one of them being the 
Best Practices and Standards Working Group (3, 4).  The goal of this platform is to ensure that 
evidence-based best practices for stroke prevention and care are integrated into the Canadian 
health system (4).  The development of the Canadian Best Practice Recommendations for Stroke 
Care is a starting point in fulfilling this goal (3).  The Best Practice manual, developed from 
extensive review of stroke research and guidelines, provides “…a synthesis of best practices in 
stroke care across the continuum and serves as a framework for provinces, territories, and 
regional health authorities as they develop and implement integrated stroke strategies” (5). 
  
2.1.5.2 Saskatchewan Integrated Stroke Strategy (SISS) 
 In accordance with the goal of the Canadian Stroke Strategy, the Saskatchewan 
Integrated Stroke Strategy (SISS) was implemented with the vision of decreasing the incidence 
and impact of stroke in Saskatchewan (6).  The goal of this initiative is to transform the health 
system in the way it views, prevents, and treats Saskatchewan stroke patients across the 
continuum of stroke care (6).  This continuum includes health promotion, primary prevention, 
risk factor management, pre-hospital care, emergency care, acute care, rehabilitation, community 
re-engagement, and risk factor management post stroke and TIA (secondary prevention) (6).  
Figure 2.3 illustrates the model of the Saskatchewan Integrated Stroke Strategy.  
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 Figure 2.3: Model of the Saskatchewan Integrated Stroke Strategy (6) 
 
  
The development of the SISS has taken place through a collaborative approach by the 
Heart and Stroke Foundation of Saskatchewan (6).  A provincial steering committee and expert 
working groups, a stroke prevention and care conference, and consultation visits with eleven 
health regions provided collaborative feedback and support to create the made-in Saskatchewan 
stroke strategy (6).  In order to achieve best practices for stroke care, as suggested by the CSS, 
the steering committee created four working groups to provide suggestions and direction for 
implementation of the practices across the continuum of care (6).  These recommendations are 
summarized in the “SISS Health System Transformation and Stroke Prevention and Care in 
Saskatchewan” report by the Heart and Stroke Foundation of Saskatchewan (6).   
 The SISS is still in its infancy, and only recently has a pilot project commenced in the 
Sunrise Health Region (Yorkton, Saskatchewan).  As announced in a press release on December 
17, 2008, the project will establish a stroke prevention clinic and improved stroke rehabilitation 
services with the goal of decreasing the incidence and impact of stroke in the health region (24).  
The ultimate goal in the province is to have an integrated provincial stroke strategy involving 
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 every health region and every key area of stroke care (25).  This pilot project is a starting point 
for this goal, with an at-risk area receiving immediate attention (25).        
 
2.1.5.3 Ontario Stroke System (OSS) 
 The province of Ontario is ahead of Saskatchewan in creating a stroke strategy, and 
therefore serves as an example of where the SISS could be in future years.  Similar to the SISS, 
the goal of the Ontario Stroke Strategy is to change the way stroke is viewed and treated in the 
province (26, 27).  The Ontario government adopted and funded the program as a way to 
organize stroke services in the province and ensure that the people of Ontario had access to 
quality stroke care (26, 28).  The strategy aims to decrease the incidence of stroke and improve 
patient care and outcomes for people who suffer a stroke (26, 27, 23).  It is thought that this 
stroke care system will: i) ensure that all Ontarians have timely access to appropriate diagnosis 
and quality stroke care, and ii) respond more effectively and efficiently to those who are at risk 
for or who have had a stroke (26, 27).  Since its inception this strategy has become known as the 
Ontario Stroke System (OSS).  The OSS includes the full continuum of care within 11 regional 
stroke care systems across the province (27).   
    Since the implementation of the OSS and its regional network model of collaborative 
care, the stroke project has been deemed a success (28, 29).  There have been significant 
improvements in the timeliness and quality of care (28).  An evaluation of the program has 
demonstrated that the OSS has made positive measureable impacts on access to stroke-related 
services, the integration and coordination of stroke care, treatment for stroke, and client and 
provider satisfaction (27).  Ontario has become recognized as a world leader in managing and 
treating people who have experienced a stroke (29).  The OSS is identified as a successful model 
to emulate across Canada (27). 
 It should also be noted that other provinces in Canada have also started the process of 
creating an integrated stroke strategy.  Information similar to the SISS can be found on the 
Alberta Provincial Stroke Strategy (APSS) (30) as well as the British Columbia Stroke Strategy 
(BCSS) (31).   
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 2.2 Quality Indicators 
 
2.2.1 What are Quality Indicators?  
In recent years, assessing the quality of care has become increasingly important in 
healthcare systems (32).  This measurement provides information regarding whether the quality 
of healthcare is good, excellent, or poor (33), and allows healthcare systems to determine what 
improvements are necessary.  Since this assessment cannot be made directly, quality indicators 
are the tools by which this evaluation is made.   
 As stated by a number of different authors, defining and specifying “what is quality care” 
is often a difficult task (32, 34, 35, 36, 37).  The formulation of quality healthcare can be narrow 
or broad, and can also depend on a number of different factors.  As put by Donabedian (34), 
“…several formulations are both possible and legitimate, depending on where we are located in 
the system of care and on what the nature and extent of our responsibilities are”.  In other words, 
quality of care will generally be defined according to what level of care is being assessed.  For 
the purposes of this project, quality of care is defined as “the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and are consistent 
with current professional knowledge” (35).      
 Quality indicators measure how well a system may be performing, and in terms of 
healthcare allow for the quality of care and services to be evaluated (32, 38).    Donabedian 
classified quality of care indicators into structure, process, and outcome (32, 34, 35).  Structural 
indicators describe characteristics of the setting in which care takes place, for instance resources 
and staff (32, 34, 35), reflecting the system’s ability to meet healthcare needs of the patients (32).  
Process indicators are concerned with what is done in giving and receiving care (32, 34, 35), an 
example being the proportion of diabetic patients given foot care (32).  These assess what was 
done for the patient, and how well it was carried out (32).  Finally, outcome indicators measure 
the effect of care on the health status of patients and populations (32, 34, 35).  There are both 
intermediate and end results outcome indicators.  Intermediate outcome indicators show changes 
in biological status that affect later health outcomes, an example being HbA1c lab tests for 
diabetics (32).  End result outcome indicators reflect states of health or events that follow care, 
such as death, disability, and morbidity (32).      
 
 15
 2.2.2 Quality Indicators and Stroke – Performance Measurement Manual 
A supplement to the Best Practices Recommendations for Stroke Care is the Performance 
Measurement Manual (4, 5).  Developed by the Information and Evaluation Working Group 
(IEWG), this manual provides detailed performance measures for the evaluation of the impact of 
provincial, regional, and local stroke activities and initiatives (5).  It offers the framework for 
monitoring and evaluation of stroke services in Canada (5), specifically the impact of 
implementing the best practice recommendations on processes of care (5).  The manual provides 
a list of performance measures along the continuum of stroke care, including primary prevention, 
hyperacute and acute stroke management, rehabilitation, secondary stroke prevention, and long-
term recovery (5).   
 
2.3 Quality Indicators in Secondary Stroke Prevention 
 
2.3.1 What is Secondary Stroke Prevention? 
If a person suffers a stroke or TIA, they are at high risk for having a secondary (or 
recurrent) stroke (6, 9).  In fact, a stroke survivor has a 20% chance of having another stroke 
within 2 years (1).  The chance of stroke recurrence depends on stroke etiology, and the 
treatment given after the first stroke event (6, 14).  Considering the implications that 
interventions have for future stroke events, secondary stroke prevention is a critical, but often 
overlooked, aspect in the care of stroke or TIA patients. 
“Secondary stroke prevention is an individually based clinical approach to reducing the 
risk of recurrent vascular events in individuals who have already experienced a stroke or TIA 
and in those who have one or more of the medical conditions or risk factors that place them at 
high risk of stroke” (4).  In other words, secondary stroke prevention encompasses many 
different areas in the life of a stroke survivor.  The secondary stroke recommendations made in 
the Best Practice manual are directed at the most relevant risk factors, including lifestyle, 
hypertension, dyslipidemia, previous stroke or TIA, atrial fibrillation, and carotid stenosis (4).  
Following a stroke or TIA, secondary stroke prevention should be addressed at all healthcare 
encounters on an ongoing basis (4).   
   
2.3.1.1 Hypertension 
Hypertension (elevated blood pressure) is the single most important modifiable risk 
factor for both first and recurrent stroke (4, 39).  No other factor has been identified that 
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 contributes more to the development of stroke (39).  Table 2.1 provides a classification of blood 
pressure for adults aged 18 years or older.  It has been reported that some 20-30% of the adult 
population and about 70% of stroke patients are affected by hypertension (39).  In Canada, 
hypertension is a major problem (4) contributing to elevated stroke risk for many people in the 
country.  
 
Table 2.1: Classification of Blood Pressure (BP) for Adults Aged 18 Years or Older (40) 
 
BP Classification Systolic BP, mmHg  Diastolic BP, mmHg 
Normal <120 and <80 
Prehypertension 120-139 or 80-89 
Stage 1 Hypertension 140-149 or 90-99 
Stage 2 Hypertension ≥160 or ≥100 
 
The relationship between blood pressure and stroke risk has recently been recognized as 
being highly sensitive (41).  A meta-analysis has shown that with each 2 mmHg reduction in 
systolic blood pressure, there is a 10% reduction in mortality from stroke (42).  There is a 
continuous and linear relationship between blood pressure and risk of stroke (41, 43).  This 
relationship is present not only in those who are hypertensive, but also those who are 
normotensive down to a blood pressure of at least 115/75 mmHg (42).  Correspondingly, several 
controlled trials have demonstrated that reducing blood pressure decreased stroke risk among 
patients not normally classified as hypertensive (44, 45).   
In secondary stroke prevention, hypertension is recognized as an important risk factor 
that should be controlled (46, 47, 48, 49).  A number of trials have shown a 28% risk reduction 
in recurrent stroke in patients treated with blood pressure lowering medication (4). 
Antihypertensive therapy and lifestyle modification are the recommended strategies for recurrent 
stroke prevention (4, 46, 47, 48, 49).  The Canadian Hypertension Education Program (CHEP) 
suggests that patients who have had a stroke or TIA be placed on blood pressure lowering 
treatment to a target blood pressure of less than 140/90 mm Hg (50).     
 
2.3.1.2 Dyslipidemia 
High blood cholesterol and lipids (dyslipidemia) is associated with an elevated risk for 
stroke (4).  Unfortunately, it has been shown that significant numbers of patients are not properly 
evaluated and treated for this condition (51). 
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 The relationship between dyslipidemia and stroke has been stated as being weakly 
positive and equivocal (48, 49, 52, 53).   Despite these statements, it has been shown that lipid-
lowering therapies offer a 25-30% relative reduction in primary and recurrent stroke risk (4).  
Several studies have shown the benefits of lipid-lowering therapy in the prevention of ischemic 
stroke, secondary stroke, and TIA (46, 52, 53, 54, 55, 56, 57, 58).  The effects of therapy on 
hemorrhagic stroke, however, remain somewhat unclear (53, 56, 57, 58).  It has therefore been 
stated that only people who have suffered an ischemic stroke or TIA should be placed on 
cholesterol-lowering medications (4).    
 Appropriate management of dyslipidemia by health care providers is imperative in 
secondary prevention of stroke (51).  The Canadian Cardiovascular Society recommends that 
lipid-lowering therapy (generally statin agents) should be prescribed for patients who have had 
an ischemic stroke or TIA (15).  High-risk individuals, this encompassing stroke and TIA 
patients, should have low density lipoprotein cholesterol (LDL-C) treatment targets lower than 
2.0 mmol/L (15). 
 
2.3.1.3 Atrial Fibrillation 
Atrial fibrillation is a significant risk factor for stroke (4).  This condition affects 1 to 
1.5% of the general population in the Western world making it the most common type of cardiac 
rhythm abnormality in adults (59).  People with atrial fibrillation have a fivefold increase in risk 
for stroke (59, 60).  It has been shown that 1 in 6 patients with atrial fibrillation will experience a 
stroke in their lifetime (61).  Strokes from atrial fibrillation are usually more severe and 
associated with an increased risk of morbidity, mortality, and poorer functional outcome than 
strokes from other causes (59).   
There are a considerable number of papers stating the value of anticoagulants in reducing 
the risk of both primary and secondary stroke in people with atrial fibrillation (4, 16, 62, 63, 64, 
65).  Anticoagulant drugs, such as warfarin, make the blood ‘thinner’ and prevent the formation 
of blood clots, which in turn may prevent stroke (16).  It has been reported that anticoagulant 
medications are superior to both antiplatelet agents and aspirin in both preventing and reducing 
the risk of stroke (16, 62, 63, 64, 64).   
Following a recent ischemic stroke or TIA, anticoagulants should be prescribed to 
patients with atrial fibrillation to prevent secondary stroke (4, 16).  A 68% relative risk reduction 
and a 33% absolute risk reduction in recurrent stroke has been found for patients who receive 
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 anticoagulation with adjusted-dose warfarin (16, 66).  It should be noted that this treatment 
pertains only to those who have had an ischemic stroke or TIA; the bleeding in hemorrhagic 
strokes generally renders anticoagulants unsuitable.  Due to the nature of the medications, 
regular blood level monitoring is required to ensure patients are within the target range (4).  
Warfarin, one of the major anticoagulants, is assessed using the international normalized ratio 
(INR) (4).  The target INR for patients on warfarin should be 2.5, range 2.0 to 3.0 (4).   
 
2.3.2 Factors Associated with Secondary Stroke Prevention 
 Even though there is a publicly funded universal healthcare system in Canada, there 
exists evidence of unequal provision of medically necessary interventions (12).  In secondary 
stroke prevention, research involving such inequalities is somewhat limited, but there have been 
papers published regarding factors related to differences in stroke prevention provision. 
 A Scottish study specific to secondary prevention of stroke found important sex- and age- 
related differences in care of patients with stroke (67).  Men with ischemic stroke were 
prescribed antiplatelet therapy more often than women (67).  Moreover, women with atrial 
fibrillation received warfarin less often than men (67).  Also, older patients received antiplatelet 
therapy more often than younger patients (67).  This evidence suggests that women and the 
elderly need to be targeted for secondary prevention therapy (67).     
 A number of studies have been conducted regarding gender differences in various aspects 
of stroke prevention.  A couple of these papers have found there to be no major gender 
differences in stroke presentation, management, or access to care (12, 68).  A different study 
found that women hospitalized for stroke had lower odds of receiving thrombolytic therapy 
treatment and lipid investigation (69).  Yet another study found that, at discharge, women 
received antithrombotic stroke prevention less often than men (70).  A final study found that 
anticoagulants were underused in older women with atrial fibrillation relative to older men with 
atrial fibrillation (71).  It is clear that the presence of gender differences in secondary stroke 
prevention is still somewhat unknown, and is in need of further investigation.   
 A couple of studies have been conducted regarding the effect of socioeconomic status 
and ethnicity on secondary stroke prevention.  One study found that some sociodemographically 
defined groups have different chances of receiving some components of care, but with no 
consistent pattern of inequality (12).  This same study found some evidence, although weakly 
associated, that people of higher socioeconomic status were more likely to be admitted to 
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 hospital and to a stroke unit (12).  A second Canadian study found that stroke patients with lower 
socioeconomic status had increased mortality and decreased access to some healthcare resources 
(72).  Considering the conflicting evidence regarding stroke care and socioeconomic status, it is 
again apparent that more research needs to be conducted in this area.   
 Finally, another study involved a literature review investigating the differences in stroke 
care between rural and urban areas in the United States (73).  It was found that acute stroke 
management practices in rural areas are suboptimal, creating a health disparity between urban 
and rural stroke patients (73).  Since this study only involved a review of the literature, it would 
be beneficial to conduct a full study on the differences in urban and rural stroke care. 
 
2.3.2.1 Health Quality Council 
The Health Quality Council (HQC) is an agency that measures and reports on quality of 
healthcare in Saskatchewan (10, 11).  As part of this mandate, they have developed the Quality 
Insight program, which has recently (2008) produced the first edition of the Quality Insight 
Report (11).  Within this document, there are sections on Post-Heart Attack Care and Diabetes 
Care, both of which provide examples for future measurement and reporting in stroke care.     
In post-heart attack care, as with stroke care, secondary prevention using drug therapy is 
important (11).  As part of their measurement, the HQC identified and reported on factors related 
to receiving medication.  They found both age and gender to be contributing factors in 
determining whether or not the patients were dispensed the recommended medications (11). 
In diabetes care, control of blood sugar and LDL-C levels is important to prevent 
complications (11).  The HQC reported on factors related to control of blood sugar and 
cholesterol as outlined by blood tests. The factors found to be related to better or worse control 
were age, ethnicity, and gender (11).   
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 CHAPTER 3: METHODOLOGY 
 
3.1 Study Design 
This study uses a multi-year cross-sectional design.  It is based on record linkage and 
secondary analysis of de-identified administrative and clinical data. 
 
3.2 Selection of Indicators 
 The indicators calculated in this study were selected directly from the Canadian Stroke 
Strategy Performance Measurement Manual (5).  A brief description of how the measures were 
developed by the Canadian Stroke Strategy is as follows. 
 As previously stated, one of the goals of the Canadian Stroke Strategy is to ensure the 
integration of evidence-based best practices for stroke prevention and care into the Canadian 
health system (4).  In working towards this objective, Canadian recommendations for stroke care 
were developed through an extensive process.  This method involved review of stroke research, 
identification of key topics, synthesis of recommendations, and, finally, assessment by a national 
expert consensus panel (4).  Following discussion and review at the panel meeting, final 
decisions were made for each recommendation, and the Canadian Best Practice 
Recommendations for Stroke Care (4) were published.  
 As a supplement to the Best Practice manual, and as a framework to measure the quality 
and consistency of stroke care, the Performance Measurement Manual was created (4, 5).  This 
manual contains indicators that correspond to the Best Practice Recommendations, and provides 
detailed definitions for each of the performance measures (4).  These indicators were selected 
based on specific criteria (5), and were developed to monitor the impact of implementing the 
Best Practice recommendations on the quality of patient care and/or patient outcomes (4). 
 In selecting the indicators to be calculated in this study, a process of literature and data 
review was undertaken.  It was important to identify the indicators that were significant, yet 
under-researched in Saskatchewan, as well as possible to calculate with the resources available.  
Following some literature review, it was clear that the area of secondary stroke prevention lacked 
sufficient research in Saskatchewan, and in general.  Therefore, the focus was on the indicators 
in the Performance Measurement Manual dealing with secondary stroke prevention.  The 
measures in the manual were specific, but not in terms of operational definitions for each 
province.  Thus, discussions took place at the HQC regarding the data available, and the 
feasibility of calculating the secondary stroke indicators.  The final decision regarding the 
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 indicators included in this study centered around which measures were most applicable for stroke 
prevention care in Saskatchewan, and had the necessary data and resources available.   
 
3.2.1 Quality Indicator Measures and Definitions 
Table 3.1 outlines the definitions of the performance measures as they appear in the 
Canadian Stroke Strategy Performance Measurement Manual (5).  These along with the criteria 
outlined for identifying the stroke and TIA cohort, based on diagnosis codes in the hospital 
discharge abstract records, were used to identify the cohort subsets for the calculation of each 
indicator. 
 
Table 3.1: Selected Performance Measures from the Canadian Stroke Strategy Performance 
Measurement Manual (5).  Indicator numbering as per the Performance Measurement Manual. 
 
Recommendation # Recommended Performance Measures 
2.2  Blood Pressure Management vii. Proportion of stroke and TIA patients prescribed blood 
pressure lowering agents on discharge from acute care  
 
ii. Proportion of stroke patients prescribed lipid-lowering 
agents for secondary prevention of stroke – either at 
discharge from acute care, through a secondary prevention 
clinic, or by primary care 
 
iii. Proportion of stroke patients with an LDL-C between 
1.8 – 2.5 mmol/L at 3 months following stroke event 
 
iv. Proportion of stroke patients with an LDL-C <2.0 
mmol/L at 3 months following stroke event 
 
2.3  Lipid Management 
v. Proportion of stroke patients with an LDL-C >2.0 
mmol/L at 3 months following stroke event 
 
i. Proportion of eligible stroke and TIA patients with atrial 
fibrillation prescribed anticoagulent therapy on discharge 
from acute care 
 
2.6  Antithrombotic Therapy in 
Atrial Fibrillation 
v. Proportion of patients on warfarin with INR in 
therapeutic range at 3 months, 6 months, and 1 year 
following index stroke event 
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 3.3 Data 
 
3.3.1 Data Sources and Acquisition 
 This study was based on data from two sources: Saskatchewan Health Administrative 
Databases, and Laboratory Data from the Saskatoon Regional Health Authority and Regina 
Qu’Appelle Regional Health Authority laboratory test results databases. 
 
3.3.1.1 Saskatchewan Health Administrative Databases 
In Saskatchewan, there are thirteen separate regional health authorities.  Health services 
are provided to the residents of the province through a publicly funded, universal health system 
(74).  This universal health care program has allowed for the accumulation of a large amount of 
health care information in computerized databases over a number of years (74).  These databases 
have been recognized as a resource for drug utilizations review, pharmacoepidemiology, and 
health economics (74), and were utilized in calculating the indicators for this study.  A list of 
Saskatchewan Health Administrative Databases used in the study is available in Appendix A. 
The de-identified administrative health data utilized was made available to the HQC 
through a standing data sharing agreement between the Ministry of Health and HQC.  Data from 
seven Ministry of Health administrative databases were abstracted and electronically linked with 
encrypted identification numbers at the individual person level.  See Appendix A for a table 
listing the databases and the key variables abstracted from each dataset.  These datasets were 
available via a secure virtual private network (VPN) connection to a data warehouse located in 
the Ministry of Health.  The data sharing agreement stipulated which data fields HQC had access 
to in each database, expectations for protection of patient privacy in use and storage of data, as 
well as in any reporting based on the data. 
 
3.3.1.2 Primary Source Laboratory Data 
In contrast to the data for the drug therapy indicators, the LDL-C and INR test indicators 
required laboratory data.  This data was obtained from two regional health authorities in 
Saskatchewan.  The regions included were the Saskatoon Regional Health Authority (SRHA) 
and the Regina Qu’Appelle Regional Health Authority (RQRHA).  The reason for including only 
these regions is because the tests of interest were done in a large number of laboratories across 
the province, and a central repository for all of the results does not yet exist.  The SRHA and 
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 RQRHA were chosen because they are the most populous areas of the province, and because 
there were existing mechanisms for sharing of laboratory data with the HQC. 
To acquire the necessary laboratory data for this study, data sharing agreements were 
established between HQC and each of regional health authorities contributing data to the study.  
For both the SRHA and RQRHA, Master Data Sharing Agreements were already in place 
between the region and the HQC, and, in accordance with the agreements, a Data Sharing 
Schedule was appended to those agreements pertaining to data sharing for this particular study.  
These Data Sharing Schedules stipulated which data was requested from the region and 
expectations for de-identification, data protection, as well as any reporting based on the data.   
 
3.3.1.3 Drug Information Acquisition 
 The original drug list obtained for use in this study was acquired from Dr. Moira Kapral, 
an internal medicine physician and stroke researcher in Ontario.  This list had been previously 
used to calculate similar drug indicators for the Ontario Stroke Strategy and was based on 
findings in the literature, as well as clinical best practices regarding stroke care. 
At the HQC, there is a process followed in creating drug lists for indicator calculations.  
Upon receiving the list from Dr. Kapral, three separate drug lists were created for each of the 
indicator calculations in the study (i.e. antihypertensives, antilipidemics, anticoagulants) using 
previously developed SAS macros.  The drug identification numbers (DINs) for medications 
belonging to the drug generic names on the list were found by searching the Ministry of Health 
“All DIN” file by generic name of the drug.  These numbers are unique to each specific drug, 
formulation, and packaging.  Records indicating dispensing of the medications of interest were 
identified by searching the Prescription Drug Plan Historical Claims database (Appendix A) for 
these DINs within the populations of interest for the indicators.  The three drug lists were then 
sent to the HQC’s pharmacotherapy consultant (a professor in the College of Pharmacy and 
Nutrition at the University of Saskatchewan) for review.   
The consultant assessed the drug lists to ensure they were complete, accurate, and listed 
the relevant drugs that would be available in Saskatchewan.  As part of the review, the consultant 
searched the literature on medication for the areas of interest related to secondary stroke 
prevention.  It was verified, based on the literature and the consultant’s clinical opinion, that no 
major drug categories were missing from each of the drug lists.  If there was a drug missing on 
the list, the consultant notified the HQC, and the HQC contacted Dr. Kapral for a clinical 
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 opinion.  Following this discussion, the missing drug was either added or left off the list.  When 
the assessment of the drug lists was complete, the consultant forwarded them to the HQC.   
      
3.4 Study Population 
 
3.4.1 Definitions Used for Study Population Criteria 
 
Hospitalization 
Inclusion in the Hospital Discharge Abstract Database (DAD) was considered as the indicator for 
hospitalization. 
 
Registered Indian Status   
Refers to those persons who reported they were registered under the Indian Act of Canada.  
 
Death   
The date of death was determined from four data sources (Person Registry System, Vital 
Statistics, Institutional Care Home File, and Hospital Discharge Abstract Database), each of 
which captured information on date of death.  However, there may have been errors in the coding 
of deaths in some of these databases and disagreements between the data in them concerning 
individuals. For example, HQC has found that historically, about 5% of cases coded as death in 
the discharge disposition field of the Hospital Discharge Abstract Database are incorrectly coded 
as deaths. 
In general the date of death found in these various data sources was in agreement, but 
where differences existed, an iterative algorithm of rules and hand checking was conducted to 
select the date that was most likely to be correct. Vital statistics is commonly used as the source 
of death information in studies. However, the vital statistics file HQC had access to did not 
contain out-of-province deaths and this information was obtained using the PRS file. As the 
HQC used an iterative algorithm of rules and hand checking, they deleted cases from the vital 
statistics file because of errors discovered when verifying with the other data files, including 
duplicate cases. They also checked the physician billing and prescription drug dispensing data 
sources to verify deaths. If there were physician billings after one week and/or drug dispensing 
activity after six months beyond the putative date of death, then the death date was considered to 
be in error and the person was considered to be still alive. In the resulting HQC verified death 
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 file 97% of the records had the same date of death as that recorded for the individuals in the vital 
statistics file; the remaining 3% of records were derived from the other data sources. 
 
Provincial Health Insurance Coverage 
The HQC had multiple historical records based on coverage and expiry dates of the health card 
(and thus coverage by Saskatchewan health insurance) which allowed for the determination of 
how many days an individual was covered by the provincial health plan within a particular 
assessment period.  The length of time an individual had to have coverage was dependent on the 
indicator being calculated. 
 
Episode of Care 
An episode of acute care may have involved stays in more than one hospital if a patient was 
transferred among hospitals. If a patient was discharged from one hospital and admitted to 
another within the same day or the next calendar day, the transfer was considered to be part of 
the same episode of care (EOC).  In other words, an EOC started on the date of admission to the 
first hospital, and extended to the discharge date of the last hospital in which a patient was 
treated.  The primary diagnosis for the first episode in the EOC had to be stroke/TIA, but any 
ensuing episodes could have been for other causes (i.e. rehab, follow-up procedures).  This 
method allowed for the capture of the entire EOC, and thus the most appropriate final discharge 
date.   
 
3.4.2 Stroke and TIA Patient Cohort 
The target population was all hospitalization episodes for Saskatchewan residents due to 
a stroke or TIA between April 1, 2001 – March 31, 2008.  This population was identified using 
the Hospital Discharge Abstract Database (DAD), which is part of the Saskatchewan Health 
administrative databases presented in Appendix A.  The International Classification of Diseases, 
version 10-CA (ICD-10-CA) codes shown in Table 3.2 (5) were used to define and identify the 
stroke and TIA cases.    
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 Table 3.2: Stroke Diagnostic Codes 
 
Stroke Subcategory ICD-10-CA codes 
Acute stroke I60 (exclude I60.8) 
I61 
I63 (exclude I63.6) 
I64 
I67.6 
H34.1 
Ischemic stroke (includes acute but 
ill-defined cerebrovascular) 
I63 (exclude I63.6) 
I64 
H34.1 
Subarachnoid hemorrhage I60 
Intracerebral hemorrhage I61 
Transient ischemic attack G45 (exclude G45.4) 
H34.0 
 
 
To be included in the study, the identified stroke and TIA cases had to meet a number of 
criteria.  The inclusion and exclusion criteria, as well as the rationale, are presented in Table 3.3. 
 
Table 3.3: Stroke and TIA Patient Cohort Criteria and Rationale 
 
Stroke and TIA Patient Cohort Rationale 
Inclusion 
Criteria 
Primary diagnosis (most 
responsible diagnosis) of stroke 
or TIA on hospital discharge 
record. 
The purpose of the study is to gain an 
understanding of condition management 
with drugs in secondary stroke 
prevention.  In order to do so, patients 
who have experienced a stroke or TIA 
need to be identified as accurately as 
possible. 
 
Individuals aged < 18 years on 
the date of the stroke or TIA; 
 
By setting the minimum age at 18, most 
of the stroke events will be captured.  
Also, this is the age of adulthood in 
Canada. 
 
All out-of-province 
hospitalizations; 
 
The study involves stroke care in 
Saskatchewan, and thus residents who 
were hospitalized elsewhere need to be 
excluded. 
 
Exclusion 
Criteria 
Individuals without valid 
Saskatchewan Health Insurance; 
Must be covered for time period of 
interest (last discharge date to service 
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 date).  Using the “service date” means 
that the reporting is based on the 
assessment date for a service (in this 
case, assessment for drugs).   
 
If no coverage, the person may have 
died or moved out of province.  In 
either case, they should not be included 
in the cohort. 
 
Individuals with no information 
on sex and date of birth; 
 
Such information is necessary for 
proper data analysis, and thus where 
information is missing the individuals 
need to be excluded. 
 
Individuals identified as 
Registered Indians; 
 
Individuals with Registered Indian 
status were identified and excluded 
since their prescription drugs are 
covered by the federal government and 
are not (consistently) captured in the 
provincial Prescription Drug Plan 
Historical Claims dataset. 
 
Individuals with no information 
available in the Prescription 
Drug Plan Historical Claims 
Database; 
 
Because the purpose of the study is to 
examine drug dispensing patterns, 
residents without drug data need to be 
excluded (presumably because their 
prescription drugs are covered 
federally). 
 
Individuals who died in hospital 
of their stroke event. 
 
The purpose of the study is to examine 
secondary stroke care, and this is 
nonexistent in individuals who did not 
survive their stroke event. 
 
 
Appendix B contains the complete Researcher Documentation (see Table 1.1 for 
definition) as used in all HQC analyses.  This document was created based on HQC methodology 
and documentation format, but the content was newly created for this study; there was no pre-
existing stroke indicator methodology available at the HQC.  Refer to Appendix B for a thorough 
understanding of the creation of the Stroke and TIA Patient Cohort. 
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 3.5 Technical Definitions 
The following variables were utilized in this study.  The definitions given here are taken 
from the HQC Quality Insight Technical Appendix (75) except for definitions necessary for the 
quality of care indicators developed in this study.   
 
3.5.1 Correlates Used in Analysis 
 
Sex 
The indication of ‘male’ or ‘female’ in the Person Registry System (PRS) was used as the 
indicator for sex. 
 
Age 
Birth month and birth year were supplied in the version of the PRS database accessed by the 
HQC.  The 15th day of the month was assigned as the birth day for purposes of calculating age. 
The reference date used for calculating age (that is, the date from which days were counted back 
to the birth date) was the date of admission into the hospital for a stroke or TIA. 
 
Regional Health Authority (RHA) 
In the version of the Person Registry System accessed by the HQC, there were multiple historical 
records per individual that identified their RHA(s) of residence over time.  For analysis of the 
indicators by RHA within a specified period of time, individuals were assigned to the RHA in 
which they resided for the greatest number of days during that period.  If RHA information was 
missing on this date, the search was extended to plus and minus six months from this date and 
RHA was assigned where the person lived most in this period. If RHA in this period could not be 
found, RHA information was treated as missing.  
Since individuals in Saskatchewan may have been hospitalized in a different RHA from 
which they live, it was also important to assign RHA to individuals according to hospital.  Thus, 
the individuals were assigned a second RHA according to the RHA of their last hospital of 
discharge.  Again, if no hospital RHA was found, the RHA information was treated as missing.   
 
Urban/Non-Urban 
To assign the urban or non-urban place of residence classification to individual PRS records, the 
Health Information Solutions Centre (HISC) at the Ministry of Health linked postal codes to 
Statistics Canada census geographic areas. Individuals that resided, or institutions located, in a 
 29
 census metropolitan area or census agglomeration as defined by Statistics Canada were 
considered as urban; otherwise they were classified as non-urban. 
 
Income Quintile  
To assign income quintiles to individual PRS records, the HISC at the Ministry of Health linked 
postal codes to census geographical data at the level of the dissemination area (DA) which is the 
lowest level of geography that Statistics Canada disseminates census data. In doing so the postal 
code conversion file was linked using the Postal Code Conversion File Plus (PCCF+) software.  
Income quintiles were based on average 2001 Census household income, with adjustment for 
household size for the linked census DAs. In the file received by HQC, 14% of individuals had 
missing income quintile (INCQTL) information due to suppressed census information for DAs 
with population less than 250. The HQC was able to calculate imputed values of INCQTL for 
most cases with missing INCQTL values, such that in the end there were only about 0.5% of 
individuals province-wide with no value for INCQTL. 
 
Hospital Category 
Hospital categories were used as classification variables.  The list of hospitals and their 
categories were obtained from the Ministry of Health.  Hospitals were categorized into the 
following types: Provincial hospitals (of which there are 6 in the province), Regional (7), District 
(9), Community (109), Northern (4).  The full listing is available in Appendix C.  Due to the 
nature of the indicators, a hospital category was assigned to each patient based their last hospital 
of discharge. 
 
Previously On Drugs 
Taking into consideration the type of medications being investigated in this study, it was possible 
that patients were taking the drugs of interest before their stroke event.  It was therefore 
important to identify these patients for the analysis.  Using the pharmaceutical dispensing data, 
patients were identified and flagged if they filled a prescription for the medication of interest 
prior to their admission date.    
 
Length of Stay 
Length of stay was the amount of time a patient was admitted to hospital for their stroke event.  
A patient’s length of stay was determined by counting the number of days they were hospitalized 
from their first admission date for stroke, to their final discharge date.  For example, if a person 
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 was admitted to hospital on November 1, 2002, and discharged on November 15, 2002, their 
length of stay was 14 days.   
 
Fiscal Year 
Fiscal year in this study implied that the service date for a patient fell between April 1st of one 
year, and March 31st of the next year (2001/02-2007/08).  For example, if a person was 
discharged from hospital on May 1st, 2005, their 3-day service date would be May 4th, 2005.  
Therefore, this patient’s fiscal year for all 3-day indicators was 2005/06.  Fiscal years were 
assigned differently for the 3-day and 90-day indicators, meaning that a patient might be in one 
fiscal year at 3 days, and the next fiscal year at 90 days.       
 
3.6 Drug Indicators 
The indicators included within this section are numbers 2.2 vii., 2.3 ii., and 2.6 i. from 
Table 3.1 as they each involved drug care for secondary stroke prevention.  Following 
methodological decisions pertaining to adapting the definitions to available data in 
Saskatchewan, a list of the revised stroke/TIA quality indicators for medications was created, 
and is presented in full form in Appendix D.  Appendix B contains the complete Researcher 
Documentation for the development of the 3-day and 90-day denominators and numerators for 
the drug indicators (see Table 1.1 for definitions).   
 
3.6.1 Medication-Related Process of Care Indicator Denominators 
For each of the medication-related indicators, the assessment for drugs was to take place 
after “discharge from acute care” (see Table 3.1).  A decision was made to make an assessment 
for medication at both 3 and 90 days post-discharge.  The reason for doing so was because of the 
difference in what was being measured.  The calculation made at the 3-day period assessed the 
hospital-based secondary stroke prevention processes of care.  If an individual was dispensed a 
medication within 3 days of discharge, it was most likely that the prescription was provided by a 
hospital-based physician, and therefore reflected hospital-based processes for initiating 
secondary stroke prevention.  On the other hand, the calculation made at the 90th day post-
discharge was an assessment of the ongoing attention to secondary stroke prevention which 
reflected processes involving the primary care/community based physician.  If an individual was 
taking medication at the 90th day following discharge, it can in part be attributed to the primary 
 31
 care physician ensuring the patient has had their prescription renewed/updated and understands 
the importance of the medication.   
In developing the separate denominators for the drug indicators, the general cohort 
criteria were used as well as additional inclusion and exclusion criteria as shown in Table 3.4 
.    
Table 3.4: Medication-Related Indicator Denominators Inclusion and Exclusion Criteria 
 
Medication 
Denominators 
Inclusion Criteria Exclusion Criteria 
3-Day Drug 
Denominator 
• Inclusion in the Stroke and 
TIA Patient Cohort; 
• Individuals with Saskatchewan 
Health Insurance coverage 
from the date of hospital 
discharge, through 3 days post 
discharge. 
 
• Individuals who died before 3 
days post-discharge; 
• Individuals whose fiscal year at 
3 days post-discharge falls into 
2008/09, which is outside of the 
study period.  See Appendix B 
for further explanation and 
rationale. 
 
90-Day Drug 
Denominator 
• Inclusion in the Stroke and 
TIA Patient Cohort; 
• Individuals with Saskatchewan 
Health Insurance coverage 
from the date of hospital 
discharge through to 15 days 
before the 90th day post-
discharge (i.e. through the 75th 
day after discharge).  See #3c 
in Appendix B for rationale. 
 
• Individuals who died before 90 
days post-discharge; 
• Individuals whose fiscal year at 
90 days post-discharge falls into 
2008/09, which is outside of the 
study period.  See Appendix B 
for further explanation and 
rationale. 
 
3-Day Atrial 
Fibrillation Drug 
Denominator 
• Inclusion in the 3-Day Drug 
Denominator; 
• Diagnosis of atrial fibrillation 
on hospital discharge record.  
 
 
90-Day Atrial 
Fibrillation Drug 
Denominator 
• Inclusion in the 90-Day Drug 
Denominator; 
• Diagnosis of atrial fibrillation 
on hospital discharge record.  
 
 
 
3.6.1.1 Drug Indicator Denominator Development 
The development of the drug indicator denominators (i.e. 3-day, 90-day, atrial 
fibrillation) are outlined in the examples contained in Figures 3.1, 3.2, and 3.3 below. 
 32
 Figure 3.1: Development of the 3-day stroke/TIA patient cohort based on the date of admission 
Hospital discharge record with stroke/TIA as the most responsible diagnosis
[ICD-10-CA codes I60 (excl. I60.8), I61, I63 (excl. I63.6), I64, H34.1, G45 (excl.G45.4), H34.0] 
between April 1, 2001 and March 31, 2008
n =13,330
Exclude all nested/transfer records after combining into
one Episode Of Care (EOC) record per stroke/TIA case
n = 978
n = 12,352 records 
Exclude Saskatchewan residents 
hospitalized out-of-province
n = 200
n = 12,125 records 
Exclude episodes where persons died in hospital
n = 1,737n = 10,388 records 
Exclude episodes were persons were age < 18 years
n = 36n = 10, 352 records 
Exclude episodes where persons were Registered Indians
n = 521n = 9,831 records 
Exclude episodes where persons had no information 
on sex or date of birth
n = 0
n = 9,831 records 
Exclude episodes that do not meet the criteria for health
plan coverage in the 3-day drug denominator definition
n = 2
n = 9,761 records 
3-Day Drug 
Denominator
n = 9,575 records 
Exclude episodes where persons had no information in 
drug file
n = 116
Exclude episodes that occurred outside the 2007/08 
fiscal year at 3 days post-discharge
n = 70
Exclude episodes where persons died before 3 days
post-discharge
n = 68
n = 9,763 records 
n = 9,645 records 
Search for all other hospital admission/discharge records that occurred 
within one day of each other for each stroke/TIA case
Link together all records starting with the first admission date that had 
the most responsible diagnosis of stroke/TIA
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 Figure 3.2: Development of the 90-day stroke/TIA patient cohort based on the date of admission  
Exclude all nested/transfer records after combining into
one EOC record per stroke/TIA case
n = 978
n = 12,352 records 
Exclude Saskatchewan residents 
hospitalized out-of-province
n = 200
n = 12,125 records 
Exclude episodes where persons died in hospital
n = 1,737n = 10,388 records 
Exclude episodes were persons were age < 18 years
n = 36n = 10, 352 records 
Exclude episodes where persons were Registered Indians
n = 521n = 9,831 records 
Exclude episodes where persons had no information 
on sex or date of birth
n = 0
n = 9,831 records 
Exclude episodes that do not meet the criteria for health
plan coverage in the 90-day drug denominator definition
n = 10
n = 9,158 records 
Exclude episodes where persons had no information in 
drug file
n = 106
Exclude episodes where persons died before 90 days
post-discharge
n = 663
n = 9,168 records 
Hospital discharge record with stroke/TIA as the most responsible diagnosis
[ICD-10-CA codes I60 (excl. I60.8), I61, I63 (excl. I63.6), I64, H34.1, G45 (excl.G45.4), H34.0] 
between April 1, 2001 and March 31, 2008
n =13,330
90-Day Drug 
Denominator
n = 8,722 records 
n = 9,052 records 
Exclude episodes that occurred outside the 2007/08 
fiscal year at 90 days post-discharge
n = 330
Search for all other hospital admission/discharge records that occurred 
within one day of each other for each stroke/TIA case
Link together all records starting with the first admission date that had 
the most responsible diagnosis of stroke/TIA
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 Figure 3.3: Development of the 3-day stroke/TIA atrial fibrillation patient cohort based on the 
date of admission  
Hospital discharge record with stroke/TIA as the most responsible diagnosis
[ICD-10-CA codes I60 (excl. I60.8), I61, I63 (excl. I63.6), I64, H34.1, G45 (excl.G45.4), H34.0] 
between April 1, 2001 and March 31, 2008
n =13,330
3-Day Drug 
Denominator
n = 9,575records 
Identify hospital discharge records with atrial fibrillation present as a diagnosis
[ICD-10-CA code I48.0]
n = 1,705
Method same as for 3-day stroke/TIA patient cohort
(Figure 3.3)
Exclude episodes that do not include a diagnosis of
atrial fibrillation
3-Day Atrial Fibrillation
Drug Denominator
n = 1,288 records 
 
 
 
3.6.2 Drug Indicator Numerators   
 
3.6.2.1 Drug Use 
Each of the drug indicators was based on the ascertainment of whether the stroke/TIA 
patients had been dispensed sufficient supply of the drug of interest to be able to be taking it on a 
given day (3rd or 90th) after discharge from hospital.  The HQC had previously developed 
methodology for estimating sufficient drug supply, and the same methodology was used for this 
project.  For complete explanation of methodology, refer to the excerpts from the HQC Quality 
Insight Technical Appendix (75) attached as Appendix E and Appendix F. 
Essentially, a calculation was made as to whether the patient would have sufficient drug 
supply from their most recent dispensing date (pharmaceutical dispensing data) to last until the 
date of interest (3-day, 90-day).  This was done by approximating the number of pills taken daily 
by the patient (based on the amount of drug dispensed and previous dispensing dates), and their 
most recent prescription date.  If the time from the last dispensing date to the, for example, 90th 
day post-discharge was fewer than the number of days of available drug, then the patient was 
said to be “on” the particular medication at the 90th day post-discharge.  Conversely, if the 
available drug amount indicated that the patient ran out of pills before the 90th day post-
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 discharge, then the patient was said to be “not on” the particular medication at the 90th day post-
discharge.   
If there was no previous dispensing data for the patient (no information on the 
approximate number of pills taken per day), the minimum pill frequency was set at 1 pill per day.  
Even though 1 pill per day may not be enough to be considered a “therapeutic dose” for all 
drugs, there are potential reasons a patient may be on a lower dose (i.e. doctor adjusting a 
patient’s drug regimen).  Thus, it seemed 1 pill per day was a reasonable standard.   
 
Drug Numerators Inclusion Criteria 
• Inclusion in the appropriate denominator; 
• “On” the medication of interest according to the outlined methodology. 
 
 
3.6.2.2 Drug Indicator Categories 
 For each of the three drug categories of interest in this project (antihypertensives, 
antilipidemics, anticoagulants), there was one major drug class in each that was calculated 
separately (statin, angiotensin-converting enzyme inhibitors (ACEI), warfarin).  This was done 
because the information on these drug classes was of major importance for clinical applicability. 
 
Antihypertensive Drug Categories 
• All antihypertensive medications 
• Only ACEI medications 
 
Antilipidemic Drug Categories 
• All antilipidemic medications 
• Only statin medications 
 
Anticoagulant Drug Categories 
• All anticoagulant medications 
• Only warfarin medications 
 
 
3.7 Indicators Using Laboratory Data 
The indicators included within this section are numbers 2.3 iii., iv., v., and 2.6 v. from 
Table 3.1 as they each involved laboratory tests that are important in secondary stroke 
prevention.  Following methodological decisions, a list of the revised stroke/TIA quality 
indicators for laboratory tests was created, and is presented in Appendix G.  Appendix B 
contains the complete Researcher Documentation (including criteria and rationale) for the 
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 development of the denominators and numerators for the laboratory indicators (see Table 1.1 for 
definitions).   
An important note is that laboratory data could only be acquired for the Saskatoon RHA 
and the Regina Qu’Appelle RHA.  It is because of this that only people who live in these RHAs 
were included in these indicator calculations. 
 
3.7.1 Low Density Lipoprotein Cholesterol (LDL-C) Indicators  
 
3.7.1.1 LDL Indicator Denominators 
For the LDL indicators, the assessment for LDL-C tests was to take place at “3-months 
post-stroke”.  To ensure there was adequate coverage of the tests given around the 3-month 
period, the timeframe was extended to 2-4 months.   
Following the initial identification of the individuals who met the criteria, it became 
apparent that the number of people was too small for the indicator calculations.  Thus, the 
percentage of people given an LDL test at 3 months was calculated using the 2-4 month criteria, 
but the timeframe was expanded to 2-12 months for the actual indicator calculations.  See Table 
3.5 for all denominator inclusion and exclusion criteria.  
 
Table 3.5: LDL-C Indicator Denominators Inclusion and Exclusion Criteria 
 
LDL 
Denominators 
Inclusion Criteria Exclusion Criteria 
LDL 2-4 Month 
Denominator 
• Inclusion in the 90-Day Drug 
Denominator; 
• Individuals who live in the 
Saskatoon RHA or the Regina 
Qu’Appelle RHA. 
 
 
LDL 2-12 Month 
Denominator 
• Same as LDL 2-4 Month 
Denominator 
 
 
LDL Test Result 
Indicator 
Denominator 
• Inclusion in the LDL 2-12 
month denominator; 
• Individuals who had an  
LDL-C test 2-12 months 
following their stroke event. 
 
• Individuals with an LDL test 
record with a missing result; 
• If there was more than one 
test result within the 
timeframe, only the most 
recent was used – all others 
were deleted. 
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 3.7.1.2 LDL Indicator Numerators 
 There were five separate indicators involving the LDL-C test.  Each indicator numerator 
involved different inclusion and exclusion criteria as shown in Table 3.6. 
 
Table 3.6: LDL-C Indicator Numerators Inclusion and Exclusion Criteria 
 
LDL Numerators Inclusion Criteria Exclusion Criteria 
LDL Test at 2-4 
Months 
• Inclusion in the LDL 2-4 
month denominator; 
• Individuals with an available 
LDL test result 2-4 months 
post-discharge. 
• Individuals with an LDL test 
record with a missing result; 
• If there was more than one 
test result within the 
timeframe, only the most 
recent was used – all others 
were deleted. 
 
LDL Test at 2-12 
Months 
• Fulfillment of the criteria, and 
inclusion in the LDL 2-12 
month denominator; 
• Individuals with an available 
LDL test result 2-12 months 
post-discharge. 
 
• Same as LDL Test at 2-4 
Months. 
 
LDL Result 1.8-2.5 • Inclusion in the LDL test 
result indicator denominator; 
• Individuals with an LDL test 
result 1.8-2.5. 
 
 
LDL Result <2.0 • Inclusion in the LDL test 
result indicator denominator; 
• Individuals with an LDL test 
result less than 2.0. 
 
 
LDL Result >2.0 • Inclusion in the LDL test 
result indicator denominator; 
• Individuals with an LDL test 
result greater than 2.0. 
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 3.7.2 INR Indicators  
 
3.7.2.1 INR Indicator Denominators 
For the INR indicator, the main criterion for inclusion was that the individual had to be 
taking warfarin.  In developing the denominators for these indicators, this criterion was used as 
well as additional inclusion and exclusion criteria as shown in Table 3.7.  
 
Table 3.7: INR Indicator Denominators Inclusion and Exclusion Criteria 
 
INR 
Denominators 
Inclusion Criteria Exclusion Criteria 
INR Test 
Denominator 
• Inclusion in the 90-Day Drug 
Denominator; 
• Individuals who live in the 
Saskatoon RHA or the Regina 
Qu’Appelle RHA; 
• Individuals who were “On” 
warfarin (according to the drug 
indicator criteria) at either 3-days 
or 90-days post-discharge. 
 
 
INR 2-4 Month 
Denominator 
• Inclusion in the INR test 
Denominator; 
• Individuals who had an INR test 2-
4 months following their stroke 
event. 
 
• Individuals with an INR 
test record with a missing 
result; 
• If there was more than one 
test result within the 
timeframe, only the most 
recent was used – all 
others were deleted. 
 
INR 5-7 Month 
Denominator 
• Inclusion in the INR Test 
Denominator; 
• Individuals who had an INR test 5-
7 months following their stroke 
event. 
 
• Same as INR 2-4 Month 
Denominator. 
INR 11-13 
Month 
Denominator 
• Inclusion in the INR Test 
Denominator; 
• Individuals who had an INR test 
11-13 months following their 
stroke event. 
• Same as INR 2-4 Month 
Denominator. 
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 3.7.2.2 INR Indicator Numerators 
For the INR indicators, the assessment for INR tests was to take place at 3 months, 6 
months, and 12 months post-stroke.  To ensure there was adequate coverage of the tests given 
around these time periods, the timeframe for each was extended by one month (i.e. for 3 months, 
the timeframe was 2-4 months).   
The numerators called for inclusion of individuals who had an INR test result “in 
therapeutic range”.  According to the Best Practice Guidelines (4), the target INR for patients on 
warfarin should be 2.5, range 2.0-3.0.  Thus, this range was used for the indicators.  See Table 
3.8 for inclusion and exclusion criteria for all INR numerators. 
 
Table 3.8: INR Indicator Numerators Inclusion and Exclusion Criteria 
 
INR Numerators Inclusion Criteria Exclusion Criteria 
INR Test at 2-12 
Months 
• Inclusion in the INR test 
denominator; 
• Individuals with an INR test 
result 2-12 months post-
discharge. 
 
• Individuals with an INR test 
record with a missing result; 
• If there was more than one 
test result within the 
timeframe, only the most 
recent was used – all others 
were deleted. 
 
INR 2.0-3.0 at 2-4 
Months 
• Inclusion in the INR 2-4 
month denominator; 
• Individuals with an INR test 
result 2.0-3.0. 
 
 
INR 2.0-3.0 at 5-7 
Months 
• Inclusion in the INR 5-7 
month denominator; 
• Individuals with an INR test 
result 2.0-3.0. 
 
 
INR 2.0-3.0 at 11-
13 Months 
• Inclusion in the INR 11-13 
month denominator; 
• Individuals with an INR test 
result 2.0-3.0. 
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 3.8 Outcome Variables and Correlates   
 Table 3.9 describes the outcome variables used in logistic regression.  Table 3.10 
describes the correlates used in logistic regression.  Cut points for categorical variables were 
selected based on their clinical significance and data availability. 
 
Table 3.9: Description of the Outcome Variables 
 
Outcome Variable Description Variable Coding 
Allhypflag90  
(Antihypertensives 
at 90 Days) 
Dichotomous variable;  
on or not on antihypertensives 
(including ACEIs) at 90 days 
post-discharge. 
0 = “not on” antihypertensives 
1 = “on” antihypertensives  
Lipstatflag90 
(Antilipidemics at 
90 Days) 
Dichotomous variable;  
on or not on antilipidemics 
(including statins) at 90 days 
post-discharge. 
0 = “not on” antilipidemics 
1 = “on” antilipidemics 
Allcoflag90 
(Anticoagulants at 
90 Days) 
Dichotomous variable;  
on or not on anticoagulants 
(including warfarin) at 90 days 
post-discharge. 
0 = “not on” anticoagulants 
1 = “on” anticoagulants 
Flag10 (LDL) 
(LDL-C Test, 2-12 
Months)  
Dichotomous variable; 
given or not given an LDL-C test 
between 2-12 months post-
discharge. 
0 = not given a test 
1 = given at least one test 
 
Testflag (INR) 
(INR Test, 2-12 
Months) 
Dichotomous variable: 
Given or not given an INR test 
between 2-12 months post-
discharge. 
0 = not given a test 
1 = given at least one test 
 
 
 
Table 3.10: Description of the Correlates 
 
Correlates Description Variable Coding 
Sex Dichotomous variable;  
male or female. 
0 = Male (ref) 
1 = Female 
Age Categorical variable with 
3 levels that indicate the 
age group of the person 
(in years) at the time of 
their stroke/TIA. 
0 = 18-74 
1 = 75-84 (ref) 
2 = 85+ 
RHA of Residence Categorical variable with 
11 levels that indicate the 
RHA of residence of the 
person during the time 
1 = “01 Sun Country” 
2 = “02 Five Hills” 
3 = “03 Cypress” 
4 = “04 Regina Qu’Appelle” 
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 period of interest (i.e. 90-
day). 
5 = “05 Sunrise” 
6 = “06 Saskatoon” (ref) 
7 = “07 Heartland” 
8 = “08 Kelsey Trail” 
9 = “09 Prince Albert Parkland” 
10 = “10 Prairie North” 
11-13 = “15 Northern Saskatchewan” 
Income Quintile Categorical variable with 
5 levels that indicate the 
person’s income quintile. 
1 = “Lowest” (ref) 
2 
3 
4 
5 = “Highest” 
Urban/Non-Urban Dichotomous variable; 
urban or non-urban.  
0 = “Urban” (ref) 
1 = “Non-Urban” 
Hospital Category Categorical variable with 
4 levels indicating the 
hospital category of the 
person’s hospital of 
discharge. 
1 = “Provincial” (ref) 
2 = “Regional” 
3 = “District” 
4 or 5 = “Community and Northern” 
Length of Stay Count variable that 
indicates the total length 
of stay in hospital for 
each stroke/TIA episode. 
0 = 0-10 days (ref) 
1 = 11-30 days 
2 = 31+ days 
Multiple Stroke/TIA Dichotomous variable 
that indicates if the 
stroke/TIA episode is a 
multiple.  “Multiple” 
meaning that a patient 
had another stroke/TIA 
within two years of their 
first episode.  See 
Appendix B for further 
description and rationale. 
0 = Not a multiple stroke/TIA (ref) 
1 = Multiple stroke/TIA  
Previously on Drugs Dichotomous variable 
that indicates if the 
individual was on a 
specific drug before their 
stroke/TIA event. 
0 = Not previously on drug (ref) 
1 = Previously on drug 
 
 
3.9 Ethics Approval and Privacy 
This study was approved by the University of Saskatchewan Biomedical Research Ethics 
Board (Bio-REB #09-105).  The study was also approved by the Regina Qu’Appelle Health 
Region (RQHR Project REB #09-34). 
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 Considering this study used secondary data that has been de-identified, there were not 
many anticipated ethical issues.  One potential problem may have been re-identification of 
patients through data matching.  The mitigation to this is that only encrypted and transformed 
identifiers were used in the data, and results were not reported based on fewer than 6 individuals.  
A confidentiality agreement was signed at the HQC, and any attempt to re-identify would have 
resulted in denial of further access to the data.   
 
3.10 Data Analysis 
 
3.10.1 Question One: Indicators of the Quality of Secondary Stroke Prevention 
Descriptive measures were the primary analytic strategy for this question.  Frequencies 
for each of the correlates (except Previously on Drugs) seen in Table 3.10 were calculated to 
define and describe the general stroke/TIA cohort.   
Each indicator was calculated using all stroke/TIA, as well as for hemorrhagic stroke.  
Treatment for stroke may vary by the type of stroke an individual has, and therefore it was 
important to calculate the overall indicators separately for hemorrhagic stroke.  Due to the small 
percentage of people who have a hemorrhagic stroke, this indicator was calculated for the entire 
province only (not for separate RHAs).   
 
3.10.1.1 Medication-Related Process of Care Indicators 
For each specific part of the question (each drug indicator), subsets of the cohort were 
identified according to the numerator and denominator descriptions outlined in Section 3.6.1 and 
3.6.2.  Following the selection of the cohort subsets, the drug indicators were calculated 
according to fiscal year at service date (3 or 90 days post-discharge).  
 
3.10.1.2 LDL Intermediate Outcome Indicators 
The cohort subset was identified according to the numerator and denominator 
descriptions outlined in Section 3.7.1.  Individuals were included in reporting of the indicator for 
a particular fiscal year according to the date at 3 months post-discharge. 
 
3.10.1.3 INR Intermediate Outcome Indicators 
 The cohort subset was identified according to the numerator and denominator 
descriptions outlined in Section 3.7.2.  The indicator was calculated according to the 3, 6 and 12 
month timeframes. 
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 3.10.2 Question Two: Correlates Associated with Receiving Secondary Stroke Prevention  
 Logistic regression was the primary analytic strategy.  For each of the outcome indicator 
variables listed in Table 3.9, logistic regression was used to identify the factors related to 
receiving the secondary stroke prevention described by the outcome indicator. 
 Univariate analysis was first performed for each of the correlates listed in Table 3.10.  
The age and length of stay variables were tested for linearity using a macro available at the HQC.  
The macro plotted a graph, and if the points were in a straight line, the variable was said to be 
linear.  If the points were not straight, the variable was said to be non-linear and had to be made 
into a categorical variable.  Both age and length of stay were found to be non-linear, and thus 
were made into categorical variables.  Therefore, all variables used in the model were categorical 
in nature.  Any variable whose univariate test had a p-value<0.25 was kept as a candidate for the 
multivariable model along with all variables of known clinical importance. 
 All of the variables identified from univariate analysis were then fitted into a 
multivariable model.  Variables that were statistically significant (p-value<0.05) and/or clinically 
important (i.e. sex, age) were retained in the model as main effects.  If any one of the categories 
for the variables achieved statistical significance the entire variable was retained in the model. 
 Once main effects were established for each of the five models, the interaction term 
sex*age was tested for statistical significance.  This interaction term was selected for testing 
because it is clinically very important to identify differences in care by both sex and age.  During 
data exploration, other interaction terms were considered for regression analysis, but they were 
either clinically not meaningful or not easily interpretable.  Further, there was no literature 
reporting other plausible interaction terms, and therefore no others were tested in the logistic 
model.  The interaction term sex*age was retained in the final model if the likelihood ratio test 
value was statistically significant at the alpha is less than 0.05 level.  Interaction terms were also 
treated as categorical variables.   
 After all main effects and interaction terms had been tested for statistical significance, a 
final model was run that only included the statistically significant variables.  To assess the fit of 
the model, the Hosmer and Lemeshow Goodness-of-Fit test was performed on each of the 
models.  The strength of the association (odds ratio) for each of the retained variables were 
subsequently calculated.   
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 3.10.3 Question Three: Geographical Variation in Secondary Stroke Prevention by 
Saskatchewan Regional Health Authority Areas 
A contrast model in logistic regression was utilized to compare the Regional Health 
Authority (RHA) areas.  Basically, each RHA was compared to a group comprising all other 
RHAs in the province for each of the indicators.  The rationale for using this type of comparison 
group is that it gives proper weight to the distribution of the province’s population, which is not 
the case when using a provincial average.  If there was variation in an RHA, the contrast showed 
statistical significance. 
When calculating the contrasts, there were occasions when a “0 cell” (no individuals in 
the numerator) or “100% cell” (same number of individuals in the numerator and denominator) 
appeared in one or more of the fiscal years.  When this occurred, one of two methods was used to 
account for these problems: 
1) If there were <6 people in the denominator, the RHA was removed from the 
contrast model analysis. 
2) If there were >6 people in the denominator, a “work around” process developed 
at the HQC was utilized to solve the problem.  Very basically, a series of 
statistical calculations were made including the problem RHA within larger 
RHAs to properly run the contrast model.  
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 CHAPTER 4: RESULTS 
 
4.1 Description of the Study Population 
 To acquire an understanding of the population hospitalized in Saskatchewan for 
stroke/TIA, descriptive statistics by stroke etiology and correlates used in the analysis were 
calculated and are presented in Tables 4.1 and 4.2 respectively.  All variables are categorical, and 
the frequency and the percentage are presented for each of the categories. 
There were many more ischemic strokes than hemorrhagic strokes (89.1% vs. 10.8%; 
Table 4.1), which is roughly consistent with the expected 80% vs. 20% split described in the 
literature (1).  The majority of people in the “stroke cohort” (i.e., the study population) 
experienced a cerebrovascular accident event that was labeled as stroke (66.8%) by the attending 
acute care physicians, but TIA events accounted for about one-third (33.3%) of the total study 
population.  Only 13.5% of the people who experienced a stroke or TIA also had a diagnosis of 
atrial fibrillation.  The total number of people included in the study population was 9,645.   
 
Table 4.1: Description of stroke etiology for the Stroke/TIA Patient Cohort 
 
Episode Type Frequency Percentage 
of Stroke 
Percentage of 
Total Stroke/TIA 
Stroke 
• Ischemic Stroke 
• Hemorrhagic Stroke 
6438
5741
695
100%
89.1%
10.8%
66.8%
TIA 3207 33.3%
Stroke/TIA cases with Atrial Fibrillation 1302 13.5%
Total Stroke/TIA 9645 100%
 
Table 4.2 indicates that the number of males and females in the study population was 
almost even, as was the distribution of people living in an urban or non-urban setting.  The 
majority of stroke/TIA events occurred in individuals over the age of 65 (82.5%). The largest 
number of stroke/TIA episodes took place in the 75-84 age-group (37.3%), and the fewest took 
place in the 18-49 age-group (4.8%).  As anticipated, the largest number of people who had a 
stroke/TIA lived in the Saskatoon (25.0%) or Regina Qu’Appelle (21.2%) health regions which 
are the most populous in the province.  The majority of stroke/TIA episodes were hospitalized in 
a provincial hospital (47.4%), while 19.1% were in a regional hospital, 12.0% were in a district 
hospital, and 21.5% were in a community or northern hospital.  For 60.9% of the patients, the 
hospital stay was1-10 days, while 23.6% stayed for 11-30 days, and 15.5% had lengths of stay 
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 greater than 31 days.  In this study population, 93.8% of the episodes were “first strokes” while 
6.2% were “multiple strokes” (i.e. second, third, fourth, etc. strokes). 
 
Table 4.2: Distribution of Correlates in the Study Cohort 
 
Correlates Category Frequency Percentage (%)
Sex Male 
Female 
4782  
4863 
49.6%
50.4%
Age 18-49 
50-64 
65-74 
75-84 
85+ 
465 
1225  
2025 
3595 
2335 
4.8%
12.7%
21.0%
37.3%
24.2%
RHA of Residence Sun Country 
Five Hills 
Cypress 
Regina Qu’Appelle 
Sunrise 
Saskatoon  
Heartland 
Kelsey Trail 
Prince Albert Parkland 
Prairie North 
Northern Saskatchewan 
655 
738 
640  
2041 
874 
2396 
563 
568 
614 
474 
59 
6.8%
7.7%
6.6%
21.2%
9.1%
25.0%
5.9%
5.9%
6.4%
4.9%
0.6%
Income Quintile 1 (Lowest) 
2 
3 
4 
5 (Highest) 
1673 
2092 
1859 
1535 
1241 
19.9%
25.0%
22.1%
18.3%
14.8%
Urban/Non-Urban Urban 
Non-Urban 
4842 
4758 
50.4%
49.6%
Hospital Category Provincial 
Regional 
District 
Community and Northern 
4575 
1838  
1156  
2074  
47.4%
19.1%
12.0%
21.5%
Length of Stay 1-10 days 
11-30 days 
31+ days 
5873 
2279 
1493  
60.9%
23.6%
15.5%
Multiple Stroke/TIA Not a multiple stroke/TIA 
Multiple stroke/TIA 
9047 
598 
93.8%
6.2%
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 4.2 Question One: Indicators of the Quality of Secondary Stroke Prevention  
  
4.2.1 Medication-Related Process of Care Indicators  
 The results for the process of care indicators show the percent of stroke/TIA cases that 
were dispensed medications for secondary stroke event prevention such that they had a daily 
supply of the medication at 3 and 90 days post-discharge.  All results are presented by fiscal 
year.  The results in fiscal year 2001/02 were unreliable due to missing information, and thus 
removed from all figures.   
 
4.2.1.1 Antihypertensive Indicator Results – All Stroke/TIA 
 Figures 4.1 and 4.2 present the results for the 3-day and 90-day antihypertensive 
indicators.  It should be noted that ACEIs are a major antihypertensive drug class subset, and 
therefore separate results are shown on the figures.  Figure 4.1 shows the percentage of 
stroke/TIA patients on ACEIs and antihypertensives at 3 days by fiscal year, while Figure 4.2 
illustrates the percentage of patients on ACEIs and antihypertensives at 90 days by fiscal year.   
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 Figure 4.1: Percentage of stroke/TIA patients on ACEI or any antihypertensive medication 
(including ACEI) at 3 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antihyps Percent 64.6 62.3 66.5 64.8 68.3 70.3
 95% CI 62.1-67.0 59.6-64.8 63.9-68.9 62.3-67.3 65.8-70.8 67.7-72.8
    
ACEI Percent 38.4 35.7 36.7 37.0 38.8 40.3
 95% CI 35.9-40.9 33.2-38.3 34.2-39.3 34.5-39.6 36.2-41.4 37.6-43.0
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 Figure 4.2: Percentage of stroke/TIA patients on ACEI or any antihypertensive medication 
(including ACEI) at 90 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antihyps Percent 61.5 59.8 62.8 60.8 65.1 63.8
 95% CI 58.9-64.2 57.1-62.4 60.1-65.4 58.2-63.4 62.5-67.7 61.0-66.4
    
ACEI Percent 33.9 34.5 34.3 34.2 37.6 35.0
 95% CI 31.4-36.6 31.9-37.1 31.7-37.0 31.7-36.8 35.0-40.3 32.4-37.7
 
 
From fiscal year 2002/03 to 2007/08 there was a statistically significant increase (<10%) 
in the number of patients on antihypertensives at 3 days post-discharge.  This change is indicated 
by the non-overlapping confidence intervals in the first and last years.  The 90-day results do not 
show this same change over time, and instead the results appear fairly constant.  In the most 
recent fiscal year, 70.3% of all stroke/TIA patients were on antihypertensives at 3 days, and 
63.8% were on medication at 90 days.  
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 4.2.1.2 Antihypertensive Indicator Results – Hemorrhagic Stroke 
Figures 4.3 and 4.4 present the results for the 3-day and 90-day antihypertensive 
indicators for patients who had a hemorrhagic stroke.  Again, it should be noted that ACEIs are a 
major antihypertensive drug class subset, and therefore separate results are shown on the figures.  
Figure 4.3 shows the percentage of hemorrhagic stroke patients on ACEIs and antihypertensives 
at 3 days by fiscal year.  Figure 4.4 illustrates the percentage of hemorrhagic stroke patients on 
ACEIs and antihypertensives at 90 days by fiscal year. 
 
Figure 4.3: Percentage of hemorrhagic stroke patients on ACEI or any antihypertensive 
medication (including ACEI) at 3 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antihyps Percent 41.1 52.9 49.6 42.6 51.4 51.1
 95% CI 31.1-51.6 42.8-62.8 40.0-59.1 32.8-52.8 41.6-61.1 40.5-61.5
    
ACEI Percent 21.1 29.8 28.3 25.7 30.3 25.5
 95% CI 13.4-30.6 21.2-39.6 20.2-37.6 17.6-35.4 21.8-39.8 17.1-35.6
 
 
 51
 Figure 4.4: Percentage of hemorrhagic stroke patients on ACEI or any antihypertensive 
medication (including ACEI) at 90 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antihyps Percent 44.7 51.0 44.4 50.0 51.9 60.0
 95% CI 33.9-55.9 40.8-61.1 34.5-54.8 39.4-60.6 42.0-61.6 49.4-69.9
    
ACEI Percent 18.8 32.0 26.3 26.1 30.6 31.6
 95% CI 11.2-28.8 23.0-42.1 17.9-36.1 17.5-36.3 22.1-40.2 22.4-41.9
 
Compared to all stroke/TIA, it looks as if a lower percentage (4%-20%) of hemorrhagic 
stroke patients were on medication in the most recent fiscal year.  In fiscal year 2007/08, 51.1% 
of hemorrhagic stroke patients were on antihypertensives at 3 days, and 60% were on at 90 days. 
 
4.2.1.3 Antilipidemic Indicator Results – All Stroke/TIA 
Figures 4.5 and 4.6 present the results for the 3-day and 90-day antilipidemic indicators.  
It should be noted that statins are a major antilipidemic drug class subset, and separate results are 
presented on these figures.  Figure 4.5 shows the percentage of stroke/TIA patients on statins and 
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 antilipidemics at 3 days by fiscal year, while Figure 4.6 illustrates the percentage of patients on 
statins and antilipidemics at 90 days by fiscal year.   
 
Figure 4.5: Percentage of stroke/TIA patients on statin or any antilipidemic medication 
(including statins) at 3 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antilips Percent 21.3 23.5 28.6 29.5 39.2 45.5
 95% CI 19.2-23.4 21.2-25.8 26.0-31.0 27.2-31.9 36.7-41.9 42.8-48.3
    
Statin Percent 19.9 22.5 27.5 28.1 38.3 43.5
 95% CI 18.0-22.0 20.3-24.8 25.2-29.9 25.8-30.5 35.7-40.9 40.8-46.3
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 Figure 4.6: Percentage of stroke/TIA patients on statin or any antilipidemic medication 
(including statins) at 90 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antilips Percent 19.8 23.3 28.5 30.6 37.7 41.0
 95% CI 17.6-22.0 21.0-25.6 26.1-31.1 28.1-33.1 35.1-40.4 38.2-43.7
    
Statin Percent 18.9 22.4 27.0 29.2 36.6 39.7
 95% CI 16.9-21.1 20.2-24.7 24.6-29.5 26.8-31.7 34.0-39.3 37.0-42.5
 
 
Due to the fact that the percentage of patients on statins and the percentage on 
antilipidemics was very close (<2% difference), the rest of the results are presented using the 
statin results only.  From fiscal year 2003/03 to 2007/08, it is apparent that the percentage of 
patients on statins at both 3 and 90 days post-discharge has doubled from approximately 20% to 
approximately 40%.  This change over time was statistically significant at both 3 and 90 days.  In 
the most recent fiscal year, 43.5% of all stroke/TIA patients were on statins at 3 days, while 
39.7% were on statins at 90 days.   
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 4.2.1.4 Antilipidemic Indicator Results – Hemorrhagic Stroke 
Figures 4.7 and 4.8 present the results for the 3-day and 90-day antilipidemic indicators 
for patients who had a hemorrhagic stroke.  Again, it should be noted that statins are a major 
antilipidemic drug class subset, and therefore separate results are shown on the figures.  Figure 
4.7 shows the percentage of hemorrhagic stroke patients on statins and antilipidemics at 3 days 
by fiscal year.  Figure 4.8 illustrates the percentage of hemorrhagic stroke patients on statins and 
antilipidemics at 90 days by fiscal year. 
 
Figure 4.7: Percentage of hemorrhagic stroke patients on statin or any antilipidemic medication 
(including statins) at 3 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antilips Percent 9.5 19.2 23.9 12.9 18.3 20.2
 95% CI 4.4-17.2 12.2-28.1 16.4-32.8 7.0-21.0 11.6-26.9 12.6-29.8
    
Statin Percent 9.5 17.3 21.2 12.9 18.3 19.1
 95% CI 4.4-17.2 10.6-26.0 14.1-29.9 7.0-21.0 11.6-26.9 11.8-28.6
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 Figure 4.8: Percentage of hemorrhagic stroke patients on statin or any antilipidemic medication 
(including statins) at 90 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Antilips Percent 4.7 10.0 18.2 15.2 19.4 24.2
 95% CI 1.3-11.6 4.9-17.6 11.1-27.2 8.6-24.2 12.5-28.2 16.0-34.1
    
Statin Percent 4.7 9.0 18.2 12.0 19.4 23.2
 95% CI 1.3-11.6 4.2-16.4 11.1-27.2 6.1-20.4 12.5-28.2 15.1-32.9
 
Contrary to those with all stroke/TIA, it appears that a much lower percentage 
(approximately 20%) of hemorrhagic stroke patients were on statin medication at both 3 and 90 
days post-discharge in the most recent fiscal year.  In 2007/08, 19.1% of hemorrhagic stroke 
patients were on statins at 3 days, while 23.2% were on statins at 90 days. 
 
4.2.1.5 Anticoagulant Indicator Results – All Stroke/TIA 
Figures 4.9 and 4.10 present the results for the 3-day and 90-day anticoagulant indicators.  
All indicators involved only those patients who had a stroke/TIA and atrial fibrillation.  It should 
be noted that warfarin is a major anticoagulant drug class subset, and therefore results are 
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 presented separately in the figures.  Figure 4.9 shows the percentage of stroke/TIA patients on 
warfarin and anticoagulants at 3 days post-discharge by fiscal year.  Figure 4.10 illustrates the 
percentage of patients on warfarin and anticoagulants at 90 days by fiscal year.   
 
Figure 4.9: Percentage of stroke/TIA patients with atrial fibrillation on warfarin or any 
anticoagulant medication (including warfarin) at 3 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Anticos Percent 62.8 61.3 66.1 66.2 68.0 58.0
 95% CI 55.6-69.7 53.2-68.8 58.9-72.8 59.0-72.8 61.5-73.9 50.6-65.1
    
Warfarin Percent 51.8 53.1 58.7 59.5 63.2 52.1
 95% CI 44.5-59.1 45.1-61.0 51.4-65.8 52.2-66.4 56.6-69.4 44.7-59.5
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 Figure 4.10: Percentage of stroke/TIA patients with atrial fibrillation on warfarin or any 
anticoagulant medication (including warfarin) at 90 days post-discharge, by fiscal year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Anticos Percent 55.1 61.3 64.6 55.0 60.2 52.2
 95% CI 47.0-63.0 53.1-69.0 56.6-72.0 47.4-62.4 53.2-66.9 44.7-59.6
    
Warfarin Percent 48.7 56.1 56.3 47.8 55.3 48.4
 95% CI 40.7-56.8 47.9-64.1 48.2-64.2 40.3-55.3 48.3-62.3 41.0-55.8
 
 From fiscal year 2002/03 to 2007/08, it seems there has not been much change in the 
number of patients taking anticoagulants at both 3 and 90 days post-discharge.  The percentage 
varied over the years between 52% and 68%.  In the most recent fiscal year, 58.0% of all 
stroke/TIA patients were on anticoagulants at 3 days, and 52.2% were on at 90 days.  
Interestingly, these percentages are the lowest of all the fiscal years, but the confidence interval 
does overlap with that from earliest year meaning there is no significant difference.  For 
comparative purposes, it should be noted that approximately 56% of stroke patients with atrial 
fibrillation were on warfarin at 3 days post-discharge over all fiscal years.   
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 4.2.2 LDL Intermediate Outcome Indicator Results 
The results for the indicators involving LDL-C tests are presented for all stroke/TIA.  All 
results are presented by fiscal year.  The results in fiscal year 2001/02 were unreliable, and thus 
removed from all figures.  As laboratory data was able to be acquired from only the Saskatoon 
and Regina Qu’Appelle RHAs, all LDL-C figures contain results for just the patients who live in 
these two RHAs.   
 Figures 4.11-4.12 present the results for the LDL-C test indicators.  Figure 4.11 shows 
the percentage of stroke/TIA patients living in Saskatoon or Regina Qu’Appelle given at least 
one LDL-C test between 2-4 months or between 2-12 months post-discharge by fiscal year.  
Figure 4.12 illustrates the percentage of stroke/TIA patients living in Saskatoon or Regina 
Qu’Appelle given at least one LDL-C test that are within the defined result ranges on their most 
recent test 2-12 months post-discharge by fiscal year.     
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 Figure 4.11: Percentage of stroke/TIA patients living in Saskatoon or Regina Qu’Appelle given 
at least one LDL-C test between 2-4 months or between 2-12 months post-discharge, by fiscal 
year 
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  2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
LDL 2-12 Percent 22.4 30.1 28.9 24.9 29.0 39.8
 95% CI 19.2-25.8 26.6-33.8 25.3-32.6 21.6-28.4 25.4-32.8 35.8-43.8
    
LDL 2-4 Percent 4.0 9.6 12.9 9.2 8.8 14.8
 95% CI 2.6-5.8 7.4-12.1 10.3-15.8 7.1-11.7 6.7-11.4 12.0-17.9
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 Figure 4.12: Percentage of stroke/TIA patients living in Saskatoon or Regina Qu’Appelle given 
at least one LDL-C test between 2-12 months post-discharge within the defined LDL-C test 
result ranges on their most recent test, by fiscal year   
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From fiscal year 2002/03 to 2007/08, there has been a substantial increase (approximately 
20%) in the number of stroke/TIA patients living in Saskatoon or Regina Qu’Appelle given at 
least one LDL-C test 2-12 months post-discharge.  This change was statistically significant as the 
confidence intervals from the earliest and latest years did not overlap.  In the most recent fiscal 
year, 39.8% of all stroke/TIA patients were given a test.  It should be noted, however, that the 
original LDL-C indicator timeline was 2-4 months post-discharge, not 2-12 months.  The 
timeline had to be extended because the test numbers at 2-4 months were too small even in the 
most recent fiscal year (14.8%).   
Over the last six fiscal years, there has been a substantial decrease in the number of 
patients with an LDL-C level higher than 2.0.  However, of the patients given a test, majority 
still had a result higher than 2.0 in the most recent fiscal year (60.3%).     
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 4.2.3 INR Intermediate Outcome Indicator Results 
The results for the indicators involving INR tests are presented for all stroke/TIA in 
patients taking warfarin at 3 or 90 days post-discharge.  All results are presented by fiscal year.  
The results begin at fiscal year 2004/05 as data before this year was unavailable.  As laboratory 
data was able to be acquired from only the Saskatoon and Regina Qu’Appelle RHAs, all INR 
figures contain results for just the patients who live in these two RHAs.   
 Figures 4.13 and 4.14 present the results for the INR test indicators.  Figure 4.13 shows 
the percentage of stroke/TIA patients on warfarin at 3 or 90 days post-discharge given at least 
one INR test 2-12 months post-discharge by fiscal year.  Further, Figure 4.14 illustrates the 
percentage of stroke/TIA patients on warfarin at 3 or 90 days post-discharge given at least one 
INR test 2-4, 5-7, or 11-13 months that have a test result 2.0-3.0 by fiscal year. 
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 Figure 4.13: Percentage of stroke/TIA patients, living in Saskatoon or Regina Qu’Appelle, on 
warfarin at 3 or 90 days post-discharge given at least one INR test 2-12 months post-discharge, 
by fiscal year 
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  2004/05 2005/06 2006/07 2007/08 
INR 2-12 Percent 59.4 78.3 76.2 78.5 
 95% CI 50.9-67.6 70.7-84.8 68.5-82.8 71.1-84.8 
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 Figure 4.14: Percentage of stroke/TIA patients, living in Saskatoon or Regina Qu’Appelle, on 
warfarin at 3 or 90 days post-discharge given at least one INR test at 2-4 months, 5-7 months, or 
11-13 months post-discharge with results 2.0-3.0, by fiscal year 
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From fiscal year 2004/05 to 2007/08, the number of stroke/TIA patients living in 
Saskatoon or Regina Qu’Appelle on warfarin and given at least one INR test in the year 
following their discharge has increased by almost 20%.  This change over time was statistically 
significant.  In the most recent fiscal year, 78.5% of patients on warfarin were given at least one 
INR test.  However, when the proportions of patients within range were examined at 3, 6, and 12 
months, it became apparent that only 40-60% of patients given an INR test were within 
therapeutic range.   
 
4.2.4 Question One Results Summary 
To provide a brief review and synopsis of the results from the indicators, the important 
points are presented below in condensed form.   
The antihypertensive indicators showed that there has been a slight increase in the 
number of patients on the medication over the time period, but about 30-40% of patients are not 
 64
 on the drugs at discharge.  Further, a lower percentage of hemorrhagic stroke patients were on 
antihypertensives in the most recent fiscal year compared to all stroke/TIA.  
The antilipidemic indicators illustrated that the percentage of patients on statins has 
doubled over the timeframe, but roughly 50-60% of all patients are not on the medication at 
discharge.  In addition, a much lower percentage of hemorrhagic stroke patients were placed on 
statins in the most recent fiscal year compared to all stroke/TIA. 
The anticoagulant indicators showed that there has not been much change over the time 
period in the number of patients with atrial fibrillation placed on medication.  However, 
approximately 40-50% of patients with atrial fibrillation are not on anticoagulants at discharge.   
In all medication-related indicators, the results at 3 and 90 days post-discharge were 
fairly similar over all fiscal years.   
The LDL-C indicators revealed that, though there has been an increase over the 
timeframe in the number of patients living in Saskatoon or Regina Qu’Appelle given a test, about 
60% of patients are not receiving even one LDL-C test 2-12 months post-discharge.  Further, 
approximately 60% of the patients who received a test have an LDL-C level higher than 2.0   
Finally, the INR indicators established that there has been an increase over the time 
period in the number of patients on warfarin (living in Saskatoon or Regina Qu’Appelle) given 
an INR test 2-12 months post-discharge.  However, about half of the patients given a test were 
not within therapeutic range. 
 
4.3 Question Two: Correlates Associated with Receiving Secondary Stroke Prevention  
 As the literature indicates that different factors may influence the provision of secondary 
stroke prevention, separate models were constructed for the various areas of care.  Five models 
were developed to predict 1) being “on” antihypertensive medication at 90 days post-discharge; 
2) being “on” antilipidemic medication at 90 days post-discharge; 3) being “on” anticoagulant 
medication at 90 days post-discharge; 4) being given at least one LDL-C test 2-12 months post-
discharge; and 5) being given at least one INR test 2-12 months post-discharge. 
 
4.3.1 Model for Being “On” Antihypertensive Medication 
 Table 4.3 describes the statistically and clinically significant correlates for being “on” 
antihypertensive medication at 90 days post-discharge. 
 
 65
 Table 4.3: Statistically and clinically significant correlates for being “on” antihypertensive 
medication at 90 days post-discharge 
 
Correlates Categories Odds Ratio 95% Confidence 
Interval 
Sex Male 
Female 
N/A N/A
Age 18-74 
75-84 
85+ 
N/A N/A
Urban/Non-Urban Urban 
Non-urban 
(ref) 
1.15
(ref) 
1.05-1.27*
Previously on Drugs Not previously on drug 
Previously on drug 
(ref) 
2.33
(ref) 
2.12-2.57*
Sex*Age Male * Age<74 
Female * Age <74 
Male * Age 75-84 
Female * Age 75-84 
Male * Age 85+ 
Female * Age 85+ 
(ref) 
0.86
(ref) 
1.39
(ref) 
2.20
(ref) 
0.75-1.00
(ref) 
1.19-1.63*
(ref) 
1.76-2.74*
    * Statistically Significant 
 
As shown in Table 4.3, patients who lived in a non-urban setting were more likely to be 
on antihypertensive medication than patients who lived in an urban setting (OR=1.15).  Also, 
people who were taking antihypertensives before their stroke event were more often on the 
medication at 90 days compared to those who were not previously on the drugs (OR=2.33).   
The presence of a statistically significant interaction term between sex and age implies 
that neither of the terms can be examined in isolation.  This means that when looking at the 
impact of sex on taking antihypertensive medication at 90 days, it must be explained in the 
context of age.  Looking at Table 4.3, females, compared to males, were more likely to be on 
antihypertensive medications, but this was dependent on age.  Older females (75-84 and 85+) 
were more likely to be on antihypertensives (OR=1.39 and OR=0.86), whereas younger females 
(<75) were not (OR=0.86).   
The Hosmer and Lemeshow goodness-of-fit test had a p-value equal to 0.9594.  This 
means that the null hypothesis (stating that the model fits) is not rejected, and that the model 
seems to fit the data quite well.    
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 4.3.2 Model for Being “On” Antilipidemic Medication 
 Table 4.4 describes the statistically and clinically significant correlates for being “on” 
antilipidemic medication at 90 days post-discharge 
 
Table 4.4: Statistically and clinically significant correlates for being “on” antilipidemic 
medication at 90 days post-discharge 
 
Correlates Categories Odds Ratio 95% Confidence 
Interval 
Sex Male 
Female 
(ref) 
0.94
(ref) 
0.84-1.06
Age 18-74 
75-84 
85+ 
1.35
(ref) 
0.47
1.19-1.53*
(ref) 
0.39-0.56*
RHA of Residence Sun Country 
Five Hills 
Cypress 
Regina Qu’Appelle 
Sunrise 
Saskatoon  
Heartland 
Kelsey Trail 
Prince Albert Parkland 
Prairie North 
Mamawetan Churchill River 
Keewatin Yatthé 
0.74
1.60
0.77
0.82
0.93
(ref) 
0.92
1.03
1.30
0.91
2.76
0.42
0.56-0.99*
1.21-2.12*
0.57-1.04
0.70-0.96*
0.72-1.22
(ref) 
0.69-1.24
0.76-1.40
0.98-1.74
0.67-1.22
0.76-10.04
0.09-2.06
Income Quintile 1 (Lowest) 
2 
3 
4 
5 (Highest) 
(ref) 
1.10
1.24
1.26
0.96
(ref) 
0.92-1.31
1.03-1.48*
1.04-1.52*
0.78-1.18
Hospital Category Provincial 
Regional 
District 
Northern 
Community 
(ref) 
0.86
0.78
1.11
0.62
(ref) 
0.69-1.08
0.62-0.99*
0.22-5.61
0.52-0.75*
Previously on Drugs Not previously on drug 
Previously on drug 
(ref) 
5.04
(ref) 
4.47-5.70*
    * Statistically Significant 
 
As shown in Table 4.4, patients who were under age 75 were more likely (OR=1.35), 
while those who were over 85 were less likely (OR=0.47) to be on antilipidemic medication 
compared to those age 75-84.  People within the income quintiles 3 (OR=1.24) and 4 (OR=1.26) 
were more often on medication than those in the lowest quintile.  Those discharged from a 
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 hospital categorized as district (OR=0.78) or community (OR=0.62) were less likely to be on 
antilipidemics than those from a provincial hospital.  Further, people who were taking 
antilipidemics before their stroke event were more often on the medication at 90 days compared 
to those who were not previously on the drugs (OR=5.04).   
 As can be seen in Table 4.4, the odds ratio for RHA is statistically significant for three of 
the twelve regions included.  Patients who lived in Sun Country (OR=0.74) or Regina 
Qu’Appelle (OR=0.82) were less likely to be on antilipidemics than those who lived in 
Saskatoon (reference).  In contrast, those who lived in Five Hills (OR=1.60) were more often on 
the medication than patients who lived in Saskatoon (reference).  
 The Hosmer and Lemeshow goodness-of-fit test had a p-value equal to <0.001.  This 
means that the null hypothesis (stating that the model fits) is rejected.  Therefore, it seems this 
model is not a good fit to the data.   
 
4.3.3 Model for Being “On” Anticoagulant Medication 
 Table 4.5 describes the statistically and clinically significant correlates for being “on” 
anticoagulant medication at 90 days post-discharge in those with atrial fibrillation. 
 
Table 4.5: Statistically and clinically significant correlates for being “on” anticoagulant 
medication at 90 days post-discharge in those with atrial fibrillation 
 
Correlates Categories Odds Ratio 95% Confidence 
Interval 
Sex Male 
Female 
(ref) 
1.19
(ref) 
0.90-1.59
Age 18-74 
75-84 
85+ 
1.11
(ref) 
0.67
0.78-1.56
(ref) 
0.48-0.93*
Income Quintile 1 (Lowest) 
2 
3 
4 
5 (Highest) 
(ref) 
1.17
1.53
2.12
1.26
(ref) 
0.79-1.73
1.00-2.33
1.35-3.32*
0.81-1.96
Length of Stay 0-10 days 
11-30 days 
31+ days 
(ref) 
1.01
0.68
(ref) 
0.73-1.41
0.48-0.96*
Previously on Drugs Not previously on drug 
Previously on drug 
(ref) 
1.56
(ref) 
1.10-2.20*
    * Statistically Significant 
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 As illustrated in Table 4.5 patients who were over age 85 were less likely to be on 
anticoagulant medication compared to those age 75-84.  People within the 4th income quintile 
were more often on medication than those in the lowest quintile (OR=2.12).  Patients who were 
hospitalized for more than 31 days were on anticoagulants less often than those with a stay 0-10 
days.  Finally, people who were taking anticoagulants before their stroke event were more often 
on the medication at 90 days compared to those who were not previously on the drugs 
(OR=1.56).   
The Hosmer and Lemeshow goodness-of-fit test had a p-value equal to 0.1825.  This 
means that the null hypothesis (stating that the model fits) is not rejected.  Therefore, this model 
seems to fit the data.    
 
4.3.4 Model for Being Given At Least One LDL-C Test 
 Table 4.6 describes the statistically and clinically significant correlates for being given at 
least one LDL-C test 2-12 months post-discharge. 
 
Table 4.6: Statistically and clinically significant correlates for being given at least one LDL-C 
test 2-12 months post-discharge 
 
Correlates Categories Odds Ratio 95% Confidence 
Interval 
Sex Male 
Female 
(ref) 
0.82
(ref) 
0.70-0.97*
Age 18-74 
75-84 
85+ 
1.56
(ref) 
0.29
1.32-1.85*
(ref) 
0.22-0.39*
Income Quintile 1 (Lowest) 
2 
3 
4 
5 (Highest) 
(ref) 
1.25
1.08
1.16
1.50
(ref) 
1.00-1.57
0.85-1.37
0.91-1.48
1.15-1.94*
Urban/Non-Urban Urban 
Non-urban 
(ref) 
0.23
(ref) 
0.18-0.29*
Length of Stay 0-10 days 
11-30 days 
31+ days 
(ref) 
0.75
0.57
(ref) 
0.61-0.90*
0.45-0.71*
    * Statistically Significant 
  
As shown in Table 4.6, patients under age 75 were more likely to be given an LDL-C test 
(OR=1.56), while those over age 85 were less likely (OR=0.29) to receive a test.  People within 
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 the highest income quintile were more often given an LDL-C test than those in the lowest 
quintile (OR=1.50), and there appears to be a gradient from lowest to highest income quintile 
(but the odds ratios were not significant).  Patients who lived in a non-urban setting were less 
likely to be given a test than patients who lived in an urban setting (OR=0.23).  Finally, patients 
hospitalized for 11-30 days (OR=0.75) and over 31 days (OR=0.57) were less likely to be given 
an LDL-C test than those hospitalized 0-10 days.  
The Hosmer and Lemeshow goodness-of-fit test had a p-value equal to 0.7813.  This 
means that the null hypothesis (stating that the model fits) is not rejected.  Therefore, this model 
seems to fit the data quite well.   
 
4.3.5 Model for Being Given At Least One INR Test 
 Table 4.7 describes the statistically and clinically significant correlates for being given at 
least one INR test 2-12 months post-discharge in those taking warfarin. 
 
Table 4.7: Statistically and clinically significant correlates for being given at least one INR test 
2-12 months post-discharge in those taking warfarin 
 
Correlates Categories Odds Ratio 95% Confidence 
Interval 
Sex Male 
Female 
(ref) 
0.87
(ref) 
0.64-1.19
Age 18-74 
75-84 
85+ 
0.95
(ref) 
0.64
0.68-1.32
(ref) 
0.40-1.01
RHA of Residence 04 Regina Qu’Appelle 
06 Saskatoon  
1.80
(ref)
1.32-2.46*
(ref)
Urban/Non-Urban Urban 
Non-urban 
(ref) 
0.20
(ref) 
0.14-0.28*
Multiple Stroke/TIA Not a multiple stroke/TIA 
Multiple stroke/TIA 
(ref) 
1.99
(ref) 
1.07-3.70*
    * Statistically Significant 
  
As can be seen in Table 4.7, people who lived in a non-urban setting were less likely to 
be given an INR test than people who lived in an urban setting (OR=0.20).  Patients who were 
included in the study population as a “multiple stroke” were more often given an INR test than 
those who had a “first stroke” (OR=1.99).   
As illustrated in Table 4.7, the odds ratio for RHA is statistically significant for one of the 
two regions included.  The reason there are only two regions was because laboratory data was 
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 only available in the Saskatoon and Regina Qu’Appelle RHAs.   Patients who lived in Regina 
Qu’Appelle (OR=1.80) were more likely to receive an INR test than those who lived in 
Saskatoon (reference).  
The Hosmer and Lemeshow goodness-of-fit test had a p-value equal to 0.8457.  This 
means that the null hypothesis (stating that the model fits) is not rejected, and that the model 
seems to fit the data.    
 
4.3.6 Question Two Results Summary 
While many of the same variables predict different outcomes related to secondary stroke 
prevention, the predictive model for each outcome varies, as seen in Table 4.8 and Table 4.9.  
These tables provide a complete synopsis of the logistic regression results. 
 
Table 4.8: Statistically significant variables in models for drug-related secondary stroke 
prevention.  Categories listed in table were significantly worse. 
 
Variable Model for 
Antihypertensive 
Medication 
Model for 
Antilipidemic 
Medication 
Model for 
Anticoagulant 
Medication 
Main Effects    
Sex X   
Age X Age 85+ Age 85+ 
RHA of Residence  Sun Country 
Regina Qu’Appelle 
 
Income Quintile  Lower Income Lower Income 
Urban/Non-Urban Urban   
Hospital Category  District or 
Community 
Hospital 
 
Length of Stay   31+ Days 
Multiple Stroke/TIA    
Previously on Drugs Not previously on 
drugs 
Not previously on 
drugs 
Not previously on 
drugs 
Interaction Terms    
Sex*Age Males, Age 75+   
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 Table 4.9: Statistically significant variables in models for intermediate outcome secondary 
stroke prevention.  Categories listed in table were significantly worse. 
 
Variable Model for LDL-C Tests Model for INR Tests 
Main Effects   
Sex Female  
Age Age 85+  
RHA of Residence  Saskatoon 
Income Quintile Lower Income  
Urban/Non-Urban Non-Urban Non-Urban 
Hospital Category N/A N/A 
Length of Stay 11-30 Days 
31+ Days 
 
Multiple Stroke/TIA  Not a multiple stroke/TIA 
Previously on Drugs N/A N/A 
    N/A = Not Applicable 
 
 
4.4 Question Three: Geographical Variation in Secondary Stroke Prevention by 
Saskatchewan Regional Health Authority Areas 
  
4.4.1 RHA Results and Logistic Contrasts for Medication Indicators 
All results stratified for RHA (hospital or patient) for the medication indicators are 
presented within this section.  The outcome (significantly better or worse) from the logistic 
contrast analyses are also presented within the RHA stratified figures.  Due to the large number 
of results for RHA, only figures for the fiscal year 2007/08 are illustrated.  Further, considering 
healthcare processes in the province, it is logical to present the 3-day medication indicators 
stratified by hospital RHA, and the 90-day medication indicators stratified by patient RHA.   
 
4.4.1.1 Antihypertensive RHA Results 
 Figures 4.15 and 4.16 present the stratified RHA results for the antihypertensive 
indicators.  Figure 4.15 shows the percentage of stroke/TIA patients on antihypertensives at 3 
days by hospital RHA and fiscal year.  The contrast analysis revealed that the Sunrise RHA, with 
a rate of 85.7%, was significantly better compared to the group of all other health regions, which 
had a rate of 68.9%.  Conversely, the Saskatoon RHA, with a rate of 64.8%, was significantly 
worse compared to the rate of 72.8% in the group of all other health regions.  Figure 4.16 
illustrates the percentage of stroke/TIA patients on antihypertensives at 90 days by patient RHA 
and fiscal year.  The contrast analysis again showed that the Sunrise RHA, with a rate of 73.4%, 
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 was significantly better compared to the group of all other health regions, which had a rate of 
62.8%.   
 
Figure 4.15: Percentage of stroke/TIA patients on antihypertensive medication at 3 days post-
discharge, by hospital RHA 
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 Figure 4.16: Percentage of stroke/TIA patients on antihypertensive medication at 90 days post-
discharge, by patient RHA 
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4.4.1.2 Statin RHA Results 
 Figures 4.17 and 4.18 present the stratified RHA results for the statin (antilipidemic) 
indicators.  In Figure 4.17, the percentage of stroke/TIA patients on statins at 3 days by hospital 
RHA and fiscal year can be seen.  The contrast analysis revealed that there were no RHAs 
significantly better or worse than all others.  Figure 4.18 illustrates the percentage of stroke/TIA 
patients on statins at 90 days by patient RHA and fiscal year.  In this instance, the contrast 
analysis showed that the Prince Albert Parkland RHA, with a rate of 54.1%, was significantly 
better compared to the rate of 38.8% in the group of all other health regions.   
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 Figure 4.17: Percentage of stroke/TIA patients on statin medication at 3 days post-discharge, by 
hospital RHA 
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 Figure 4.18: Percentage of stroke/TIA patients on statin medication at 90 days post-discharge, 
by patient RHA 
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4.4.1.3 Anticoagulant RHA Results   
 Figures 4.19 and 4.20 present the stratified RHA results for the anticoagulant indicators.  
Only stroke/TIA patients with atrial fibrillation were included.  Due to the smaller number of 
patients, three RHAs were used for analysis – Saskatoon, Regina Qu’Appelle, and All Others.  
Figure 4.19 shows the percentage of stroke/TIA patients with atrial fibrillation on anticoagulants 
at 3 days by hospital RHA and fiscal year.  The contrast analysis revealed that the Saskatoon 
RHA, with a rate of 45.7%, was significantly worse in having patients on anticoagulants at 3 
days compared to the group with all other health regions combined (rate 65.3%).  Figure 4.20 
illustrates the percentage of stroke/TIA patients with atrial fibrillation on anticoagulants at 90 
days by patient RHA and fiscal year.  This time the contrast analysis showed that there were no 
RHAs significantly better or worse compared to the group with all others health regions 
combined. 
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 Figure 4.19: Percentage of stroke/TIA patients with atrial fibrillation on anticoagulant 
medication at 3 days post-discharge, by hospital RHA 
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 Figure 4.20: Percentage of stroke/TIA patients with atrial fibrillation on anticoagulant 
medication at 90 days post-discharge, by patient RHA 
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4.4.2 RHA Results for the Laboratory Test Indicators 
All results stratified for RHA (patient) for the laboratory test indicators are presented 
within this section.  Considering laboratory data was only available for the Saskatoon and Regina 
Qu’Appelle RHAs, contrast analyses were not performed.  Considering the timeframe of these 
indicators and the healthcare processes in the province, it is logical to present the results by 
patient RHA only.    
 
4.4.2.1 LDL RHA Results 
 Figure 4.21 presents the stratified RHA results for LDL-C Test at 2-12 Months.  The 
other indicator for LDL-C involved test results, which is subsequent to actually being given a 
test.  Hence, the RHA results are presented for only the test indicator.  The percentage of 
stroke/TIA patients given at least one LDL-C test 2-12 months post-discharge by RHA and fiscal 
year can be seen in Figure 4.21.  Examining the results from the 2007/08 fiscal year, it is 
apparent that the Regina Qu’Appelle RHA is significantly better than the Saskatoon RHA in 
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 giving patients an LDL-C test 2-12 months post-discharge.  This is evident in how the 
confidence intervals do not overlap in the most recent fiscal year. 
 
Figure 4.21: Percentage of stroke/TIA patients given at least one LDL-C test 2-12 months post-
discharge, by patient RHA and fiscal year 
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LDL 2-12  2004/05 2005/06 2006/07 2007/08 
Regina Qu’Appelle Percent 29.7 19.6 26.2 49.8
 95% CI 24.6-35.1 15.4-24.3 21.4-31.5 43.9-55.7
   
Saskatoon Percent 28.1 30.3 31.9 30.2
 95% CI 23.1-33.5 25.4-35.7 26.6-37.5 25.1-35.7
 
 
4.4.2.2 INR RHA Results 
 Figure 4.22 presents the stratified RHA results for INR Test at 2-12 Months.  The other 
indicators for INR involved test results, which is subsequent to actually being given a test.  
Hence, the RHA results are presented for only the test indicator.  Stroke/TIA patients on warfarin 
at 3 or 90 days post-discharge were included.  The percentage of stroke/TIA patients on warfarin 
given at least one INR test 2-12 months post-discharge by RHA and fiscal year can be seen in 
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 Figure 4.22.  It is apparent from the results that there is no statistically significant difference 
between the Regina Qu’Appelle and Saskatoon RHAs in the most recent fiscal year. 
 
Figure 4.22: Percentage of stroke/TIA patients on warfarin at 3 or 90 days post-discharge given 
at least one INR test 2-12 months post-discharge, by patient RHA and fiscal year 
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INR 2-12  2004/05 2005/06 2006/07 2007/08 
Regina Qu’Appelle Percent 68.3 77.6 76.6 84.6
 95% CI 55.0-79.7 64.7-87.5 64.3-86.2 73.5-92.4
   
Saskatoon Percent 53.0 78.8 75.9 73.8
 95% CI 41.7-64.1 68.6-86.9 65.3-84.6 63.1-82.8
 
 
4.4.3 Question Three Results Summary 
To provide a brief review and synopsis of the results from the contrast analysis, the 
important points are presented below in condensed form.   
 In having patients on antihypertensive medication, the Sunrise RHA was better than the 
group of all others at both 3 and 90 days, while the Saskatoon RHA was worse at 3 days.  The 
Prince Albert Parkland RHA was better than the group of all others at having patients on statins 
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 at 90 days.  The Saskatoon RHA was worse than the group of all others at having patients with 
atrial fibrillation on anticoagulants at 3 days.  In the most recent fiscal year, the Regina 
Qu’Appelle RHA was better than the Saskatoon RHA at giving an LDL test to patients 2-12 
months post-discharge.  Finally, there was no difference between the Saskatoon RHA and 
Regina Qu’Appelle RHA in giving an INR test 2-12 months post-discharge in patients on 
warfarin. 
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 CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 
5.1 Question One: Indicators of the Quality of Secondary Stroke Prevention  
 For all of the elements of secondary stroke prevention studied in this question, it was 
hypothesized that half or fewer of the patients discharged from Saskatchewan hospitals would 
receive the recommended care. 
 In interpreting the results for the medication-related indictors, it should be kept in mind 
that the “ideal” percentage on medication is not 100%.  It is unrealistic to believe that 100% of 
stroke/TIA patients can be placed on the medications investigated in this study.  This is because 
there are contraindications with the medication, as well as complications while taking the drug.  
If there is no stated benchmark, the ideal percentage in all medication indicators is considered to 
be “approaching 100%”, keeping in mind that 100% can never be achieved.    
 Another thing to be kept in mind is that this study calculates quality indicators, not 
quality measures. Quality indicators measure how well a system is performing, and may point to 
potential problem areas that need further investigation (36).  In order to identify the nature and 
extent of a problem, quality measures must be calculated (84).  Quality measures, unlike quality 
indicators, are direct measures of clinical processes and reflective of evidence-based practice.   In 
terms of the results of this study, the quality indicators portray on a macro level the quality of 
secondary stroke prevention in Saskatchewan using administrative data.  In order to further 
investigate any identified problems at a micro or clinical level, quality measures need to be 
developed and calculated using clinical data.   
 One result that was similar for all medication indicators was the similarity of results 
between the 3 and 90 day calculations for all stroke/TIA.  In all three medication types, there was 
only a small drop (<10%) in percentage of patients on medication at 90 days compared to 3 days.  
This drop can be expected due to complications with the medication, medication adjustment 
periods, and patient nonadherence (4, 76).  However, the similarity of results at 3 and 90 days in 
all cases seems to signify that blood-pressure care, lipid-lowering care, and atrial fibrillation care 
in the hospital (as indicated by the 3-day results), and care in the primary setting (as indicated by 
the 90-day results) are fairly consistent in Saskatchewan.   
 As the rest of the results are specific to each indicator, they will be discussed separately. 
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 5.1.1 Medication-Related Process of Care Indicators – Antihypertensive Medications 
 According to the Best Practice Recommendations, blood pressure lowering treatment 
should be initiated before discharge from hospital for all stroke/TIA patients (4).  There is no 
current benchmark stating the proportion of patients who should be on antihypertensives (77).   
As indicated by the study results it seems that, although there has been improvement over 
the study period, approximately 30-40% of stroke/TIA patients are not on antihypertensives at 
discharge.  This percentage is a bit worse than results from Ontario, where approximately 25% of 
patients over 65 were not on antihypertensives at 90 days in 2005/06 (77).  Similarly, in a study 
done in the United States, approximately 25% of patients were not on antihypertensives after 
admission to an inpatient rehabilitation facility (78).  It is possible that stroke etiology is a factor 
in treatment since a lower percentage of hemorrhagic stroke patients were placed on 
antihypertensives at 3 days compared to all stroke/TIA.  This is interesting considering it seems 
contraindicative that those with hemorrhagic stroke were less likely to be on antihypertensives 
bearing in mind the stroke etiology.  Regardless, the proportion of patients who are not on 
medication is too large to be accounted for by this reason only.   
Overall, it appears there is room for improvement in secondary stroke prevention in 
Saskatchewan in the area of blood pressure management.  A higher proportion of stroke/TIA 
patients should be placed on antihypertensives at discharge from hospital and/or primary care to 
prevent the recurrence of stroke.  
 
5.1.2 Medication-Related Process of Care Indicators – Antilipidemic (Statin) Medications 
According to the Best Practice Recommendations, statin agents should be prescribed for 
most patients who have had an ischemic stroke or TIA; these medications have little effect in 
reducing hemorrhagic stroke (4).  In addition, caution should be used in prescribing statins to 
patients who have had a hemorrhagic stroke and/or are at risk of bleeds (4, 52).  There is no 
current benchmark stating the proportion of patients who should be placed on statins (77).   
 In examining the percentage differences between those who had an ischemic stroke/TIA 
and those who had a hemorrhagic stroke, it is apparent that there is a difference in treatment 
regime based on stroke etiology.  This finding is consistent with the literature as there is still 
debate on the benefits/risks of prescribing statins to patients who had a hemorrhagic stroke (4, 
52, 57, 58).  It should be noted, however, that the lower percentage of hemorrhagic stroke 
patients taking statins does contribute to the overall finding that only about 40% of all 
 83
 stroke/TIA patients are on antilipidemics at discharge.  Regardless, the results show that, 
although there has been improvement, roughly 50-60% of all stroke/TIA patients are not being 
placed on statins at discharge.  This percentage, though quite low, is fairly similar to results 
found in two Ontario studies (77, 79) as well as a Swedish study (80).    
Currently, there seems to be a gap in secondary stroke care in the area of lipid 
management.  It is apparent there is vast room for improvement in Saskatchewan in that a much 
higher number of ischemic stroke/TIA patients should be placed on statin medication at 
discharge from hospital and/or primary care.  
 
5.1.3 Medication-Related Process of Care Indicators – Anticoagulant Medications 
 The Best Practice Recommendations state that patients who have atrial fibrillation who 
had an ischemic stroke/TIA should be treated with anticoagulants (4).  There is no current 
benchmark stating the proportion of patients with atrial fibrillation who should be placed on 
anticoagulants (77).    
 As indicated by the study results, it seems that approximately 40-50% of stroke/TIA 
patients with atrial fibrillation are not being placed on anticoagulants at discharge.  With this 
type of medication, however, there is a much higher chance for people having major 
contraindications such as recent bleeding (81, 82) rendering them unable to take anticoagulants.  
Some studies show that this is the case for up to a third of patients with atrial fibrillation (81, 82).  
Thus, the percentage not taking anticoagulants may be explained in part by both 
contraindications and complications with the medication.  In spite of this, the approximate 
percentage of stroke/TIA patients with atrial fibrillation on warfarin over all fiscal years 
(approximately 52%) is not yet on par with similar results in Ontario (77, 79, 83), where 
approximately 70% of patients over age 65 were on warfarin at 90 days.  These results suggest 
there is room for improvement in Saskatchewan. 
Presently, it seems there is potential for some improvement in the area of atrial 
fibrillation management in secondary stroke prevention.  A higher number of Saskatchewan 
stroke/TIA patients with atrial fibrillation should be prescribed anticoagulant medication at 
discharge from hospital.  The percentages should increase to be on par with those in other 
provinces such as Ontario.    
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 5.1.4 Laboratory Test Intermediate Outcome Indicators – LDL-C 
 According to the Best Practice Recommendations, adults at any age should have their 
blood lipids measured if they have a history of ischemic stroke or TIA (4).  The recommended 
LDL-C target for stroke patient is <2.0 mmol/L (54).   
 In examining the study results, it seems that a large proportion of stroke/TIA patients 
living in the Saskatoon or Regina Qu’Appelle health regions (approximately 60%) are apparently 
not being given even one LDL-C test in the year following their discharge.  Further to this, the 
majority of those given a test (approximately 60%) have an LDL-C level higher than 
recommended.  Unfortunately, no other studies were found that had similar indicator calculations 
for comparison.  One major reason for patients not receiving an LDL-C test may be non-
adherence to physician recommendations.  Receiving an LDL-C test involves fasting for 12 
hours, commuting to a laboratory, and having blood drawn.  Each of these requirements may 
influence a patient into non-adherence with the test because of discomfort and/or inconvenience.  
Another explanation may be due to the fact that information was not captured for any laboratory 
outside of the urban areas of Saskatoon and Regina.  The other non-urban parts of these RHAs 
did not have information in the laboratory dataset.  In other words, some patients who live in the 
non-urban parts of the RHAs (approximately 10%) may have had tests done in a laboratory 
outside of Saskatoon or Regina, but this information was not captured.   
Regardless of the missing data, it is apparent that LDL-C testing needs to improve in 
stroke patients to help facilitate bringing lipid levels into the recommended range of <2.0 
mmol/L.  Given that lipid levels should be monitored in all persons who had a stroke (4), these 
results suggest a gap in lipid-lowering secondary stroke care in Saskatchewan.    
 
5.1.5 Laboratory Test Intermediate Outcome Indicators – INR 
 The Best Practice Recommendations state that patients on warfarin medication require 
regular monitoring of blood levels to ensure they are within the target range 2.0-3.0 (4).  The 
goal is to have all patients within the target INR range to reduce stroke risk as well as prevent 
complications from warfarin (4). 
 According to the study results, it appears that the majority of patients on warfarin are 
having at least one INR test in the year following discharge from stroke/TIA.  It is, however, 
crucial for everyone taking warfarin to be tested due to the nature of the medication (4), and 
about 20% of patients are not receiving even one INR test.  Furthermore, of those tested during 
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 the 3, 6, and 12 month timeframes, only about half were in therapeutic range at any given month 
and fiscal year.  In other words, half of the patients are not within the recommended INR range 
for those on warfarin.  Unfortunately, no other province has the same exact indicator calculations 
for comparison.  One possible reason patients on warfarin are not receiving an INR test may be 
due, again, to non-adherence with physician recommendations.  An INR test involves 
commuting to a laboratory and having blood drawn, which may be inconvenient and/or 
uncomfortable.  In addition, it is possible that physicians are not fully communicating the 
importance of getting regular INR tests to their stroke/TIA patients, meaning they have a lack of 
understanding.  Also, patients may simply forget to go and have their INR test if they do not 
have a regular reminder from the physician.  For these reasons, a patient may be non-adhering to 
physician recommendations.  Another possible explanation may be that some patients are taken 
off warfarin due to complications.  If this is the case, they likely do not need an INR test, but this 
information was not captured in the indicator calculation.  A final reason may be because 
information was not captured for any laboratory outside of the urban areas of Saskatoon and 
Regina.  The other non-urban parts of these RHAs did not have information in the laboratory 
dataset.  In other words, some patients who live in the non-urban parts of the RHAs 
(approximately 25%) may have had tests done in a laboratory outside of Saskatoon or Regina, 
but this information would not have been captured.   
In sum, it seems that Saskatchewan has improved in the last four years in terms of giving 
stroke/TIA patients on warfarin at least one INR test in the year post-discharge, but there is still 
much opportunity for betterment.  Further, a higher proportion of patients should be within the 
target INR test range to prevent future complications. 
 
5.2 Question Two: Correlates Associated with Receiving Secondary Stroke Prevention  
For this question, it was hypothesized that there would be variations in quality of 
secondary stroke prevention related to such factors as age, gender, income, and urban/non-urban 
place of residence.  
 In the literature, there were a limited number of studies that have outlined factors 
associated with receiving secondary stroke prevention.  The documented correlates include sex 
(67, 69, 70, 71), age (67), socioeconomic status (12, 72), and urban/non-urban place of residence 
(73). 
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 5.2.1 Medication-Related Models 
In the drug-related secondary stroke prevention models, only two variables were 
statistically significant in all three models: previously on drugs and age.  Having been on the 
medication of interest before the stroke/TIA event meant a patient was more likely to be on 
medication following discharge.  This is not surprising considering it is likely easier to continue 
taking a medication than it is to adhere to a newly prescribed one.  In both the antilipidemic and 
anticoagulant models, patients over 85 were less likely to be on the medication compared to the 
age 75-84 reference group.  In addition, the antilipidemic model showed that patients age 18-74 
were more likely to be on the medication than the age 75-84 reference group.  This finding that 
older patients are receiving less medication care is consistent with the literature that suggests the 
elderly need to be targeted for secondary prevention therapy (67, 76).  The results of this study 
seem to reflect a greater need for secondary stroke prevention in elderly patients.   
 Income quintile achieved statistical significance in the antilipidemic and anticoagulant 
models.  In both models, patients who were mid-range for income were more likely to be on the 
medication of interest than patients in the lowest quintile.  The results are consistent with a 
previous study where socioeconomic status was weakly associated with various components of 
stroke care (12); the odds ratios were quite small with confidence intervals fairly close to the null 
value of 1.0.  It is difficult to explain this finding.  It is possible that how patients were assigned 
to a quintile was somewhat inaccurate as postal codes were the method of division; just because 
a person lives in a certain area of Saskatchewan does not necessarily mean they are in a specific 
income quintile.   
 Urban/Non-urban place of residence was statistically significant in the model for 
antihypertensive medications.  A weak association was found indicating that patients who live in 
non-urban areas of Saskatchewan were more likely to be on medication than those the urban 
areas.  This finding contradicts the study found on stroke care in urban and non-urban areas of 
the United States, which stated that acute stroke care in non-urban areas was suboptimal (73).  
This finding was surprising and unexplainable as there are generally more services available for 
health care (i.e. stroke care) in urban areas.  Further studies need to be conducted to investigate 
this finding.  
 Hospital category was statistically significant in the model for antilipidemic medication.  
It was found that those discharged from a hospital categorized as district or community were less 
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 likely to be on medication than those from a provincial hospital.  An explanation for this might 
be that there are better protocols for secondary stroke prevention at provincial hospitals.  It 
should be noted, however, that the relevance of this variable at 90 days post-discharge is likely 
minimal.  At 90 days post-discharge, secondary stroke prevention should be the responsibility of 
the primary care physician, not the physicians at the patient’s hospital of discharge.  This 
variable would be more relevant in a model for 3-days post-discharge.   
 A patient’s length of stay in the hospital was found to be significant for the anticoagulant 
model.  If a stroke/TIA patient with atrial fibrillation was in hospital past 30 days, they were less 
likely to be on the medication at discharge.  A possible explanation for this might be that patients 
who were in hospital longer had more complications from their stroke event, and thus were more 
likely to have a contraindication with anticoagulant medications.  
 Regional Health Authority (RHA) of residence was only statistically significant in the 
model for antilipidemic medications.  Considering the differences in care between RHAs were 
investigated further using the logistic regression contrast model, the results will be discussed in 
that context (see Section 5.3.1).    
 Surprisingly, being a multiple stroke patient was not significant in any of the three 
models for drug-related secondary stroke prevention.  It is logical to think that if a person had 
more than one stroke within two years that they would be more likely to be on secondary stroke 
prevention medications than a person who had a first stroke.  However, it is apparent that this is 
not the case. 
 The sex*age interaction term was significant in only the model for antihypertensive 
medications.  Females over the age of 75 were more likely than males of the same age to be 
placed on antihypertensive medications.  In contrast, females under the age of 75 were less likely 
than males of the same age to be on antihypertensives.  The results from this study are 
contradictory to most of the findings in the literature. In the limited studies done on sex 
differences in secondary stroke prevention, the results generally showed that women were less 
likely to receive various treatments than men (69, 70, 71).  The reason for this difference may be 
due to what was being measured.  In the referenced studies (69, 70, 71), they talk about a patient 
“receiving” medication; in other words, they explore the prescribing patterns of the physicians.  
This study, in contrast, explores the dispensing of medication to patients; in other words, whether 
or not the person is taking the drug of interest.  The results are more in line with a Swedish study, 
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 where they found that women were more likely to purchase some secondary prevention 
treatments than men (80).  This study may have identified a difference in attitude towards 
treatment in older men and women; older men being less likely to adhere to physician orders.  In 
order to more accurately explain this finding, however, a more in-depth study on gender 
differences in secondary stroke prevention needs to be carried out.   
 
5.2.2 LDL and INR Intermediate Outcome Models 
In the laboratory outcome secondary stroke prevention models, only one variable was 
statistically significant in both models: urban/non-urban place of residence.  A patient living in a 
non-urban area was less likely to receive an LDL-C or INR test than a patient living in an urban 
area.  This finding is not surprising, and can be explained by the fact that data was only available 
for the laboratories in the urban areas of the Saskatoon RHA and Regina Qu’Appelle RHA.  
Being that only people who live in the Saskatoon and Regina Qu’Appelle RHAs were included 
in the indicator calculations, there would be a limited number in the dataset from a non-urban 
area.  Those who were, however, may have had their tests done in a laboratory that does not have 
information in this dataset.  Therefore, the association found for a non-urban area may not be 
accurate due to missing information. 
The correlates sex and age were significant for only the LDL-C test model.  Interestingly, 
females were less likely to receive an LDL test than males.  This is a surprising finding that is 
not easily explained.  There, unfortunately, is nothing for literature regarding factors related to 
receiving LDL tests.  Considering that the association is weak and the confidence interval for this 
model is fairly close to the null value of 1.0, the finding could be an anomaly with the stroke/TIA 
patient cohort.   In terms of age, patients under the age of 75 were more likely to receive a test 
while those over 85 were much less likely.  Again, there is not much for literature regarding 
factors related to receiving LDL tests, but these results are consistent with the medication-related 
literature that identifies a gap in secondary stroke prevention in the elderly (67, 76).  A possible 
explanation for patients age 85+ not receiving an LDL test may be that they have other major 
health problems, and LDL-C levels are not a priority.   
 Income quintile achieved statistical significance in the LDL-C test model.  Patients who 
were in the highest income quintile were more likely to have a test than those in the lowest 
quintile.  These results are consistent with a previous study where socioeconomic status was 
weakly associated with various components of stroke care (12).  It is possible that patients in the 
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 highest income quintile were more easily able to access laboratory tests than those in the lowest 
quintile.  As it appears there was a gradient from lowest to highest income quintile (though the 
odds ratios were not significant), the finding seems to be substantiated.  It should be noted, 
however, that the significant odds ratio was not large.  
 A patient’s length of stay in the hospital was found to be significant for the LDL-C test 
model.  If a stroke/TIA patient was in the hospital past 10 days, they were less likely to receive 
an LDL-C test 2-12 months after discharge.  A possible explanation for this might be that 
patients who were in hospital longer had more complications from their stroke event, and thus 
LDL levels were not a priority.  Another possible reason might be that the patient received an 
LDL test while admitted to hospital.  This information would not have been captured in the 
indicator. 
Regional Health Authority (RHA) of residence was only statistically significant in the 
model for INR tests.  For consistency in discussion, these findings will be reported along with 
the results from the logistic regression contrast model (see Section 5.3.2).     
 Finally, being a multiple stroke patient was associated with a higher likelihood of being 
given an INR test in those on warfarin.  This finding is logical in that if a person has had more 
than one stroke in two years, they might be more likely to comply with physician 
recommendations and have their laboratory test completed.  Again, there is no literature related 
to this type of laboratory indicator for comparison. 
   
5.3 Question Three: Geographical Variation in Secondary Stroke Prevention by 
Saskatchewan Regional Health Authority Areas 
 For Question Three, it was hypothesized that there would be variation in secondary 
prevention between the different Saskatchewan Regional Health Authority Areas. 
 Statistically significant differences were found in the contrast model for some of the 
outcome variables in the study.  These findings are discussed according to the medication-related 
or laboratory outcome indicators. 
 
5.3.1 Medication-Related Indicators 
 Contrast models for each of the medication-related indicators were calculated at 3-days 
and at 90-days for hospital RHA and patient RHA respectively.   
 For hospital RHA at 3 days it was found that the Sunrise RHA was better than the group 
of all other RHAs at dispensing antihypertensives to patients at discharge from hospital.  In 
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 addition, the Saskatoon RHA was worse than the group of all other RHAs at dispensing both 
antihypertensives and anticoagulants at discharge.  There are a couple potential reasons for these 
findings.   
First, the Sunrise RHA may be better than the group of all other RHAs because of their 
methodology surrounding secondary stroke prevention.  The RHA may have improved processes 
for ensuring that stroke/TIA patients receive the recommended antihypertensive care following a 
stroke event.  Further, the physicians at the hospitals in the Sunrise RHA may simply be more 
inclined to prescribe antihypertensives at discharge than doctors in the other Saskatchewan 
RHAs.   
A potential reason the Saskatoon RHA is significantly worse at dispensing both 
antihypertensives and anticoagulants at discharge could be due to the fact that sicker patients are 
admitted to the hospitals in this RHA.  Because there is access to different types of care, patients 
are transferred to the hospitals in the Saskatoon RHA when care is unavailable or inadequate in 
their RHA of residence.  In terms of dispensing antihypertensives, in sicker patients this simply 
may not be a priority.  This explanation is certainly feasible taking into account the fact that at 3 
days the Regina Qu’Appelle RHA (another RHA where patients are transferred) is not much 
better at dispensing antihypertensives than Saskatoon.  Similarly, considering the likelihood of 
contraindications for anticoagulant use may be higher in sicker patients, it is possible that this is 
the reason the Saskatoon RHA came out worse than the group of all other RHAs.   
It is interesting to note that the number of patients with atrial fibrillation on 
anticoagulants at 3 days in Saskatoon is about 20% lower than both the Regina Qu’Appelle RHA 
and the All Others RHA.  This same difference is not seen at 90 days, and instead the Regina 
Qu’Appelle RHA has a lower percentage.  These findings suggest that more research needs to be 
conducted to determine if there are differences between the RHAs for this anticoagulant 
indicator.   
For patient RHA at 90 days, the Sunrise RHA was again better than the group of all other 
RHAs at dispensing antihypertensive medication.  Moreover, the Prince Albert Parkland RHA 
was significantly better than the group of all other RHAs at dispensing statin medications.  The 
explanation for both of these findings may again be explained by the fact that these RHAs may 
have improved processes, this time in the primary care setting, for secondary stroke prevention 
regarding medications.  It could also be that primary care physicians in these areas are more 
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 inclined to prescribe the medication, and/or are better at following up with the stroke/TIA 
patients.   
 
5.3.2 LDL and INR Intermediate Outcome Indicators 
 Since the laboratory data was limited to the Saskatoon and Regina Qu’Appelle RHAs, 
differences between the regions will be discussed using the RHA figures (Section 4.4.2) and 
logistic regression results. 
 In examining the LDL-C test figure, the proportion of people given a test in the 
Saskatoon RHA has remained steady over the past four years at approximately 30%, while in 
Regina Qu’Appelle there was a large increase (approximately 25%) in the most recent year.  
Despite this, patient RHA was not a significant correlate in the model for LDL-C tests.  The 
reason for this is likely because all of the fiscal years were included in the logistic regression 
model, not just the most recent year.  In the years prior to FY2007/08, the Regina Qu’Appelle 
RHA actually seemed to have a smaller percentage of patients given an LDL test.  Considering 
the result in the most recent fiscal year was significantly better in Regina Qu’Appelle than in 
Saskatoon, it seems that the Regina Qu’Appelle RHA may be improving the proportion of 
patients given an LDL-C test at a faster rate than the Saskatoon RHA.  However, this inference 
cannot be drawn until data and results for more recent years are acquired. 
 The figure for the INR test indicator suggests that the Regina Qu’Appelle RHA is 
slightly, though not statistically, better at giving stroke/TIA patients on warfarin an INR test in 
the most recent year.  This inference is consistent with the logistic regression results as the 
Regina Qu’Appelle RHA was found to be significantly better than the Saskatoon RHA at giving 
INR tests to patients on warfarin.  These results may, again, simply imply that the Regina 
Qu’Appelle RHA has more quickly improved the proportion of patients on warfarin given an 
INR test compared to the Saskatoon RHA.  However, as the results for both RHAs were very 
similar in fiscal years 2005/06 and 2006/07, data from more recent years is necessary to examine 
this potential change.  
 
5.4 Study Strengths 
 While this study has shortcomings, there are strengths associated with the study design 
and methodology.  First, this is a multi-year cross-sectional study, which by nature of the design 
has additional strengths than a traditional cross-sectional study.  For instance, because cross-
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 sections of the stroke/TIA patient population in Saskatchewan were taken at seven time points 
during the study, potential changes in secondary stroke care could be identified, where in a 
regular cross-sectional study this is not possible.  
 The second major strength of this study is its use of the Saskatchewan Health 
Administrative Databases.  This data contains a large amount of information on Saskatchewan 
patients that was collected without a specific goal, meaning the data is free of certain types of 
bias common with survey data (i.e. recall and selection bias).  In addition, the data allowed for a 
large sample size in the study.  This increases the probability that the sample population is 
representative of the general population in Saskatchewan.   
 Further, another strength of this study is the seven year ascertainment period for 
information on stroke/TIA patients.  Being able to assess whether patients were taking 
medication at 3 and at 90 days post-discharge allowed time for people to fill their prescriptions.  
Only assessing at one point in time could result in an inaccurate portrayal of the proportion of 
patients on medication.  Similarly, having the ability to acquire information about the 
medications people were taking before their stroke/TIA allowed for a more accurate assessment 
of the correlates associated with being on the various drugs.    
 Finally, this study was done in accordance with the standards set at the Health Quality 
Council (HQC).  Following their guidelines and using previous work to develop the 
methodology has resulted in a high-quality study.     
 
5.5 Study Limitations 
 As with all research, there are certain limitations to this study.  Results must be 
considered with these in mind.  Many of the issues arose from inherent limitations in both the 
administrative and laboratory data sources. 
 In the initial stages of this study, administrative data was only available to the end of the 
fiscal year 2007/08.  It was therefore decided that all indicator calculations would occur up to 
this point.  For this reason, stroke/TIA patients who had a stroke in the latter half of fiscal year 
2007/08 often had to be eliminated from the 90-day indicator calculations as data for them was 
missing.  This could potentially limit the clinical usefulness of this study as the most recent 
results are from two years ago.  However, the results still give an overall indication of what has 
been happening in secondary stroke prevention in Saskatchewan.  
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 As previously mentioned, drug information for Registered Indians was unavailable in the 
database.  For consistency in the study, Registered Indians were left out of all analyses.  
Considering Registered Indians are an important portion of the Saskatchewan population and that 
their health needs are often different from the general population, it is unfortunate that secondary 
stroke prevention could not be explored within this subgroup.   
 Due to the fact that there are only a certain number and type of variables available in the 
administrative database, the correlates explored in the logistic regression models were also 
limited.  For instance, it would have been beneficial to have a variable that more accurately 
portrayed a patient’s socioeconomic status.  The available income quintile variable is not a 
reliable indicator of socioeconomic status.  By the same token, having a limited number of 
variables does not allow for a complete assessment of confounders.   It is certainly possible that 
other variables might affect the results of the logistic models. 
 Accuracy of the coding for stroke patients with atrial fibrillation is questionable due to 
the small numbers that were found.  Patients with this condition were identified by taking the 
stroke/TIA cohort, and finding any people that had a further diagnosis of atrial fibrillation.  It is 
uncertain if all stroke/TIA patients with atrial fibrillation were coded as such in the database.  
This problem could have meant that some people with atrial fibrillation who had a stroke were 
missed in the pull from the database, causing a small number in the cohort.  However, in a 
Swedish study that identified stroke patients with atrial fibrillation, it was found that 12% of all 
stroke/TIA patients had atrial fibrillation (80).  This percentage is similar to the 13.5% identified 
in this study.  This similarity seems to suggest that the coding is fairly accurate, but further 
investigation is required to ascertain that this is not a study limitation.  
 Initially, lab data sharing agreements were drawn up for the Saskatoon, Regina 
Qu’Appelle, and Sunrise RHAs.  Unfortunately, data from the Sunrise RHA was not able to be 
acquired.  Thus, the laboratory results and interpretation is limited to the Saskatoon and Regina 
Qu’Appelle RHAs.  This also means that, in terms of laboratory outcomes, this study is not 
useful for the evaluation of the Saskatchewan Integrated Stroke Strategy.  The evaluation team 
will likely have to collect their own data for the calculation of these specific laboratory 
indicators.  
 As previously discussed, information for the LDL and INR tests in the Saskatoon and 
Regina Qu’Appelle RHAs was limited to the laboratories located in the urban centers of 
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 Saskatoon and Regina.  This has obvious limitations in terms of interpretation.  There were likely 
some patients included in the indicator calculations that did have an LDL or INR test done in the 
non-urban areas of the RHAs, but the information was not captured in the dataset.  This could 
potentially have caused an underestimation of the number of patients who had at least one LDL 
or INR test within a year post-discharge.   
 It is important to note that the indicators calculated in this study are not directly 
applicable to the clinical practice of secondary stroke prevention.  As with many patient care 
procedures, secondary stroke prevention measures given to stroke patients are based on the needs 
of the individual.  This study calculated quality indicators (not quality measures) and the results 
are broad, meaning they are not focused on the individual patients or the specific nature of their 
stroke.  Thus, the results of this study should not be interpreted to suggest that every stroke 
patient should receive the specific care recommended in the Canadian Stroke Strategy Best 
Practice Recommendations, as indirectly measured by the indicators in this study.  Instead, the 
results provide an overall indication of the general nature of secondary stroke prevention in the 
province, and should be used as guidance for decisions at a population level regarding action to 
improve care for stroke patients in Saskatchewan. 
 
5.6 Practical Implications of Results and Directions for Future Research 
 One of the major purposes of this study was to begin the development of an evaluation 
measurement system for the Saskatchewan Integrated Stroke Strategy (SISS) in the area of 
secondary stroke prevention.  The methods and results from the medication-related indicators 
and models can be used directly by the SISS for this purpose.  Since laboratory data was 
inaccessible for the Sunrise RHA, there unfortunately are no results for the laboratory indicators 
and models.  However, the proper methods for calculation of these indicators are laid out in this 
study, and when data becomes available the SISS will be able to follow the methodology and 
quickly acquire results. 
 In order to improve secondary stroke prevention in Saskatchewan, it is first essential to 
know how the province is performing in this area of care.  This is the first study of its kind in 
Saskatchewan examining areas of secondary stroke prevention.  In terms of the calculated 
indicators, the study found that medication-related and laboratory outcome secondary stroke 
prevention is generally sub-optimal across the province.  The results suggest that improvements 
in these areas need to be made to prevent recurrent strokes in Saskatchewan residents.  The SISS 
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 is a great starting point for making the necessary changes in the province, and the hope is that all 
other RHAs will be able to follow suit in the near future.  To ascertain if changes in secondary 
stroke prevention have been beneficial, it will be important to have a regular assessment of these 
prevention areas.  A future study in this area might involve investigating whether the processes 
put in place for secondary stroke prevention have impacted the outcome – especially the 
proportion of people who experience recurrent stroke.   
 While the results from the indicators are quite clear, there are certainly many avenues for 
future studies in secondary stroke prevention in Saskatchewan.  Considering that this study found 
there were differences in treatment between all stroke/TIA and hemorrhagic stroke, a future 
study is needed to examine the full extent and meaning of these variations.  These differences 
also point out the need for more detailed clinical investigations about the appropriateness of 
stroke secondary prevention at the level of individual patients and care providers, since a precise, 
localized evaluation of quality of care will depend on many factors not well captured in 
administrative health data, such as the stroke etiology and comorbidities of individual stroke 
patients.    
Unfortunately, an important sub-population in Saskatchewan was not represented in this 
study because information on medication use was missing for Registered Indians.  The feasibility 
of acquiring this information in future is currently unknown as there are still barriers with both 
obtaining the data, as well as linking it with provincial information.  However, progress is being 
made, and in future the hope is that a study can be done examining secondary stroke prevention 
within this important subpopulation of the province. 
 This study also found some evidence of differences in the provision of secondary stroke 
prevention based on certain correlates.  While this information is important for the province to 
recognize, additional studies are required to examine these potential differences at a finer level of 
detail. 
 In examining the secondary stroke prevention areas within the separate Saskatchewan 
RHAs, it was found that some RHAs were better or worse compared to all others in the province.  
These regional differences should be further examined by the province to determine their validity 
and magnitude, as well as ensure that all residents are receiving the same level of care regardless 
of where they live in Saskatchewan.  More importantly though, given that the differences 
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 between the RHAs were not large, the results seem to suggest that there is a need for a province-
wide initiative to overall improve secondary stroke prevention in Saskatchewan.   
While this study was able to take a snap-shot of secondary stroke prevention in the 
province, it was not able to answer the more meaningful questions “Why is secondary stroke 
prevention sub-optimal in the province” and “How can secondary stroke prevention be improved 
within the health care system?”.  The SISS is designed to address these questions, and having the 
information from this study will given them a starting place for important discussions.  It is clear, 
however, that future studies and discussions within the health care system need to take place in 
order to improve secondary stroke prevention in Saskatchewan. 
 
5.7 Conclusions 
 While specific areas of secondary stroke prevention were examined in this study, it is 
apparent that future research needs to be conducted in this area.  This study described what is 
currently happening in Saskatchewan secondary stroke prevention, but it was not able to explain 
why, or how improvements could be made.  Regardless, the results serve as a baseline for 
evaluation of the impact of the Saskatchewan Integrated Stroke Strategy in the area of secondary 
stroke prevention. 
 Using the guidelines and performance measures from the Canadian Stroke Strategy (4, 5), 
this study was able to conclusively show that secondary stroke prevention in the province is sub-
optimal in the management of hypertension, dyslipidemia, and atrial fibrillation.  It also 
identified that there may be differences in provision of care based on various factors such as age 
and income.  Finally, evidence was found suggesting that there may be variations in care 
between regional health authorities.  These findings indicate that there is a need for further 
studies in this area, and that improvements need to be made in secondary prevention to help 
stroke patients in Saskatchewan avoid the devastation of a recurrent stroke event.   
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 APPENDIX A: SASKATCHEWAN HEALTH ADMINISTRATIVE 
DATABASES 
 
List of the Saskatchewan Health Administrative Databases and the variables abstracted from 
each dataset 
 
Dataset Basic Description Key Variables Used 
Person Registry 
System (PRS) 
A registry system tracking 
Saskatchewan residents 
eligible for health benefits 
• Health Services Number  (HSN) 
(encrypted)  
• Age 
• Sex 
• Registered Indian status 
• Coverage effective date 
• Coverage expiry date 
• Coverage expiry reason 
 
Geographical 
Information File 
(GEO) 
Statistics Canada data 
linked to de-identified PRS 
data by Saskatchewan 
Health 
• HSN (encrypted)  
• Urban residence indicator 
• Income quintile (geographic 
average) 
• RHA where resident lives 
Prescription Drug Plan 
Historical Claims 
(PDP) 
Database of drug 
prescriptions dispensed 
• HSN (encrypted)  
• Drug identification number (DIN) 
• Date of dispensing 
• Pills dispensed 
Prescription Drug Plan 
– DIN File  
DINs and drug categories 
for each prescription drug 
• Drug identification number (DIN) 
• Generic name of drug 
• Strength of drug 
• Dosage  
• Form of drug 
 
Vital Statistics (VS) Births and deaths • HSN (encrypted)  
• Date of death 
 
Hospital Discharge 
Abstract Database 
(DAD) 
Hospital discharges • HSN (encrypted)  
• Date of admission 
• Date of discharge 
• Diagnosis Codes (ICD-10-CA) 
• Hospital name 
• Hospital category 
 
 105
 Dataset Basic Description Key Variables Used 
Physician Services 
Claims File: Medical 
Services Branch 
(MSB) 
Physician services fee 
claims 
• HSN (encrypted)  
• Provider MSB number (encrypted) 
• Date of service 
• Number of services 
• Type of service or major group code 
• Diagnosis Codes (ICD-9 or MSB) 
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 APPENDIX B: RESEARCHER DOCUMENTATION 
 
Complete researcher documentation as used in all HQC analyses 
 
Steps Criteria Rationale Date: 
Added 
Common Criteria #1. Step 1. Identify stroke/TIA patient cohort 
These criteria define the denominator for the indicators 
A separate file must be created for each fiscal year, 01/02 to 07/08 
1 a All those who experienced a stroke 
or TIA and admitted to hospital 
between April 1, 2001 and March 
31, 2008, inclusive 
 
Use ICD-10-CA codes (note: no 
IDC-9 codes because using data 
after 2001)  
(see Section 3.4.1 of thesis 
document) 
 
Keep all records that have any of 
the following in the first diagnosis 
code (most responsible diagnosis): 
I60, I61, I64, G450, G451, G452, 
G453, G458, G459, H341, I630, 
I631, I632, I633, I634, I635, I638, 
I639, I676 
 
The purpose of the study is to 
gain an understanding of 
condition management with 
drugs in secondary stroke 
prevention.  In order to do so, 
patients who have experienced a 
stroke or TIA need to be 
identified.   
 
The dates were chosen 
according to availability of data 
and consistency in coding. 
 
All strokes are important, and 
therefore all included for now – 
will subset later according to 
indicator. 
 
 
 
 
 b Two denominator groups: 
 
Group 1: All stroke and TIA 
Create flags for stroke and TIA 
1 = stroke                1 = TIA 
0 = no stroke           0 = no TIA 
Create group using flags 
 
Group 2: Only stroke 
Create flag for stroke 
1 = stroke 
0 = no stroke 
Create group using flags 
 
Reason for two groups is to 
capture what happens when TIA 
is included/excluded in the 
indicators. 
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 Steps Criteria Rationale Date: 
Added 
 c Link episodes of care (EOC) so 
that all transfers and nests are 
included within the same EOC 
 
Note: The EOC started with a 
primary Dx of stroke in ALL 
cases.  Anything that happened 
following the stroke (ie. rehab) was 
also included in the EOC. 
Only want to count each stroke 
once, not more than once if, for 
instance, they transfer hospitals. 
 
If episodes following the stroke 
Dx are NOT included, it may 
create an absence of drug care 
(because of hospital stay), when 
really none exists.  
 
In data exploration it was found 
that the average length of stay 
(los) was increased for approx. 
3000 patients when the episodes 
following stroke were included.  
This change was significant and 
had the potential to impact the 
results.  Therefore, this 
“extended EOC” was used for 
the study.  
 
 d All those who were ≥ age 18 on the 
date of their stroke or TIA 
By setting the minimum age at 
18, most of the stroke events 
will be captured.  Also, this is 
the age of adulthood in Canada. 
 
 
 e All those who were hospitalized 
within the province  (must 
permanently delete all out of 
province cases) 
The study involves stroke care 
in Saskatchewan, and thus 
residents who were hospitalized 
elsewhere need to be excluded. 
 
 
 f All those who had valid 
Saskatchewan Health Insurance 
coverage: 
• For those that die within 
the fiscal year of their 
stroke, must have 
coverage from last 
discharge date to service 
date (3 and/or 90 days) 
Must be covered for time period 
of interest (last discharge date to 
service date).  Using the 
“service date” means that the 
reporting is based on the 
assessment date for a service (in 
this case, assessment for drugs).   
 
If no coverage, the person may 
have died or moved out of 
province.  In either case, they 
should not be included in the 
cohort. 
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 Steps Criteria Rationale Date: 
Added 
 g All individuals with information on 
sex and DOB 
Such information is necessary 
for proper data analysis, and 
thus where information is 
missing the individuals need to 
be excluded. 
 
Assume day 15 of a given 
month for DOB because dataset 
does not include birth day.  This 
assumes an even distribution of 
birth days over a month. 
 
 
 h All individuals who are not 
Registered Indians 
Individuals with Registered 
Indian status were identified and 
excluded since their prescription 
drugs are covered by the federal 
government and are not 
(consistently) captured in the 
provincial Prescription Drug 
Plan Historical Claims dataset. 
 
 
 
 
 
i 
 
All individuals who have drug 
information in drug file 
Because the purpose of the 
study is to examine drug 
dispensing patterns, residents 
without drug data need to be 
excluded (presumably because 
their prescription drugs are 
covered federally or they did not 
require any prescriptions during 
the course of the study). 
 
 
 
 
 
j All individuals who survived their 
stroke or TIA event to the referent 
“service date” for each indicator 
The purpose of the study is to 
examine secondary stroke care, 
and this is nonexistent in 
individuals who did not survive 
their stroke event. 
 
 
 k Create flags for ischemic and 
hemorrhagic stroke: 
 
Ischflag: 
1 = ischemic stroke 
0 = other stroke 
 
Hemorrflag: 
1 = hemorrhagic stroke 
0 = other stroke 
Need to be able to distinguish 
between stroke types for later 
calculations as the etiology and 
treatments for each may vary. 
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 Steps Criteria Rationale Date: 
Added 
 l Create fiscal year flags for service 
reporting. 
This will include: 
• Year at admission 
• Year at 3-day post 
discharge 
• Year at 90 day post 
discharge 
 
“Service Date” refers to the case 
where reporting is based on the 
assessment date for a service.  In 
this study, the reporting is based 
on the assessment for drugs at 3 
and 90 days following discharge 
for a stroke/TIA. 
 
 
 m Create length of stay (los) variable: 
last discharge date – first admit 
date 
This variable is needed for 
analysis using logistic 
regression as it may be an 
important determinant in 
receiving secondary stroke care. 
 
 
 n Create a flag to identify the people 
in the data set who have had more 
than one stroke/TIA. 
 
To be a multiple stroke the person 
had to have another stroke/TIA 
within two years of the first one in 
the data set (2-year washout period 
2001/02, 2002/03) 
 
Pts_multi: 
1 = multiple stroke 
0 = not multiple stroke 
 
It is important to identify the 
people in the dataset who have 
had more than one stroke/TIA 
episode as this may be a 
determinant of their secondary 
stroke care (ie. they may already 
be on the necessary drugs 
because of their first stroke/TIA 
episode). 
 
  Create 3-day and 90-day 
denominators; Create Atrial 
Fibrillation denominators 
  
     
DRUG DENOMINATORS 
3-Day Drug Denominator ( ) 
2 a • Common Criteria #1 
 
  
 b Alive at 3 days post-discharge 
 
The purpose of the study is to 
examine secondary stroke care, 
and this is nonexistent in 
individuals who did not survive 
their stroke event to the service 
date of interest. 
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 Steps Criteria Rationale Date: 
Added 
 c Coverage is defined by: 
• Covered from last 
discharge date to last 
discharge date+3 
 
Must be covered for time period 
of interest (last discharge date to 
service date).  Using the 
“service date” means that the 
reporting is based on the 
assessment date for a service (in 
this case, assessment for drugs 
at 3 days post-discharge).   
 
If there is no coverage during 
this time period, the person may 
have died or moved out of 
province.  In either case, they 
should not be included in the 
cohort. 
 
 
 d RHA is defined by: 
• 1) Where the patient is 
living at the 3rd day after 
discharge for stroke 
• 2) The RHA of the last 
hospital of discharge for 
the patient 
• If no rha exists in this 
time period, patient 
excluded 
 
People with missing RHA 
information will be excluded 
from analysis ONLY on the 
RHA variable.   
 
 e All individuals who are within the 
outlined fiscal years (2001/02 – 
2007/08) at 3 days post-discharge. 
 
Because this indicator is 3 days 
after discharge from stroke, the 
fiscal year for the individual 
may have been pushed into 
2008/09 and therefore come up 
as “missing”.  As there is no 
information for these 
individuals, they had to be 
excluded from the cohort. 
 
 
     
90-Day Drug Denominator () 
3 a • Common Criteria #1 
 
  
 b Alive at 90 days post-discharge The purpose of the study is to 
examine secondary stroke care, 
and this is nonexistent in 
individuals who did not survive 
their stroke event to the service 
date of interest. 
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 Steps Criteria Rationale Date: 
Added 
 c Coverage is defined by: 
• Covered from last 
discharge date to last 
discharge date+75 
 
The 15th day before the indicator 
reference date was chosen 
because the lowest number of 
pills dispensed (rare exceptions) 
was 15 pills.  Thus, as long as 
the patients were covered 15 
days before the assessment date, 
it can be said that the 
prescription lasted 15 days, and 
that they had sufficient drugs to 
be taking it on the assessment 
date. 
 
 
 d RHA is defined by: 
• 1) Where patient is living 
at the 90th day after 
discharge for stroke 
• 2) The RHA of the last 
hospital of discharge for 
the patient 
• If no rha exists in this 
time period, patient 
excluded 
People with missing RHA 
information will be excluded 
from analysis ONLY on the 
RHA variable.   
 
 e All individuals who are within the 
outlined fiscal years (2001/02 – 
2007/08) at 90 days post-
discharge. 
 
Because this indicator is 90 days 
after discharge from stroke, the 
fiscal year for the individual 
may have been pushed into 
2008/09 and therefore come up 
as “missing”.  As there is no 
information for these 
individuals, they had to be 
excluded from the cohort. 
 
 
     
Atrial Fibrillation 3-Day Drug Denominator () 
4 a • Common Criteria #1   
 b • 3-Day Drug Denominator 
criteria 
  
 c Diagnosis of atrial fibrillation on 
hospital discharge record. 
 
ICD10-CA code: I480 
 
Create flag for atrial fibrillation: 
 
Afib: 
1 = atrial fibrilation 
0 = no atrial fibrillation 
 
Keep all records where afib=1. 
 
The purpose of one of the 
indicators is to gain an 
understanding of condition 
management with drugs in 
secondary stroke prevention in 
those with atrial fibrillation.  In 
order to do so, patients who 
have atrial fibrillation need to be 
identified.   
 
 
     
Atrial Fibrillation 90-Day Drug Denominator () 
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 Steps Criteria Rationale Date: 
Added 
5 a • Common Criteria #1   
 b • 90-Day Drug 
Denominator criteria 
  
 c Keep all records where afib=1. 
 
  
     
     
     
DRUG NUMERATORS 
Common Criteria #2.  Drug Numerators. 
These criteria define the numerators for the drug indicators 
6 1 For the drug lists created by the 
pharmacotherapy consultant, pull 
all DIN numbers from ALL the 
alldin files from SK Health 
  
 2 For HSN’s resulting from 
Common Criteria #1 and the 
appropriate denominator definition 
(or at least Common Criteria #1): 
• Pull all prescriptions for 
the DIN’s found from step 
6.1, from all the drug 
claims of the years of 
interest 
  
 a For HSN’s resulting from 
Common Criteria #1 and the 
appropriate denominator definition 
(or at least Common Criteria #1): 
• Pull ALL hospital records 
from the most recent EOC 
file 
  
     
Statinflag3 
7 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on Statin 
medication (combination of any 
DINs that are statins) 3 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Lipstatflag3 
8 1 • Common Criteria #2   
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 Steps Criteria Rationale Date: 
Added 
 2 Using drug rule 4: 
=1 if patient is on ANY 
antilipidemic medication 
(combination of any DINs that are 
antilipidemics) 3 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
ACEIflag3 
9 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on ACEI 
medication (combination of any 
DINs that are ACEIs) 3 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Antihypflag3 
10 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on ANY 
antihypertensive medication 
(combination of any DINs that are 
antihypertensives) 3 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Warfarinflag3 
11 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on warfarin 
medication (combination of any 
DINs that are warfarin) 3 days 
after discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Anticoflag3 
12 1 • Common Criteria #2   
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 Steps Criteria Rationale Date: 
Added 
 2 Using drug rule 4: 
=1 if patient is on ANY 
anticoagulant medication 
(combination of any DINs that are 
anticoagulants) 3 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Statinflag90     
13 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on Statin 
medication (combination of any 
DINs that are statins) 90 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Lipstatflag90     
14 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on ANY 
antilipidemic medication 
(combination of any DINs that are 
antilipidemics) 90 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
ACEIflag90     
15 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on ACEI 
medication (combination of any 
DINs that are ACEIs) 90 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Antihypflag90     
16 1 • Common Criteria #2   
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 Steps Criteria Rationale Date: 
Added 
 2 Using drug rule 4: 
=1 if patient is on ANY 
antihypertensive medication 
(combination of any DINs that are 
antihypertensives) 90 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Warfarinflag90     
17 1 • Common Criteria #2   
 2 Using drug rule 4: 
=1 if patient is on warfarin 
medication (combination of any 
DINs that are warfarin) 90 days 
after discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
Anticoflag90     
18 1 • Common Criteria #2   
  2 Using drug rule 4: 
=1 if patient is on ANY 
anticoagulant medication 
(combination of any DINs that are 
anticoagulants) 90 days after 
discharge 
Assumed lowest frequency: 1 
 
Hospitalization days must be 
accounted for. 
See Appendix F - Explanation 
of Drug Rule 4  
 
Drugs in hospital do not show 
up on the drugs claims files.  If a 
patient is hospitalized, it may be 
that their Rx that was filled 
before the hosp will not be used 
up at the expected time because 
of free drugs. 
 
     
     
     
LABORATORY INDICATORS 
LABORATORY DENOMINATORS - LDL 
LDL 2-4 Month Denominator 
19 a • Common Criteria #1   
 b • 90-Day Drug 
Denominator criteria 
Since the indicator is at “3 
months post-stroke”, those who 
died before 3 months should not 
be included in the denominator, 
and therefore this dataset was 
utilized. 
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 Steps Criteria Rationale Date: 
Added 
 c All individuals who live in the 
Saskatoon or Regina Qu’Appelle 
RHA. 
 
Keep rha=4 or rha=6 
Laboratory data was only 
available for these RHAs.  Thus, 
to make the indicator calculation 
correct, people who live outside 
of RHA 4 or 6 needed to be 
excluded from the denominator. 
 
     
LDL 2-12 Month Denominator 
20 a • Common Criteria #1  20 
 b • 90-Day Drug 
Denominator criteria 
Since the indicator is at “3 
months post-stroke”, those who 
died before 3 months should not 
be included in the denominator, 
and therefore this dataset was 
utilized. 
 
 c All individuals who live in the 
Saskatoon or Regina Qu’Appelle 
RHA. 
 
Keep rha=4 or rha=6 
Laboratory data was only 
available for these RHAs.  Thus, 
to make the indicator calculation 
correct, people who live outside 
of RHA 4 or 6 needed to be 
excluded from the denominator. 
 
     
LDL Test Result Indicator Denominator 
21 a • LDL 2-12 Month 
Denominator criteria 
  
 b Merge the 90-Day Drug 
Denominator key_hsns with the 
current laboratory data file(s).   
  
 c Create flag for those who had an 
LDL test done between 2-12 
months post-discharge: 
 
Flag10: 
1 = collect date between last 
discharge date+60 and last 
discharge date+365 
0 = collect date not within 
timeframe 
 
Keep all records where Flag10=1 
This flag identifies the 
individuals who had an LDL test 
done within a year of their 
discharge. 
 
 d All individuals with a test result. Some of the recorded laboratory 
tests were missing the test 
results.  These individuals 
needed to be excluded. 
 
 e Keep only the most recent test 
result within the time frame. 
Some people have more than 
one LDL test within the time 
period.  Because only one test 
result is needed from each 
person, the most recent result 
was used. 
 
     
LABORATORY NUMERATORS - LDL 
Flag3 
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 Steps Criteria Rationale Date: 
Added 
22 a • LDL 2-4 Month 
Denominator criteria 
  
 b Create flag for those who had an 
LDL test done between 2-4 months 
post-discharge: 
 
Flag3: 
1 = collect date between last 
discharge date+60 and last 
discharge date+120 
0 = collect date not within 
timeframe 
 
Keep all records where Flag3=1 
This flag identifies the 
individuals who had an LDL test 
done around 3 months post-
discharge. 
 
**This flag originally created 
the denominator for the 
indicator calculation, but the 
number of people was too small, 
and therefore the timeframe had 
to be expanded. 
 
 c All individuals with a test result. Some of the recorded laboratory 
tests were missing the test 
results.  These individuals 
needed to be excluded. 
 
 d Keep only the most recent test 
result within the time frame. 
Some people have more than 
one LDL test within the time 
period.  Because only one test 
result is needed from each 
person, the most recent result 
was used. 
 
     
Flag10 
23 a • LDL 2-12 Month 
Denominator criteria 
  
 b Create flag for those who had an 
LDL test done between 2-12 
months post-discharge: 
 
Flag10: 
1 = collect date between last 
discharge date+60 and last 
discharge date+365 
0 = collect date not within 
timeframe 
 
Keep all records where Flag10=1 
This flag identifies the 
individuals who had an LDL test 
done within a year of their 
discharge. 
 
 c All individuals with a test result. Some of the recorded laboratory 
tests were missing the test 
results.  These individuals 
needed to be excluded. 
 
 d Keep only the most recent test 
result within the time frame. 
Some people have more than 
one LDL test within the time 
period.  Because only one test 
result is needed from each 
person, the most recent result 
was used. 
 
     
Flag18 
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 Steps Criteria Rationale Date: 
Added 
24 a • LDL Test Result Indicator 
Denominator criteria 
  
 b =1 if patient has a test result 
between 1.8-2.5 during the 2-12 
month timeframe 
  
Flagunder2 
25 a • LDL Test Result Indicator 
Denominator criteria 
  
 b =1 if patient has a test result <2.0 
during the 2-12 month timeframe 
  
     
Flagover2 
26 a • LDL Test Result Indicator 
Denominator criteria 
  
 b =1 if patient has a test result >2.0 
during the 2-12 month timeframe 
  
     
LABORATORY DENOMINATORS - INR 
INR Test Denominator 
27 a • Common Criteria #1   
 b • 90-Day Drug 
Denominator criteria 
Since the indicators start at “3 
months post-stroke”, those who 
died before 3 months should not 
be included in the denominator, 
and therefore this dataset was 
utilized. 
 
 c All individuals who live in the 
Saskatoon or Regina Qu’Appelle 
RHA. 
 
Keep rha=4 or rha=6 
Laboratory data was only 
available for these RHAs.  Thus, 
to make the indicator calculation 
correct, people who live outside 
of RHA 4 or 6 needed to be 
excluded from the denominator. 
 
 d Keep all individuals with: 
 
Warfarinflag3=1  OR 
Warfarinflag90=1 
Since the indicator involves the 
patients who are “On” warfarin 
therapy following discharge, 
keeping all individuals who are 
“On” warfarin at 3 or 90 days 
post-discharge is appropriate for 
this denominator. 
 
     
INR 2-4 Month Denominator 
28 a • INR Test Denominator 
criteria 
  
 b Merge the 90-Day Drug 
Denominator key_hsns with the 
current laboratory data file(s).   
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 Steps Criteria Rationale Date: 
Added 
 c Create flag for those who had an 
INR test done between 2-4 months 
post-discharge: 
 
Flag3: 
1 = collect date between last 
discharge date+60 and last 
discharge date+120 
0 = collect date not within 
timeframe 
 
Keep all records where Flag3=1 
This flag identifies the 
individuals who had an INR test 
done 2-4 months post-discharge. 
 
 d All individuals with a test result. Some of the recorded laboratory 
tests were missing the test 
results.  These individuals 
needed to be excluded. 
 
 e Keep only the most recent test 
result within the time frame. 
Some people have more than 
one LDL test within the time 
period.  Because only one test 
result is needed from each 
person, the most recent result 
was used. 
 
     
INR 5-7 Month Denominator 
29 a • INR Test Denominator 
criteria 
  
 b Merge the 90-Day Drug 
Denominator key_hsns with the 
current laboratory data file(s).   
  
 c Create flag for those who had an 
INR test done between 5-7 months 
post-discharge: 
 
Flag6: 
1 = collect date between last 
discharge date+150 and last 
discharge date+210 
0 = collect date not within 
timeframe 
 
Keep all records where Flag6=1 
This flag identifies the 
individuals who had an INR test 
done 5-7 months post-discharge. 
 
 d All individuals with a test result. Some of the recorded laboratory 
tests were missing the test 
results.  These individuals 
needed to be excluded. 
 
 e Keep only the most recent test 
result within the time frame. 
Some people have more than 
one LDL test within the time 
period.  Because only one test 
result is needed from each 
person, the most recent result 
was used. 
 
     
INR 11-13 Month Denominator 
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 Steps Criteria Rationale Date: 
Added 
30 a • INR Test Denominator 
criteria 
  
 b Merge the 90-Day Drug 
Denominator key_hsns with the 
current laboratory data file(s).   
  
 c Create flag for those who had an 
INR test done between 11-13 
months post-discharge: 
 
Flag12: 
1 = collect date between last 
discharge date+330 and last 
discharge date+390 
0 = collect date not within 
timeframe 
 
Keep all records where Flag12=1 
This flag identifies the 
individuals who had an INR test 
done 11-13 months post-
discharge. 
 
 d All individuals with a test result. Some of the recorded laboratory 
tests were missing the test 
results.  These individuals 
needed to be excluded. 
 
 e Keep only the most recent test 
result within the time frame. 
Some people have more than 
one LDL test within the time 
period.  Because only one test 
result is needed from each 
person, the most recent result 
was used. 
 
     
LABORATORY NUMERATORS - INR 
Flag10 
31 a • INR Test Denominator 
Criteria 
  
 b Create flag for those who had an 
INR test done between 2-12 
months post-discharge: 
 
Flag10: 
1 = collect date between last 
discharge date+60 and last 
discharge date+365 
0 = collect date not within 
timeframe 
 
Keep all records where Flag10=1 
This flag identifies the 
individuals who had an INR test 
done within a year of their 
discharge. 
 
 c All individuals with a test result. Some of the recorded laboratory 
tests were missing the test 
results.  These individuals 
needed to be excluded. 
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 Steps Criteria Rationale Date: 
Added 
 d Keep only the most recent test 
result within the time frame. 
Some people have more than 
one LDL test within the time 
period.  Because only one test 
result is needed from each 
person, the most recent result 
was used. 
 
     
2-4 Month Rangeflag 
32 a • INR 2-4 Month 
Denominator Criteria 
  
 b =1 if patient has a test result 
between 2.0-3.0 during the 2-4 
month timeframe 
The original indicator numerator 
asks for all those in “therapeutic 
range” on their INR test.  
According to the literature, 
therapeutic range is 2.0-3.0. 
 
     
5-7 Month Rangeflag 
33 a • INR 5-7 Month 
Denominator Criteria 
  
 b =1 if patient has a test result 
between 2.0-3.0 during the 5-7 
month timeframe 
The original indicator numerator 
asks for all those in “therapeutic 
range” on their INR test.  
According to the literature, 
therapeutic range is 2.0-3.0. 
 
     
11-13 Month Rangeflag 
34 a • INR 11-13 Month 
Denominator Criteria 
  
 b =1 if patient has a test result 
between 2.0-3.0 during the 11-13 
month timeframe 
The original indicator numerator 
asks for all those in “therapeutic 
range” on their INR test.  
According to the literature, 
therapeutic range is 2.0-3.0. 
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 APPENDIX C: LIST OF CATEGORIZED SASKATCHEWAN HOSPITALS 
 
Saskatchewan Hospitals Classified by Hospital Category (75) 
 
Hospital Category Facility Name RHA 
Saskatoon City Hospital Saskatoon 
St. Paul’s Hospital Saskatoon 
Royal University Hospital Saskatoon 
Regina General Hospital Regina Qu’Appelle 
Pasqua Hospital Regina Qu’Appelle 
Provincial 
n=6 
Plains Health Centre  
(closed November 20, 1998) 
Regina Qu’Appelle 
Lloydminister Hospital Prairie North 
Moose Jaw Union Hospital Five Hills 
Battlefords Union Hospital Prairie North 
Holy Family Hospital  
(closed October 1, 1997) 
Prince Albert Parkland 
Victoria Hospital Prince Albert Parkland 
Swift Current Regional Hospital Cypress 
Regional 
n=7 
Yorkton Regional Health Centre Sunrise 
St. Joseph’s Hospital Sun Country 
St. Elizabeth’s Hospital Saskatoon 
Kindersley Integrated Health Care Facility Heartland 
Northwest Health Facility Prairie North 
Melfort Hospital Kelsey Trail 
St. Peter’s Hospital Sunrise 
Nipawin Hospital Kelsey Trail 
Tisdale Hospital Kelsey Trail 
District 
n=9 
Weyburn General Hospital Sun Country 
Arborfield and District Health Care Centre Kelsey Trail 
Arcola Health Centre Sun Country 
Assiniboia Union Hospital Five Hills 
Balcarres Integrated Care Centre Regina Qu’Appelle 
Beechy Health Centre Heartland 
Bengough Health Centre Sun Country 
Biggar Union Hospital Heartland 
Big River Health Centre Prince Albert Parkland 
Birth Hills Medical Centre/Birchview 
Nursing Home 
Prince Albert Parkland 
Borden Community Health Centre Saskatoon 
Broadview Union Hospital Regina Qu’Appelle 
Prairie Health Care Centre Cypress 
Canora Hospital Sunrise 
Carrot River Health Centre Kelsey Trail 
Community 
n=109 
Central Butte Union Hospital Five Hills 
 Border Health Centre Cypress 
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 Coronach Health Centre Sun Country 
Craik and District Health Centre Five Hills 
Cudworth Nursing Home/Health Centre Saskatoon 
Cupar Health Centre Regina Qu’Appelle 
Cut Knife Health Complex Prairie North 
Davidson Health Centre Heartland 
Dinsmore Health Care Centre Heartland 
Eastend Wolf Willow Health Centre Cypress 
Eatonia Health Care Centre Heartland 
Lady Minto Health Care Centre Prairie North 
Elrose Health Centre Heartland 
St. Anthony’s Hospital Sunrise 
Eston Health Centre/Jubilee Lodge Heartland 
Fillmore Union Health Centre Sun Country 
L. Gervais Memorial Health Centre Prairie North 
St. Joseph’s Hospital Five Hills 
Grenfell Health Centre Regina Qu’Appelle 
Gull Lake Special Care Centre Cypress 
Hafford Hospital and Special Care Home Prince Albert Parkland 
Herbert Morse Hospital Cypress 
Hudson Bay Health Care Facility Kelsey Trail 
Long Lake Valley Integrated Facility Regina Qu’Appelle 
Indian Head Union Hospital Regina Qu’Appelle 
Invermay Health Centre/Gateway Lodge Sunrise 
Ituna Pioneer Health Care Centre Sunrise 
Kamsack Hospital/Kamsack and District 
Nursing Home 
Sunrise 
Kelvington Hospital Kelsey Trail 
Kerrobert Integrated Health Care Facility Heartland 
Kincaid Health Centre Five Hills 
Kinistino Health Centre Prince Albert Parkland 
Kipling Memorial Health Centre Sun Country 
Kyle and District Health Centre Heartland 
Lafleche and District Health Centre Five Hills 
Lampman Community Health Centre Sun Country 
Langenburg Health Complex/Centennial 
Special Care Home 
Sunrise 
Lanigan Hospital Saskatoon 
Leader Hospital Cypress 
Evergreen Health Centre Prince Albert Parkland 
St. Joseph’s Integrated Care Centre Regina Qu’Appelle 
Loon Lake Union Hospital and Special Care 
Home 
Prairie North 
Lucky Lake Health Care Centre Heartland 
St. Joseph’s Health Centre Heartland 
Maidstone Hospital Prairie North 
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 Prairie View Health Centre Cypress 
Maple Creek Hospital Cypress 
Mainprize Manor and Health Centre Sun Country 
Montmartre Health Centre Regina Qu’Appelle 
Providence Place Five Hills 
Moosomin Union Hospital Regina Qu’Appelle 
Manitou Health Centre Prairie North 
Nokomis Health Centre/Puffer Special Care 
Home Corp 
Saskatoon 
Norquay Health Centre/Gateway Lodge Sunrise 
Outlook Union Hospital Heartland 
Galloway Health Centre Sun Country 
Pangman Health Centre Sun Country 
Paradise Hill Hospital Prairie North 
Ponteix Health Centre/Foyer St. Joseph 
Nursing Home 
Cypress 
Porcupine Carragana Hospital Kelsey Trail 
Preeceville Hospital Sunrise 
Radville Marian Health Centre Sun Country 
Redvers Health Centre Sun Country 
Grasslands Health Centre Five Hills 
Rosetown and District Health Centre Heartland 
Rose Valley Health Centre Kelsey Trail 
Rosthern Hospital Saskatoon 
St. Walburg Health Complex Prairie North 
Shaunavon Hospital and Care Centre Cypress 
Shellbrook and District Hospital Prince Albert Parkland 
Smeaton Health Centre Kelsey Trail 
Spalding Community Health Centre Kelsey Trail 
Spiritwood and District Health Complex Prince Albert Parkland 
Theodore Health Centre Sunrise 
Riverside Health Complex Prairie North 
Unity and District Health Centre Heartland 
Vanguard Health Centre Cypress 
Wadena Hospital Saskatoon 
Wakaw Hospital Saskatoon 
Watrous Hospital Saskatoon 
Watson Health Complex/Quill Plains 
Centennial Lodge 
Saskatoon 
Wawota Memorial Health Centre/Deer 
View Lodge 
Sun Country 
Whitewood Community Health Centre Regina Qu’Appelle 
Wilkie and District Health Centre/Poplar 
Courts 
Heartland 
Wolseley Memorial Union Hospital Regina Qu’Appelle 
Wynyard Integrated Facility Saskatoon 
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 Buffalo Narrow Health Centre Keewatin Yatthé 
Cumberland House Kelsey Trail 
Sandy Bay Health Centre Mamawetan Churchill 
River 
Yutthé Dene Nakóhódí Health Centre Athabasca Health 
Authority 
Pinehouse Health Centre Mamawetan Churchill 
River 
Beauval Heatlh Centre Keewatin Yatthé 
Fort Qu’Appelle Indian Hospital Inc. Regina Qu’Appelle 
St. Joseph’s Hospital Keewatin Yatthé 
La Ronge Health Centre Mamawetan Churchill 
River 
Uranium City Municipal Hospital  
(closed June 1, 2003)  
Athabasca Health 
Authority 
La Loche Health Centre Keewatin Yatthé 
Northern 
n=4 
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 APPENDIX D: REVISED MEDICATION QUALITY INDICATORS 
 
List of the revised stroke/TIA quality indicators for medications 
 
Indicator Numerator for 
Aggregate Measure 
Denominator for 
Aggregate Measure 
Rationale 
2.2 vii. a. 
Antihypertensives 3 
Days 
Proportion of people 
hospitalized for a 
stroke/ TIA 
dispensed blood 
pressure lowering 
agents as assessed at 
the 3rd day post-
discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
of antihypertensives 
on their last 
dispensing date 
during the 3 days 
post-discharge to 
ensure they have 
sufficient medication 
for at least a 
minimum daily dose 
on the 3rd day. 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
This process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  This rate 
of adequate drug 
dispensing during the 
3 days post-discharge 
is assumed to be 
primarily a function 
of drug prescribing 
by the hospital 
physician at 
discharge. 
2.2 vii. b. 
ACEI 3 Days 
Proportion of people 
hospitalized for a 
stroke/ TIA 
dispensed 
angiotensin-
converting enzyme 
inhibitors (ACEI) as 
assessed at the 3rd 
day post-discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
ACEI on their last 
dispensing date 
during the 3 days 
post-discharge to 
ensure they have 
sufficient medication 
for at least a 
minimum daily dose 
on the 3rd day. 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
This process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  This rate 
of adequate drug 
dispensing during the 
3 days post-discharge 
is assumed to be 
primarily a function 
of drug prescribing 
by the hospital 
physician at 
discharge. 
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 2.2 vii. c. 
Antihypertensives 90 
Days 
Proportion of people 
hospitalized for a 
stroke/ TIA dispensed 
blood pressure 
lowering agents as 
assessed at the 90th 
day post-discharge. 
 
 
 
 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
of antihypertensives 
on their last 
dispensing date during 
the 90 days post-
discharge to ensure 
they have sufficient 
medication for at least 
a minimum daily dose 
on the 90th day. 
 
 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
 
 
 
 
 
 
The process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  The rate 
of adequate drug 
dispensing during 
the 90 days post-
discharge is a 
function of both 
drug prescribing by 
the hospital 
physician at 
discharge and 
prescribing in the 
primary care setting 
during the post-
discharge period. 
2.2 vii. d. 
ACEI 90 Days 
Proportion of people 
hospitalized for a 
stroke/ TIA dispensed 
angiotensin-
converting enzyme 
inhibitors (ACEI) as 
assessed at the 90th 
day post-discharge. 
 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
of ACEI on their last 
dispensing date during 
the 90 days post-
discharge to ensure 
they have sufficient 
medication for at least 
a minimum daily dose 
on the 90th day. 
 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
 
The process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  The rate 
of adequate drug 
dispensing during 
the 90 days post-
discharge is a 
function of both 
drug prescribing by 
the hospital 
physician at 
discharge and 
prescribing in the 
primary care setting 
during the post-
discharge period. 
2.3 ii. a. 
Antilipidemics 3 
Days 
Proportion of people 
hospitalized for a 
stroke/ TIA dispensed 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
of antilipidemics on 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
This process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
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 lipid-lowering agents 
as assessed at the 3rd 
day post-discharge. 
their last dispensing 
date during the 3 days 
post-discharge to 
ensure they have 
sufficient medication 
for at least a minimum 
daily dose on the 3rd 
day. 
the year in which the 
indicator is being 
measured.   
beneficial.  This 
rate of adequate 
drug dispensing 
during the 3 days 
post-discharge is 
assumed to be 
primarily a function 
of drug prescribing 
by the hospital 
physician at 
discharge. 
2.3 ii. b. 
Statins 3 Days 
Proportion of people 
hospitalized for a 
stroke/ TIA dispensed 
statin medication as 
assessed at the 3rd day 
post-discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
of statin medication on 
their last dispensing 
date during the 3 days 
post-discharge to 
ensure they have 
sufficient medication 
for at least a minimum 
daily dose on the 3rd 
day. 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
This process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  This 
rate of adequate 
drug dispensing 
during the 3 days 
post-discharge is 
assumed to be 
primarily a function 
of drug prescribing 
by the hospital 
physician at 
discharge. 
2.3 ii. c. 
Antilipidemics 90 
Days 
Proportion of people 
hospitalized for a 
stroke/ TIA dispensed 
lipid-lowering agents 
as assessed at the 90th 
day post-discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
of antilipidemics on 
their last dispensing 
date during the 90 
days post-discharge to 
ensure they have 
sufficient medication 
for at least a minimum 
daily dose on the 90th 
day. 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
The process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  The rate 
of adequate drug 
dispensing during 
the 90 days post-
discharge is a 
function of both 
drug prescribing by 
the hospital 
physician at 
discharge and 
prescribing in the 
primary care setting 
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 during the post-
discharge period. 
2.3 ii. d. 
Statins 90 Days 
Proportion of people 
hospitalized for a 
stroke/ TIA dispensed 
statin medication as 
assessed at the 90th 
day post-discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA who were 
dispensed a quantity 
of statin medication on 
their last dispensing 
date during the 90 
days post-discharge to 
ensure they have 
sufficient medication 
for at least a minimum 
daily dose on the 90th 
day. 
The number of adults 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
The process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  The rate 
of adequate drug 
dispensing during 
the 90 days post-
discharge is a 
function of both 
drug prescribing by 
the hospital 
physician at 
discharge and 
prescribing in the 
primary care setting 
during the post-
discharge period. 
2.6 i. a. 
Anticoagulants 3 
Days 
Proportion of people 
hospitalized for a 
stroke/ TIA with atrial 
fibrillation dispensed 
anticoagulants as 
assessed at the 3rd day 
post-discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA with atrial 
fibrillation who were 
dispensed a quantity 
of anticoagulants on 
their last dispensing 
date during the 3 days 
post-discharge to 
ensure they have 
sufficient medication 
for at least a minimum 
daily dose on the 3rd 
day. 
The number of adults 
with atrial fibrillation 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
This process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  This 
rate of adequate 
drug dispensing 
during the 3 days 
post-discharge is 
assumed to be 
primarily a function 
of drug prescribing 
by the hospital 
physician at 
discharge. 
2.6 i. b. 
Warfarin 3 Days 
Proportion of people 
hospitalized for a 
stroke/ TIA with atrial 
fibrillation dispensed 
warfarin as assessed at 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA with atrial 
fibrillation who were 
dispensed a quantity 
of warfarin on their 
The number of adults 
with atrial fibrillation 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
This process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  This 
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 the 3rd day post-
discharge. 
last dispensing date 
during the 3 days post-
discharge to ensure 
they have sufficient 
medication for at least 
a minimum daily dose 
on the 3rd day. 
the year in which the 
indicator is being 
measured.   
rate of adequate 
drug dispensing 
during the 3 days 
post-discharge is 
assumed to be 
primarily a function 
of drug prescribing 
by the hospital 
physician at 
discharge. 
2.6 i. c. 
Anticoagulants 90 
Days 
Proportion of people 
hospitalized for a 
stroke/ TIA with atrial 
fibrillation dispensed 
anticoagulants as 
assessed at the 90th 
day post-discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA with atrial 
fibrillation who were 
dispensed a quantity 
of anticoagulants on 
their last dispensing 
date during the 90 
days post-discharge to 
ensure they have 
sufficient medication 
for at least a minimum 
daily dose on the 90th 
day. 
The number of adults 
with atrial fibrillation 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
The process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  The rate 
of adequate drug 
dispensing during 
the 90 days post-
discharge is a 
function of both 
drug prescribing by 
the hospital 
physician at 
discharge and 
prescribing in the 
primary care setting 
during the post-
discharge period. 
2.6 i. d. 
Warfarin 90 Days 
Proportion of people 
hospitalized for a 
stroke/ TIA with atrial 
fibrillation dispensed 
warfarin as assessed at 
the 90th day post-
discharge. 
The number of adults 
discharged from 
hospitalization for 
stroke/TIA with atrial 
fibrillation who were 
dispensed a quantity 
of warfarin on their 
last dispensing date 
during the 90 days 
post-discharge to 
ensure they have 
sufficient medication 
for at least a minimum 
daily dose on the 90th 
day. 
The number of adults 
with atrial fibrillation 
discharged alive from 
hospitalization for 
which the most 
responsible diagnosis 
is stroke/TIA during 
the year in which the 
indicator is being 
measured.   
The process of care 
indicator describes 
whether or not the 
patient received an 
intervention that has 
been shown to be 
beneficial.  The rate 
of adequate drug 
dispensing during 
the 90 days post-
discharge is a 
function of both 
drug prescribing by 
the hospital 
physician at 
discharge and 
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prescribing in the 
primary care setting 
during the post-
discharge period. 
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 APPENDIX E: DRUG USE METHODOLOGY (75) 
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Drug Uu
The medication use quality indicator. are based on asCel1ainlllem of whether patiems are (likely)
taking the dl1lg at the date of ill1erest (i.e.. 3. 9Q. or 365 days post-discharge)" Since the indicator i.
based on phamlaceutical dispeming data. we need a methodology for e.timating: whether a patient
will ha\"e a .ufficiem supply of the medication at the d.1le of intere.t To do this. we infemd. ba.ed
on the amount of medication dispensed. the number of pills a patient was to take daily and
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cA!c\l[lIled whether they would hAve sufficient dnlg supply relllAining frolll the dispensing dllle pri,
to thc datc ofintcl'c,t (i.c. 3. 90 or 365 dap po,t-di,chargc).
The expected nnmber of piUs to be taken eaclt day during the peliod between the most recent
di"pcming prior to thc datc of intcrcstand thc datc of intcrcst itself was infcrrcd bascd on thc
number of pills dispensed to that person in recent plioI' hi>tory as shown in Figure 2.2.
Figure 2.2: Example of how daily pill count is inferred
~- JOda".. 15da"..
1(')(0 0~ ~ ~
.. .. ..
r
90trl day posf-
dischargeDispenSing dates of
medication
Discharge
from
hospital
--I----+----+--
I
To infer the number of pills to be taken per day during period C, leading up fo
the 90ltI day post-discharge, fhe average number of dally pills in periods A and
B were calculated as the sum of the pills dispensed on dates 1 and 2 dil/ided by
the number of days between dispensing dates 1 and 3.
So, in this example,
60 + 60 / 60 = 2 pills Iday.
At the expected rote of usage of 2 pills per day, the 60 pills dispensed atUme 3
would be expected to last well beyond the 15 days between dispensing 3 and
the date of interest (90111 day post-discharge); so the patient would be counted
in the indicator numerator (as being on the medication at the 90'" day post-
discharge).
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Ba~ed on the inferred d.1ily pill count (or a minimum count of a half-pill per day for beta-blocker~
and one pill per day for the other medicatiom med in the post.AMI report). we calculate when the
patient would nut out of pil1~. If the time from the last prior dispensing to the 901h day post·
di~charge i~ fe\\"er d.1Y~ than the number of day~ of available dmg. we conclude that the patient wa~
on the particular medication on the 90th day po~t-discharge. On the other hand. if the drug count
indicates that the patient did 11m om of pills before the 90th day post-discharge. then our conclusion
i~ dmtthe patient wa, not on the pal1icular medication on the 90th day po,t-di~charge.
Again. knowing that the minimum dmg count ~hould be half or one pill a day (depending on the
specific dmg). if the calculated a\'erage pill frequency was less than the minimum dose. or if there
were no previou~ pre~cription~. then the pill frequency for the patient defauhed to the amlllled
lowe,t frequency.
Hospital days are subtracted from that interval. as medications are cO\'ered in hospital stays. Refills
are taken into accolUlt by extending the imerval by the appropriate nlUuber of pill~ (depending on
the a~~umed lowe~t frequency).
For all drug u~e indicators. the time period that the patient was on a ~pecific drug i~ calculated by
the date of ~en'ice (dmg di,peming) occuned.
Figure 2.3 presents the way drug use is detenuined on 3. 90. and 365 days post-discharge. Day 0
indicates the discharge d.1te. and the lines represent the time period during which the patient was
di~pe1J<,ed the dmg. Note tlmt individu.11~ can qualify for inclu~ion in indicatol'~ for ,everal of the
time period, po,t-di>eharge. The patient, in Figure 2.3 are li~ted in Table 2.2 to ,how which are
included in the 3-d.1Y. 90-d.1Y. and 365-day drug indicators. For example. Patients A. B. and C Me
con~idered taking the dmg during the first time period only. and therefore included only in the 3·
day indicator. Patient~ P. R. and S are con~idered taking the drug during the ,econd time period. and
included for 90-day drug indicator. Howe\·er. patients Rand S were abo taking the drug during the
first3 d.1yS after discharge. so they would also included in the 3-day indicato!'. Similal'1y while
patient X i~ included only in the 365-day dmg indicator. patient Y i~ included both in 90· and 365-
day drug indicatol'~. and patient Z i~ included in indicator~ for all tluee period~.
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Figure 2,3: Drug use on 3, 90, and 365 days post.discharge
n
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 APPENDIX F: EXPLANATION OF DRUG RULE 4 (75) 
 
Drug Rule 4 
This is otherwise known as the ‘inferred frequency rule’. For each prescription in the drug 
database, we infer the pill frequency as follows. We examine the previous two prescriptions 
dispensed for the same medication and calculate the average pill frequency over those two 
prescriptions.  The average pill frequency is equal to the total number of pills dispensed in those 
two prescriptions, divided by the number of days elapsed between the third prescription date and 
the earlier of the previous two prescriptions.  
 
If previous prescriptions were not written, then the half pill, or one pill depending on which drug 
was dispensed, frequency assumption applies. The intent, as above in drug rule 3, is to ascertain 
if the patient is taking the drug at the date of interest (3 or 90days). 
 
Hospital days are subtracted from that interval, as medications are covered in a hospital stay. 
Refills are taken care of by extending the interval by the appropriate number of pills (depending 
on the assumed lowest frequency). 
 
The main difference between drug rule 3 and drug rule 4, is, instead of assuming what the pill 
frequency is, we are calculating the frequency based on the patients’ previous two prescriptions, 
and using that pill frequency to calculate the time period.  Drug rule 3 is liberal is its assumption 
of the pill frequency, and therefore drug rule 4 is likely to be more accurate. 
 
 
 
 
                         Day        Day                                Day            
                           0            3                                 90     
                                   1st Time Period (Patient A) 
                                          1st Time Period (Patient B) 
                             1st Time Period (Patient C) 
 
                                                                2nd Time Period (Patient A)  
                                                                  2nd Time Period (Patient B) 
                                                          2nd Time Period (Patient C)  
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 APPENDIX G: REVISED LABORATORY TEST QUALITY INDICATORS 
 
List of the revised stroke/TIA quality indicators for laboratory tests 
 
Indicator Numerator for 
Aggregate Measure 
Denominator for 
Aggregate Measure 
Rationale 
2.3 a. 
LDL-C Test at 2-4 
Months 
Proportion of 
stroke/TIA patients 
given an LDL-C test 
between 2-4 months 
following their stroke 
event 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle 
discharged from 
hospitalization for 
stroke/TIA with at 
least one LDL-C test 
result (most recent) 
2-4 months post-
discharge. 
 
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle 
discharged from 
hospitalization for 
stroke/TIA (most 
responsible 
diagnosis) and alive 
at 90 days. 
The LDL-C levels of 
stroke/TIA patients 
should be monitored 
following discharge 
from hospital. 
The intermediate 
outcome indicator 
describes whether or 
not stroke/TIA 
patients are being 
given LDL-C tests, 
and therefore being 
monitored, at the 
recommended 3 
months post-
discharge. 
  
2.3 b. 
LDL-C Test at 2-12 
Months 
Proportion of 
stroke/TIA patients 
given an LDL-C test 
between 2-12 months 
following their stroke 
event 
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle 
discharged from 
hospitalization for 
stroke/TIA with at 
least one LDL-C test 
result (most recent) 
2-12 months post-
discharge. 
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle 
discharged from 
hospitalization for 
stroke/TIA (most 
responsible 
diagnosis) and alive 
at 90 days. 
The LDL-C levels of 
stroke/TIA patients 
should be monitored 
following discharge 
from hospital. 
The intermediate 
outcome indicator 
describes whether or 
not stroke/TIA 
patients are being 
given LDL-C tests, 
and therefore being 
monitored post-
discharge. 
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 2.3 iii.  
LDL-C 1.8-2.5 
Proportion of 
stroke/TIA patients 
with a most recent 
LDL-C level 
between 1.8-2.5 at 
2-12 months 
following their 
stroke event 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA with a 
most recent LDL-C 
result between 1.8-2.5 
at 2-12 months post-
discharge.  
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA who 
had at least one LDL-C 
test (most recent) 
between 2-12 months 
post-discharge. 
The recommended 
LDL-C target level 
for people who 
have had a stroke 
or TIA should be 
less than 
2.0mmol/L. 
The intermediate 
outcome indicator 
describes whether 
or not the LDL-C 
levels of 
stroke/TIA patients 
are within the 
recommended 
range. 
   
2.3 iv.  
LDL-C <2.0 
Proportion of 
stroke/TIA patients 
with a most recent 
LDL-C level less 
than 2.0 at 2-12 
months following 
their stroke event 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA with a 
most recent LDL-C 
result less than 2.0 at 
2-12 months post-
discharge.  
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA who 
had at least one LDL-C 
test (most recent) 
between 2-12 months 
post-discharge. 
The recommended 
LDL-C target level 
for people who 
have had a stroke 
or TIA should be 
less than 
2.0mmol/L. 
The intermediate 
outcome indicator 
describes whether 
or not the LDL-C 
levels of 
stroke/TIA patients 
are within the 
recommended 
range.  
   
2.3 v.  
LDL-C >2.0 
Proportion of 
stroke/TIA patients 
with a most recent 
LDL-C level greater 
than 2.0 at 2-12 
months following 
their stroke event 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA with a 
most recent LDL-C 
result greater than 2.0 
at 2-12 months post-
discharge.  
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA who 
had at least one LDL-C 
test (most recent) 
between 2-12 months 
post-discharge. 
The recommended 
LDL-C target level 
for people who 
have had a stroke 
or TIA should be 
less than 
2.0mmol/L. 
The intermediate 
outcome indicator 
describes whether 
or not the LDL-C 
levels of 
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 stroke/TIA patients 
are within the 
recommended 
range.   
 
2.6 v. a. 
INR Test at 2-12 
Months 
Proportion of 
stroke/TIA patients 
given at least one 
INR test between 2-
12 months following 
their stroke event 
 
 
 
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA and 
placed on warfarin 
with at least one INR 
test result between 2-
12 months post-
discharge. 
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA who 
were placed on 
warfarin. 
The INR levels of 
stroke/TIA patients 
should be 
monitored 
following 
placement on 
warfarin. 
The intermediate 
outcome indicator 
describes whether 
or not stroke/TIA 
patients are being 
given INR tests, 
and therefore being 
monitored post-
discharge. 
 
2.6 v. b. 
INR 2.0-3.0 at 2-4 
Months 
Proportion of 
stroke/TIA patients 
on warfarin with a 
most recent INR 
level between 2.0-
3.0 at 2-4 months 
following their 
stroke event 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA and 
placed on warfarin 
with a most recent INR 
result between.2.0-3.0 
at 2-4 months post-
discharge.  
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA who 
were placed on 
warfarin and had at 
least one INR test 
(most recent) between 
2-4 months post-
discharge. 
The recommended 
target INR level for 
people who have 
had a stroke or TIA 
is 2.5 (range 2.0-
3.0). 
The intermediate 
outcome indicator 
describes whether 
or not the INR 
levels of 
stroke/TIA patients 
on warfarin are 
within the 
recommended 
range around 3 
months post-
discharge.   
 
2.6 v. c. 
INR 2.0-3.0 at 5-7 
Months 
Proportion of 
stroke/TIA patients 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
The recommended 
target INR level for 
people who have 
had a stroke or TIA 
is 2.5 (range 2.0-
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on warfarin with a 
most recent INR 
level between 2.0-
3.0 at 5-7 months 
following their 
stroke event 
for stroke/TIA and 
placed on warfarin 
with a most recent INR 
result between.2.0-3.0 
at 5-7 months post-
discharge.  
 
for stroke/TIA who 
were placed on 
warfarin and had at 
least one INR test 
(most recent) between 
5-7 months post-
discharge. 
3.0). 
The intermediate 
outcome indicator 
describes whether 
or not the INR 
levels of 
stroke/TIA patients 
on warfarin are 
within the 
recommended 
range around 6 
months post-
discharge.   
 
2.6 v. d. 
INR 2.0-3.0 at 11-
13 Months 
Proportion of 
stroke/TIA patients 
on warfarin with a 
most recent INR 
level between 2.0-
3.0 at 11-13 months 
following their 
stroke event 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA and 
placed on warfarin 
with a most recent INR 
result between.2.0-3.0 
at 11-13 months post-
discharge.  
 
The number of adults 
who live in 
Saskatoon/Regina 
Qu’Appelle discharged 
from hospitalization 
for stroke/TIA who 
were placed on 
warfarin and had at 
least one INR test 
(most recent) between 
11-13 months post-
discharge. 
 
The recommended 
target INR level for 
people who have 
had a stroke or TIA 
is 2.5 (range 2.0-
3.0). 
The intermediate 
outcome indicator 
describes whether 
or not the INR 
levels of 
stroke/TIA patients 
on warfarin are 
within the 
recommended 
range around 12 
months post-
discharge.   
 
